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Abbreviation index 
% Percent  
°C Degree Celsius 
α Alpha 
β Beta 
β-Gal Beta-galactosidase 
γ Gamma 
δ Delta 
µm Micrometre 
ABTS 2,2’-azino-bis(3-ethylbenzthiazoline-6-
sulfonic) 
ACK Ammonium chloride-potassium 
hydrogen carbonate 
AEC 3-amino-9-ethylcarbozole 
ag Antigen 
α-GalCer, MPEG Alpha-galactosyl-ceramide, pegylated 
AIDS Acquired immunodeficiency syndrome 
APC Antigen-presenting cell 
APC Allophycocyanin (section 4.3.1) 
AS03 Alumosilicate 3 
AS04 Alumosilicate 4 
ASC Antibody-secreting cell 
BAL Bronchoalveolar lavage 
BALT Bronchial-associated lymphoid tissue 
BPPcysMPEG S-[2,3-bispalmitoyiloxy-(2R)-prpoyl]-R-
cysteinyl-amido-monomethoxyl 
polyethylene glycol 
BSA Bovine serum albumin 
CARD Caspase-recruitment domain 
CCL-2, 3, 4 Chemokine ligand-2, 3, 4 
CCR Chemokine receptor 
CD 3/4/8 Cluster of differentiation (e.g. 3,4,8) 
c-di-AMP cyclic-dimeric-adenosine 3’,5’-
monophosphate 
c-di-GMP cyclic-di-guanosine monophosphate 
CEE chronic environmental enteropathy 
CFDA-SE Carboxyfluorescein diacetate 
Succinimidyl ester 
cLN Cervical lymph nodes 
CNS Central nervous system 
ConA Concanavalin A 
CPM Counts per minute 
CT Cholera toxin 
CTB Cholera toxin subunit B 
CTL Cytotoxic T lymphocyte 
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CTLA-4 Cytotoxic T-cell antigen 4 
C-type lectin Calcium-dependent-type lectin 
CXCL8 CXC-motif-chemokine 8 
DC, plural DCs Dendritic cell; pl. Dendritic cells 
DEPO (pregn-4-ene-3,20-dione, 17-
(acetyloxy)-6-methyl-, (6α-)) 
DMEM Dulbecco’s modified eagle medium 
DMF Di-methylformamide 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DQ Diff-Quik 
E. coli Escherichia coli 
e.g. Exempli gratia 
E2 Estradiol 
EDTA Ethylendiaminetetraacetic acid 
ELISA Enzyme-linked immunosorbant assay 
ELISPOT Enzyme-linked immune spot technique 
FACS Fluorescence activated cell sorter 
Fc Fragment crystallisable 
FCS Foetal calf serum 
FITC Fluorescein isothiocyanate 
FoxP3 Forkhead box transcription factor 
protein 3 
FSC-A/-H/-W Forward scatter-area/-height/-width 
g Gram 
GALT Gut-associated lymphoid tissue 
G-CSF Granulocyte-colony stimulating factor 
GM-CSF Granulocyte-macrophage-colony 
stimulating factor 
GFP Green fluorescent protein 
h hour 
HA haemagglutinin 
H2O2 Hydrogen peroxide 
H5N1 Hemaglutinin5-Neuraminidase1 
HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid ) 
HIV Human immunodeficiency virus 
HLT Heat-labile toxin 
HPV Human papilloma virus 
HRP Horseradish peroxidase 
HSV-1/HSV-2 Herpes simplex virus 1/2 
i.e. Id est 
iLN Iliac lymph node 
i.n. Intranasal/ intranasally 
i.p. Intraperitoneal/ -ly 
IRIV Immunopotentiating reconstituted 
influenza virosomes 
ITAM Immunoreceptor signalling motif 
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i.v. Intraveniously 
i.vag. Intravaginal/-ly 
IBD Inflammatory Bowel disease 
ICBC Iterative chip-based cytometry 
IFN-γ Interferon-gamma 
IgA/E/G/M Immunoglobulin A/E/G/M 
IGR Intergenetic region 
IL Interleukin 
IL-17RA Interleukin-17A-receptor  
kbp Kilo base-pairs 
KHCO3 Potassium bicarbonate 
khZ Kilo Hertz 
KO knockout 
l Litre 
LD Lethal dose 
LL /BAL Lung lavage/Broncheoalvear lavage 
LPS Lipopolysaccharide 
LTI Lymphoid-tissue inducer 
LV Large variant 
m2 Square metre 
MALP-2 Mycoplasma macrophage activating 
lipopeptide-2 
MALT Mucosa-associated lymphoid tissue 
M-cells Microfold-cells 
mg Milligram 
MHC Major histocompability-complex 
MIP Macrophage-inflammatory protein 
MIP-1 Macrophage-inflammatory protein-1 
MLD Mouse lethal dose 
mM Millimolar 
MOI Multiplicity of infection 
MPL Monophosphoryl-lipid A 
MyD88 Myeloid differentiation primary 
response gene 88  
NA Neuraminidase 
NALP3 nucleotide-binding site and leucine-rich 
repeats with N-terminal pyrin domain 
containing 3 
NALT Nasal-associated lymphoid tissue 
NaOH Sodium hydroxide 
NFkB Nuclear factor ‘kappa-light-chain-
enhancer’ of activated B-cells 
NH4Cl Ammonium chloride 
NK Natural killer 
NKT Natural killer T-cell 
NL Nasal lavage 
NLR nucleotide oligomerisation domain like 
receptors 
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nm nanometres 
NOD nucleotide oligomerisation domain 
OB Olfactory bulb 
OVA ovalbumin 
p-value Probability value 
P4 Progesterone 
PAMP Pathogen-associated molecular pattern 
PBS Phosphate buffered saline 
PE Phycoerythrin 
PFA Paraformaldehyde 
PFU Plaque-forming units 
pg Picogram 
pH Potential hydrogenii 
p.i. Post infection 
PI3K Phosphoinositide 3-kinase 
PMSF Phenylmethanesulfonyl- fluoride 
PRR, plural PRRs Pathogen-recognition receptor, -s 
PYCARD apoptosis-associated speck-like protein 
containing a caspase-recruitment 
domain 
RA Rheumatoid arthritis 
RAR Retinoic acid receptor 
RIG Retinoic acid-inducible gene 
RNA ribonucleic acid 
RORC RAR-related orphan receptor C 
RORγt RAR-related orphan receptor gamma 
RPM Rounds per minute 
RPMI Royal Park Memorial Institute 
RT Room temperature 
s.c. subcutaneous 
SD Standard deviation 
SEM Standard error of the mean 
SFU Spot-forming units 
s.l. Sublingual-ly 
SI Stimulation index 
sIgA Secretory IgA 
SLIT Sublingual immunotherapy 
SPF Specific pathogen free 
SSC-A/-H/-W Side scatter-area/-height/-width 
STAT Signal transducer and activator of 
transcription protein 3 
STD, plural STDs Sexual transmitted disease,-s 
STI, plural STIs Sexual transmitted infection,-s 
STING stimulator of IFN genes  
TCR (γδ) T cell receptor (gamma, delta) 
TGF-β Transcription-growth-factor-β 
Th1 T helper 1 
Th2 T helper 2 
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TLR Toll-like receptor 
TNF Tumour-necrosis factor 
Tregs Regulatory T cell 
Trif TIR (Toll/interleukin-1 receptor) 
domain-containing adaptor protein 
inducing interferon β 
UL Unique long 
Us5 Unique short sequence locus 5 
VALT Vagina-associated mucosal tissue 
VHS Virion-host shut off 
VL Vaginal lavage 
WHO World health organisation 
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Ia Kurzzusammenfassung 
Die meisten Pathogene dringen über mukosale Oberflächen in den Wirt ein. Vakzinierung über 
mukosale Routen ist daher ein sehr vielversprechender Ansatz, schützende Immunantworten 
dort zu initiieren, wo der erste Kontakt mit den Krankheitserregern stattfindet. Weiterhin wird die 
mukosale Immunisierung besser akzeptiert als der Nadelgebrauch beim parenteralen Impfen. 
Auch hat es die Vorteile, dass es nicht zur Kreuzkontamination durch horizontalen Transfer 
zwischen Individuen kommt, dass durch die einfache Handhabung eine Selbstapplikation 
möglich ist und dass es weniger Nebenwirkungen birgt. Bisher schien die Administration über 
die intranasale (i.n.) Route der vielversprechendste Ansatz für mukosale Impfungen, da die i.n. 
Mukosa ein Gewebe repräsentiert, das nach Infektion oder Vakzinierung sehr potent humorale 
und zelluläre Immunantworten hervorruft. Leider stellte sich heraus, dass Vakzine, die über 
diese Route appliziert werden aufgrund ihres enthaltenen Adjuvants, bestehend aus 
Toxinuntereinheiten, zum olfaktorischen Bulbus redirigiert werden und schwere 
Nebenwirkungen verursachen können. Auch die Mukosa des Genitaltrakts repräsentiert eine 
wichtige induktive Seite für schützende Immunantworten. Allerdings ist die Immunisierung über 
diese Route nur dann effizient, wenn die Frauen in einem bestimmten Zyklusabschnitt 
immunisiert werden. Die sublinguale (s.l.) Gabe von Vakzinformulierungen gilt als potentielle 
Alternative zur i.n. Route. Die s.l. Mukosa wird als etabliertes Verfahren zur Immuntherapie bei 
Allergiebehandlungen eingesetzt, es sind keine Nebenwirkungen bekannt. Wie bei i.n. 
Immunisierung ruft auch die s.l. Immunisierung starke lokale und systemische Immunantworten, 
sogar an entfernten Seiten wie der vaginalen Mukosa, hervor.  
Hauptziel dieser Arbeit war, das Potential der s.l. Vakzinierung als Alternative zur etablierten i.n. 
Strategie zu untersuchen und zu prüfen, ob starke lokale und systemische Immunantworten, 
auch an distalen Geweben, hervorgerufen werden. Um die effizienteste Vakzinierungsstrategie 
zur Stimulation starker Immunantworten im Genitaltrakt zu bestimmen, wurden verschiedene 
mukosale Anwendungsrouten verglichen. Dazu wurden verschiedene Adjuvantien in 
Kombination mit Modelantigenen über i.n., intravaginale und s.l. Routen appliziert. In der 
mukosalen Wirtsabwehr scheinen IL-17 und Th17 Zellen eine wichtige Rolle zu spielen, 
dennoch ist nur wenig über ihre Funktion im Genitaltrakt bekannt. Daher wurde die Rolle von IL-
17/Th17 bei der Immunität gegen Genitalinfektionen durch Modulation der IL-17/Th17 Antworten 
untersucht. Zu diesem Zweck wurden die Adjuvantien zyklisches di-Adenosin-3´,5´-
Monophosphat und pegyliertes alpha-Galactosylceramid eingestzt, welche in der Lage sind, die 
Produktion von IL-17 zu steigern bzw. zu hemmen. Die erzielten Ergebnisse zeigen, dass die 
Immuisierung über die s.l. Route sowohl lokal als auch systemisch starke humorale und 
zelluläre Immunantworten hervorruft und damit einen vielversprechenden Ansatz für mukosale 
Vakzinierungen darstellt. 
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Ib Abstract 
Most pathogens enter the host via mucosal surfaces. Thus, vaccination via mucosal 
routes is a very promising approach to elicit protective immune responses at the area of 
antigen contact. Furthermore, unlike the use of needles for parental immunisation, 
mucosal immunisation is more accepted. In addition, it offers several advantages, such 
as the lack of risk of cross-contamination, an easy administration logistic which would 
even allow self-administration and much lower risk for local side effects. Until now, 
administration via the intranasal route has seemed to be the most promising approach 
for mucosal vaccination, since the intranasal mucosa constitutes a very potent inductive 
site for humoral and cellular immune responses. Unfortunately, recent findings showed 
that vaccines applied by this route which contained A-B moiety toxins as adjuvants 
were redirected to the olfactory bulb, and lead to concerning side effects. The mucosa 
of the genital tract also constitutes an important inductive site for protective immune 
responses. However, only women in a specific stage of their oestrus cycle can be 
effectively immunised via this route. Sublingual (s.l.) administration of vaccine 
formulations represents a potential alternative to the intranasal (i.n.) route. Like i.n. 
immunisation, s.l. vaccination stimulates strong local and systemic immune responses, 
even at distant sites such as the vaginal mucosa.  
The major aim of this thesis was to investigate the potential of s.l. vaccination as 
alternative approach to the well described i.n. immunisation strategy to promote local 
and systemic immune responses, as well as protection at local and distant mucosal 
sites. Different mucosal application routes were compared in order to identify the most 
efficient vaccination strategy to stimulate immune responses at the level of the genital 
tract. To this end, different adjuvants were used in combination with model-antigens 
administered via the i.n., intravaginal and s.l. routes. Despite that fact that IL-17 and 
Th17 cells seem to play a crucial role in mucosal host defence, little is known about 
these effectors and their function in the genital tract. To this end, the role of IL-17/Th17 
in immunity to vaginal infections was investigated by modulating the IL-17/Th17 
responses using the adjuvants cyclic-dimeric-adenosine 3’,5’-monophosphate and 
pegylated alpha-galactosyl-ceramide, which were able to enhance or inhibit IL-17 
production following vaccination. The obtained results indicate that the s.l. route 
constitutes a promising alternative for mucosal vaccination strategies aimed at 
stimulating strong humoral and cellular immune responses both at local and systemic 
level. 
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1. Introduction  
1.1. Vaccination as effective strategy for disease prevention 
1.1.1. Impact of infection and vaccination 
Today, a quarter of deaths worldwide are due to infectious diseases. Among 
them, over 25% are caused by respiratory tract pathogens, whereas about 20% 
can be attributed to acquired immunodeficiency syndrome (AIDS). A significant 
number of people also die from diarrhoea (for example caused by Salmonella), 
tuberculosis, malaria, measles, tetanus and others [1]. In addition, according to 
the World Health Organisation (WHO) Regional Office for Europe, more than 
340 million new cases of sexually transmitted bacterial and viral infections occur 
every year worldwide. Thus, the spread of infectious diseases urgently needs to 
be reduced. Vaccination represents one of the most cost-effective interventions 
in the fight against infectious diseases. Today, millions of people are vaccinated 
every year to help prevent the spread of numerous diseases. As declared in 
1980 by the WHO, the small-pox vaccine was even able to eradicate the small-
pox at a worldwide scale. However, vaccine formulations are still not perfect. 
Numerous vaccines seem very promising in preclinical animal studies, but are 
not successful in large clinical trials [2]. A central challenge associated with the 
creation of new vaccines is to create a formulation that would not harm the 
vaccinee, but retain the capacity to be recognised by the host’s immune system, 
thereby triggering the elicitation of protective immunity. 
 
1.1.2. Types of vaccines 
Most of the vaccines licensed for human use are live attenuated, whole cell 
inactivated, or subunit-vaccines. Live attenuated vaccines consist of a 
weakened version of the pathogen, which is unable to cause disease, but 
retains the capacity to persist and even to some extend replicate inside the host. 
Examples of live attenuated vaccines include: measles, mumps, rubella, yellow 
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fever, and small-pox. These vaccines induce a strong antibody and cellular 
immune response in the vaccines, which mimic the immunity that occurs after 
natural infection [3], [4]. These vaccines are able to promote both humoral and 
cellular immunity. 
 
On the other hand, inactivated vaccines are made from killed pathogens, for 
example vaccines against hepatitis A, whooping cough and cholera. After 
vaccination with this type of vaccines, antigenic fragments of the protein 
components of the vaccine formulation will be presented via major 
histocompability-complex II (MHC class II)-molecules and specific co-receptors 
to T-cells, thereby stimulating CD4+ T-helper-cells [5]. However, since the 
pathogen is dead, it would not be able to produce proteins in the cytosol of the 
host cell. This means viral peptides cannot be efficiently presented via MHC 
class I-molecules. As a result, efficient cytotoxic CD8+ T-cell responses would 
not be stimulated [5]. In fact, for stimulation of cytotoxic CD8+ T-cells, the 
antigens need to be processed by antigen-presenting cells (APCs) and 
presented via MHC class I-molecules. Then, antigen-specific activated CD8+ T-
cells would be able to recognise the antigens displayed by infected cells, which 
would be in turn killed. Since this process does not efficiently occur with 
inactivated vaccines, these vaccines provided limited protection against 
intracellular pathogens, such as many viruses [5].  
 
Finally, subunit vaccines consist of purified fragments of the pathogen intended 
to elicit protective immunity in the host. Today these vaccines are the most 
common types of vaccines under development, but unfortunately purified 
antigens are weakly immunogenic. Consequently, the so-called adjuvants (lat. 
adiuvare = to help) should be incorporated into the formulation to strength and 
modulate antigen-specific immune responses [3]. In studies by Bowen and 
Simmons, it was shown that certain adjuvants, like cholera toxin (CT), can 
stimulate mucosal cytotoxic T-lymphocytes (CTL) responses after oral or i.n. 
administration of formulations containing protein and peptide subunits [6], [7]. 
Approximately half of the vaccines available on the market today include 
adjuvants needed to enhance and/or modulate the immune responses 
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stimulated after vaccination. Examples of subunit vaccines enhanced by 
adjuvants include: Cervarix® and Gardasil® for HPV infection, Boostrix® for 
diphtheria and tetanus, and Meningitec® for meningococcus. 
 
1.1.3.  Adjuvants 
1.1.3.1. Licensed adjuvants 
Globally, only five adjuvants are currently licensed for use in humans: alum, 
adjuvant system 03 (AS03), adjuvant system 04 (AS04), MF59 and liposomes 
[8].  
Introduced in the 1930s, alum is an aluminium salt-based adjuvant that can be 
emulsified with the co-administered antigen [9]. It induces a T-helper 2 (Th2)-
biased immune response and is able to induce Toll-like receptor (TLR)-
independent antibody responses. Furthermore, it directly affects IL-4 producing 
Gr1+ cells that prime B-cells to undergo clonal expansion leading to optimal 
antibody production [10], [4], [11]. According to Koll et al., murine studies 
indicated that monocytes with the phenotype CD11b+Ly6ChighLy6G-F4/80int are 
recruited to the injection site after alum vaccination [12]. Then, these cells take 
up the antigen and invade the draining lymph nodes where they undergo 
differentiation into inflammatory dendritic cells (DCs). In a recent publication it is 
also shown that alum binds to the lipid plasma membrane of DCs [13]. This 
triggers lipid sorting, aggregation of immunoreceptor signalling motif (ITAM)-
containing receptors and an inflammatory phagocytic response mediated by 
phosphoinositide 3-kinase (PI3K). The antigen uptake is due to endocytosis. 
The endosomal antigen-processing therefore leads to CD4-responses, also 
humoral immune responses and B-cell activation [13]. In another publication, 
the nucleotide-binding site and leucine-rich repeats with N-terminal pyrin domain 
containing 3 (Nalp3) inflammasome was identified as the element on which 
alum is acting, resulting in an inflammasome pathway directing a humoral 
adaptive immune response [14]. The Nalp3 belongs to the cytosolic nucleotide 
oligomerisation domain (NOD) like receptors (NLR)-family and forms together 
with the apoptosis-associated speck-like protein containing a caspase-
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recruitment domain (CARD) [Pycard] a caspase-1 activated inflammasome, 
which for example regulates the release of pro-inflammatory cytokines [15].  
 
A disadvantage of alum is that it does not efficiently stimulate cell-mediated Th1 
or cytotoxic T cell responses [16]. Consequently, it is not able to induce optimal 
protective immunity needed for viral pathogens or parasites, such as the human 
immunodeficiency virus (HIV) and plasmodium.  
 
MF59 consists of a squalene based oil-in-water emulsion [17]. This adjuvant is 
co-administered with certain influenza vaccines and has been licensed in 
Europe since 1997 [4], [18]. MF59 promotes an early CD4+ T cell response and 
has been shown to promote the elicitation of persistent protective antibodies 
against H5N1 influenza [8], [19]. According to Mosca et al., MF59 strongly 
induces cytokines, their receptors, and certain adhesion molecules, triggering 
also the influx of CD11b+ blood cells according to what observed in murine 
studies [20]. Furthermore, in vitro studies in human cells performed by Seubert 
et al. showed that the adjuvant MF59 (as well as alum) has the potential to 
induce chemokine secretion as well, for example chemokine-ligand 2 (CCL2), 
CCL3, CCL4 and CXC-motiv-chemokine 8 (CXCL8) [21]. These chemokines 
have a role in recruiting cells from blood into peripheral tissues. MF59 targets 
monocytes, macrophages and even granulocytes. MF59 seems to augment 
antigen uptake, promoting also upregulation of homing receptors enabling DCs 
to home and prime adaptive immune responses, leading to the recruitment of 
immune cells to the site of vaccination [21]. 
 
AS03 is an adjuvant based on a 10% oil-in-water emulsion and is very similar to 
MF59. It contains α-tocopherol and squalene as oil-in-water emulsion [22]. It 
was tested for the use in an influenza A vaccine and licensed in the vaccine 
Prepandrix® from GlaxoSmithKline [16], [23].  
AS04 is a combination adjuvant composed of 3-O-desacyl-4’-monophosphyril 
lipid A (MPL), a TLR 4 ligand, adsorbed to alum [24]. This adjuvant is licensed 
for two vaccines, Cervarix®, a vaccine against HPV, and Fendix®, a vaccine 
against hepatitis B [24], [25], [26], [27]. MPL is a detoxified derivate from 
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lipopolysaccharide (LPS) isolated from Salmonella minesota R595 and acts as 
TLR 4 agonist. TLR 4 stimulation leads to nuclear-factor ‘kappa-light-chain-
enhancer’ of activated B-cells (NFκB) transcriptional activation, which in turn 
results in the expression of pro-inflammatory cytokines, like IL-6 and tumour-
necrosis factor-α (TNF-α), and enhanced activation and maturation of APCs 
[24], [28], [29], [30], [31], [32], [33]. The increased number of antigen (ag)-
specific DCs and monocytes in the lymph nodes draining the injection site in 
turn leads to the activation of adaptive immune responses by increasing the 
number of ag-specific T-cells [33]. While alum alone promotes a Th2-biased 
immune response, the addition of MPL is able to drive a Th1-biased response.  
 
Liposomes are vesicles containing an aqueous core enclosed in phospholipid 
layers [34],[35]. They can serve as vehicles for ags and fuse with the plasma 
membrane of APCs. Liposomes are able to stimulate humoral and cellular 
immune responses. Although CD8+ T-cells can be also stimulated [36], CTL 
responses are usually not very strong. This is a bottleneck, since this type of 
response is critical to combat intracellular pathogens, such as viruses, 
Mycobacterium tuberculosis and Listeria monocytogenes. This shortcome can 
be solved by the use of virosomes, which are liposomes containing proteins 
from the influenza virus. This favours the release of the virosomes cargo into the 
cytoplasm, subsequent processing and presentation by MHC class I-molecules, 
and elicitation of CTL responses.  
 
The virosomal influenza formulation [immunopotentiating reconstituted influenza 
virosomes (IRIV)] is one example. It is composed of reconstituted virus 
envelopes containing viral surface glycoproteins, but not genetic material [37]. 
This formulation retains cell binding and membrane fusion capabilities of the 
virus [38]. The main constituents of IRIVs are naturally occurring phospholipids 
and phosphatidylcholine [39]. Up to 30% of the membrane component is formed 
by envelope phospholipids from the influenza virus, providing the glycoproteins 
neuraminidase (NA) and haemagglutinin (HA). The NA, a tetramer composed of 
four equal, spherical hydrophobically subunits, intercalates into the 
phospholipids membrane and is centrally embedded in the IRIV membrane. The 
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influenza HA is intercalated into the phospholipid bilayers and stabilises the 
liposome, preventing fusion with other liposomes [40]. HA is also responsible for 
the fusion of the virus with the endosomal membrane [41], [42], [43]. The 
number of lipid layers and the electric charge can influence their adjuvant 
properties, affecting their capacity to promote humoral and cellular immune 
responses [44], [45]. Virosomes have been also exploited as delivery system for 
a current vaccine against the hepatitis A vaccine (Epaxal™).  
 
1.1.3.2. Innovative adjuvants 
The development of subunit vaccines has highlighted the limitations of the 
currently available adjuvants. Moreover, no licensed mucosal adjuvants exist so 
far. Thus, the generation of new innovative adjuvants is crucial to the 
development of new vaccines. In this context, stimulation of the innate immune 
responses via microbial proteins or pathogen-associated molecular patterns 
(PAMPs), like the LPS from Escherichia coli (E. coli), offers promising adjuvant 
candidates. The innate immune system recognises these PAMPs by conserved 
structures, the so-called pattern-recognition receptors (PRRs), which are 
expressed by numerous cells, e.g. DCs and macrophages [46]. PRRs, such as 
TLRs, C-type lectin receptors, NLRs and retinoic acid inducible gene-based-like 
receptors (RIG), recognise bacterial cell wall components, their 
deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), as well as conserved 
structures of viruses or fungi [16], [47], [48], [49], [50], [51], [52], [53]. Moreover, 
by stimulation of different TLRs it would be possible to modulate the elicited 
immune responses, since TLR agonists can activate a broad range of pathways. 
As an example, DCs primed by TLR 3, 7 or 9 induce a Th1-biased immune 
response, whereas activation of DCs by TLR 6 or 2 results in Th2 or regulatory 
T-cell (Treg)-dominated immune responses [16], [54]. On the one hand, Th17 
responses can be induced via stimulation of dectin-1, a C-type lectin [55], [54]. 
Regarding the decision for lineage commitment, transcription factors control 
which kind of T-cell will develop. Each transcription factor is activated by a 
combination of cytokines that are produced after PRR stimulation via TLRs on 
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DCs. Then, naïve T cells are primed to differentiate into the correct phenotype. 
[54].  
 
There are known adjuvants signalling through TLRs, which exert their activities 
when administered via the mucosal route. For example, the synthetic S-[2,3-
bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxyl polyethylene 
glycol (BPPcysMPEG) is a TLR 2/6 agonist showing potent adjuvant properties 
for cross-priming against cellular ags [56]. This adjuvant is a synthetic derivate 
of the macrophage activating lipopeptide-2 (MALP-2) of Mycoplasma fermentas, 
which is able to signal via TLR 2 in a myeloid differentiation primary response 
gene 88 (MyD88)-dependent signalling pathway [57]. MALP-2 acts on 
macrophages, B-cells and DCs, stimulating their maturation and activation [58], 
[59]. MALP-2 effector functions on B-cells are exerted in a T-cell independent 
manner [58], [60]. This adjuvant is also promoting proteasome maturation [59].  
 
 
 
Figure 1: Stimulation of TLRs leads to induction of specific Th-phenotype development 
[54] 
 
 
It has been suggested that the use of adjuvants might result in non targeted 
immune reactions, thereby contributing to chronic diseases. For example, in a 
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mouse model lacking TLR 4 or MyD88, it is shown that atherosclerosis can be 
reduced [61], [62]. TLR 9 was also suspected to participate in activation of 
autoreactive B-cells secreting autoantibodies, the so-called rheumatoid factor. 
These autoreactive B-cells are persistent in healthy individuals, but co-
stimulation of the ag-receptor and TLR 9 could result in their activation with 
secretion of rheumatoid factor [63].  
 
However, there were other molecules tested as adjuvants, which do not act via 
TLRs. Recently, cyclic-di-nucleotides were tested as mucosal adjuvants and 
were shown to elicit protective immune responses [64]. The cyclic-di-guanosine 
monophosphate (c-di-GMP) is not detected by TLRs that generally sense 
nucleic acids [65]. Studies were performed using cells in which the TIR 
(Toll/interleukin-1 receptor) domain-containing adaptor protein inducing 
interferon β (trif) and MyD88 were knocked-out. The MyD88-/-Trif-/- double-
knockout cells are not able to signal through known TLRs, but they are still able 
to respond to nucleic acid ligands via the cytosolic immunosurveillance 
pathways [65], [66], [67]. When c-di-GMP was tested in these cells, it was able 
to stimulate them. This indicates that there must be a distinct non- TLR pathway 
for the recognition of the c-di-GMP. Additional studies showed that also other c-
di-nucleotides can exert adjuvant properties [64], [68]. Recently, the stimulator 
of IFN genes (STING) was identified as an innate immune sensor of cyclic 
dinucleotides (cited from [69]). It detects pathogen-derived cytosolic DNA-like c-
di-nucleotides, leading to a type I interferon response (cited from [69]), [70], [65], 
[71], [72]. 
 
In this thesis, cyclic-dimeric-adenosine 3’,5’-monophosphate (cyclic-di-AMP) 
was assessed as potential adjuvant for use in various mucosal immunisation 
routes (i.n., intravaginal (i.vag.) and s.l.). The c-di-AMP is a second messenger 
molecule in bacteria and archeae and is involved, for example, in the 
sporulation processes of Bacillus subtilis and signalling for DNA integrity [73], 
[74], [68]. The adjuvant cyclic-di-AMP was shown to induce strong 
Th1/Th2/Th17 responses when co-administered with the model-ag β-
galactosidase (β-Gal) via the i.n., i.vag. or s.l. route [68].  
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The α-GalCerMPEG is a pegylated synthetic derivate of the alpha-
galactosylceramide, which was originally isolated from an extract of the marine 
sponge Agelas mauritianus and is known to induce natural killer T-cells (NKT-
cell) activity via stimulation of the T-cell receptor (TCR) of NKT cells by CD1d 
molecules of APCs [75] [76]. NKT cells are categorised into 3 different kinds: (i) 
the classic invariant NKT cell that possesses invariant Vα14-Jα18 TCR α-chains 
and reacts to α-GalCer in a CD1d-dependent manner, (ii) non-classic NKT-cells 
that do not react to α-GalCer and have various TCR α-chains and are CD1d-
dependent, and finally (iii) CD1d-independent NKT cells, which do not react to 
α-GalCer and have various TCR α-chains [77]. Once NKT cells receive an 
activation signal, they produce Th1 and Th2 cytokines that up-regulate humoral 
and cellular immune responses [78]. It exist also CD44high 
NK1.1negCD4negRORγtpos iNKT-cells which produce large amounts of IL-17 after 
stimulation with e.g. α-GalCer [79], [80]. These cells secrete only very low 
amounts of IFN-γ and IL-4 [80].  
 
1.1.4. Disadvantages of parenteral vaccination 
Nearly all vaccines currently available are administered via the parenteral route, 
either intramuscularly or subcutaneously. In general, parenteral vaccines do not 
efficiently stimulate primary immune responses in the mucosal tissues. This is a 
major disadvantage because most pathogens enter via mucosal surfaces. In 
addition, parenteral vaccine formulations mainly induce Th2-biased responses, 
which are able to neutralise bacterial toxins and can protect the host against 
extracellular infections. However, in order to clear intracellular and viral 
infections, a Th1-biased immune response is required [23]. Another practical 
drawback is that acceptance of parenteral vaccines is low, since they are 
applied with needles, being associated with pain and stress.  
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1.1.5. Benefits of mucosal immunisation 
Most pathogens enter the host through mucosal routes. Because the most 
powerful immune responses can be elicited at the pathogen’s site of invasion, 
mucosal immunisation is ideal. According to Czerkinsky, the immune system of 
a healthy adult comprises about 400m2 mucosal surfaces and contains about 
80% of all the body’s lymphocytes [81], [82]. These membranes defend against 
pathogens at this large portal of entry using several mechanical and chemical 
cleansing mechanisms. They also have a huge potential as site of vaccination. 
Possible routes for mucosal immunisation are conjunctival, i.n., oral, s.l., i.vag. 
and intrarectal. Unlike parenteral immunisation, local mucosal immunisation 
through these routes elicits secretory immunoglobulin A (sIgA) and CTL 
responses at the mucosal site [83]. In addition, it has the possibility to stimulate 
systemic responses. With a vaccine formulation administered via the mucosal 
route, many infectious diseases, e.g. sexually transmitted diseases (STDs), 
could be curtailed. With parenteral immunisation, mostly Th2-biased immune 
responses are stimulated, for example alum, which is one of the few approved 
human adjuvants, elicits no Th-1 response [84]. These Th1-biased immune 
responses can be enhanced through mucosal immunisation, which is critical for 
protection against HIV infection [85], [86].  
 
Mucosal immunisation also offers other societal and logistical advantages. For 
example, there is no risk of cross contamination through the use of needles, 
which helps to increase their safety profile [87]. Moreover, medical staff would 
not be required for administration, allowing for the possibility of self-vaccination. 
This is especially important in the context of resource limited settings. The 
development of effective mucosal vaccines would therefore provide a more cost 
effective and safer alternative to existing vaccines. Thus, the establishment of 
approaches to develop mucosal vaccines able to confer maximal protection 
without adverse side effects is a major aim in vaccinology.  
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1.2. The mucosal port of entry 
The portal of entry for most pathogens is the mucosa. For example, the nasal 
mucosa for the influenza virus, the oral or eye mucosa for the herpes-simplex-
virus type 1 (HSV-1), and the vaginal, urethral or rectal mucosa for HIV. Since 
these mucosal surfaces are covered by a protective mucous, the risk of invading 
pathogens rises with surface dehydration or the presence of lesions.  
 
There are two major subtypes of mucosal surfaces. Type I mucosal surfaces 
have a simple columnar epithelium, like that of the gut and lung. Type II 
mucosal surfaces possess protective stratified squamous epithelia, like that 
covering the eye, mouth and vagina. To be precise, the endocervix and uterus 
consists of type I mucosa and the outer area (close to vulva) and inner areas of 
the vagina and the ectocervix consist of type II. The type I mucosa has IgA 
transport mechanisms and mucosa associated lymphoid tissue (MALT), 
whereas the type II mucosa is not linked to MALT [88] . 
 
 
Figure 2: Anatomy of the genital mucosa [88]. 
In the picture from Iwasaki et al. it is shown where the type I and II mucosal surfaces are located 
in female genital tract. 
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The MALT can be further divided into subclasses based on location, e.g. the 
nasal-associated lymphoid tissue (NALT), the broncheoalvelar-associated 
lymphoid tissue (BALT), gut-associated lymphoid tissue (GALT) and the vagina-
associated lymphoid tissue (VALT). These act as the induction sites for immune 
responses [89]. MALT also contains accumulations of lymphoid cells in the 
exocrine glands and the parenchyma of mucosal organs, which are the areas of 
effector immune responses. The priming of the mucosa-associated cells occurs 
in the draining lymph nodes.  
 
In the type II mucosa, the mucus is locally produced by secreting epithelial cells. 
This mucus contains mucins, antimicrobial peptides, immunoglobulins (Ig) and 
the complement system. These components play specific roles: [88] (i) mucins 
contain glycoproteins that are able to cover pathogen structures and prevent 
penetration of the mucosal tissue; (ii) antimicrobial peptides are a component of 
the innate immune system that non-specifically kill invading pathogens; and (iii) 
the Igs exhibit an important role in the immune response, since they can (a) 
neutralise bacterial toxins, (b) mediate phagocytosis by opsonisation of bacteria 
in the extracellular space, and (c) activate the classical complement pathway 
[5]. The complement system is another component of the innate immune system 
that produces a cascade of proteolytic reactions on the surface of 
microorganisms, resulting in either their death by lysis or uptake by professional 
phagocytes. 
 
MALT exhibits a high degree of compartmentalisation and is independent of the 
systemic immune system. This high degree of compartmentalisation allows 
activated lymphocytes to migrate and act at distant mucosal sites within these 
compartments [81]. Therefore, immunisation at one site can also lead to 
immune responses at distant sites. For example, activated s.l. lymphocytes are 
able to migrate to the vaginal mucosa. As reviewed in Hervouet et al., s.l. 
immunisation with an HIV subunit vaccine induces antibodies and CTLs in the 
genital tract of female mice [90]. Here, antibody-secreting cells (ASC) originated 
from extra-genital lymphoid organs, the cervical lymph nodes, home to the 
genital tract after s.l. immunisation. This process is facilitated by the selective 
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recruitment of mucosal lymphocytes to specific tissues using homing- and 
chemokine-receptors linked to tissue-specific adressins and epithelial cell-
derived chemokines that are differentially expressed at the various effector 
tissues. Additionally, for the nasal route, studies have shown that i.n. 
immunisation elicits immune responses at the genital tract of mice and humans. 
In an experiment conducted in Sweden, women were immunised either i.n. or 
i.vag. with cholera toxin B subunit (CTB) and CTB-specific IgA responses were 
found in the vaginal secretions of the i.n. vaccinated women [91].  
 
In addition to fighting infection throughout the body, vaginal immunisation also 
has the potential to fight a wide variety of infectious diseases. At the genital 
tract, an infection with human papilloma virus (HPV) can promote the 
development of cervical cancer. According to Connie Celum, Bulletin WHO 
2004, pre-existing genital HSV-2 infection double the risk of acquiring HIV 
through sexual transmission [92]. This is due to ulcerations and micro trauma of 
the genital epithelium caused by the HSV-2, which facilitates the entry of 
sexually transmitted pathogens, like HIV. Moreover, these lesions are invaded 
by CD4+ T-cells which are the target of HIV. Consequently, vaccines against 
STDs could help to eradicate and reduce the spread of a number of different 
diseases, which represent a heavy burden in the context of human public 
health. 
 
1.3. Herpes-simplex-virus 
Two types of Herpes-viruses exist in the subfamily Alphaherpesvirinae, type I 
(HSV-1) and II (HSV-2). These double-stranded DNA viruses measure between 
150 and 200 nm in diameter and were first classified in 1962 [93]. Their DNA 
genomes encode a viral core, an icosaedric capsid consisting of 162 
capsomeres, and surrounding tegument proteins that are partially involved in 
important regulatory tasks, such as the transport of viral DNA out of the capsid 
during the early stages of infection [94]. The capsid and tegument proteins are 
enclosed by a lipid membrane, bearing several glycoproteins (gB-gN), these 
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proteins can bind to certain cellular receptors and allow the virus to enter host 
cells. For example, gD binds to nectin-1, a critical receptor for viral entry into 
vaginal mucosal cells [95]. These gylcoproteins are also important because they 
can induce neutralising antibody-responses in infected individuals supporting 
viral clearance [96].  
The genome of HSV-1 is 152 kilo base pairs (kbp) and shows 83% DNA 
homology to the protein coding regions of HSV-2 [97], [98]. The genes of HSV 
can be categorised into immediate early (α), early (β), early late (γ1) and late (γ) 
genes, based on when they are expressed during infection. The α-genes 
encode transcription inducers, the β-genes encode viral enzymes like DNA-
polymerase and γ-genes encode structural proteins [99].  
 
HSV exists in a couple of different life stages. For example, the virus can exist in 
an active stage, called lytic phase, where replication into host cells occurs and 
leads to death of host cells. But the virus can also persist in a latent stage 
without reproduction and host cells are able to survive. In the latent stage, the 
virus persists in the sensory nerve ganglia and clearance by the immune system 
is avoided [100]. Depending on the health status of the host and other factors, 
such as secondary infections, sun-exposure and/or stress reactivation can be 
promoted. Otherwise, the latent stage can be maintained for long periods, since 
herpes- viruses have co-evolved with humans and are well adapted to the 
human immune system [100]. In fact, many viral components are directly 
involved in immune escape, thereby promoting viral persistent infection [101], 
[102], [103]. 
 
Both types of HSV are able to infect either the oral mucosa (preferentially HSV-
1) or the genital mucosa (preferentially HSV-2) of humans [104]. Typically, they 
are transmitted to the host by direct contact, during sexual intercourse or 
through oral/genital contact. Once infected, the virus causes painful blisters at 
the mucosal surfaces and in certain situations can even lead to death (e.g. due 
to encephalitis, neonatal infections are often deadly) [105], [106]. Approximately 
95% of humans suffer from HSV-1 and 30% from HSV-2 infection [1]. In this 
study, the HSV-1 strain LV was used to perform immunisation and challenge 
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studies to assess the comparative efficacy of the i.vag and s.l. routes of 
immunisation, since this virus has the capacity to naturally infect the host via 
these routes. As shown by Manservigi et al., the LV strain is highly pathogenic 
“causing stromal keratitis with neurological involvement, resulting in encephalitis 
and death of animals” [107].  
 
 
 
Figure 3: Structure of the HSV-1 virus. [108] 
 
1.4. Mucosal immunisation routes 
1.4.1. Oral immunisation 
The oral mucosa is an immune-privileged site able to promote tolerance against 
specific ags, which are in continuous contact with the host. Thus, it is in principle 
possible to promote both tolerance and effector adaptive responses following 
immunisation by this route. Therefore, a major challenge for the host immune 
system is to be able to discriminate between self and non-self, as well as 
between harmful and non-harmful non-self-structures. A high amount of non-
harmful ags are ingested or inhaled and the immune system does not respond 
to them. When the host immune system is able to suppress reaction to a foreign 
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body, such as an allergen, this is called tolerance [109]. Both DCs and T-cells 
are involved in tolerance.  
 
Tolerance can be induced by low- or high-dose ag administration, but they 
involve different mechanisms [110]. With low doses of ag, DCs are stimulated 
which induce Tregs. These Tregs express cytotoxic T-cell ag-4 (CTLA-4) and 
cytokines like interleukin-10 (IL-10) or interleukin-6 (IL-6) and promote active 
suppression [111], [110]. High ag dosages are mostly presented by non-
professional APCs, here enterocytes, which are able to present ag without co-
stimulatory molecules like CD80/CD86. This results in the promotion of ag 
specific T-cell anergy or deletion [111].  
 
Oral vaccine formulations require careful consideration due to the strong acidic 
and enzymatic environment at the gastrointestinal tract. If a stable formulation is 
administered via the oral route, the ag is captured and processed by specialised 
microfold (M-) cells located in the Peyer’s patches of the intestine and also by 
DCs (reviewed in [112]). Consequently, T-cells are stimulated to develop a 
protective memory immune response.  
The advantages of oral immunisation include ease of administration and the 
potential to stimulate local and systemic immune responses occurring at the 
small intestine, proximal colon, as well as in the salivary and mammary glands 
[113], [112], [114], [115], [91], [116], [117]. The local production of IgA is often 
important for conferring protective immunity against enteric pathogens [111], 
[112]. However, a major disadvantage of this route is the high amount of ag 
needed, which can increase the incidence of adverse side effects. Another 
concern associated with oral immunisation is the development of chronic 
environmental enteropathy (CEE). This is a condition in which defects in 
digestive tract affect the absorptive properties of the gut, a serious problem 
common in developing countries [81]. Furthermore, the overgrowth of intestinal 
flora and lack of vitamin A and zinc might also contribute to limited efficacy of 
oral vaccines in developing countries. Nevertheless, it is important to highlight 
that there are several examples of successfully implemented oral vaccines. In 
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fact, one of the first vaccines administered by mucosal route was the oral polio 
vaccine, which nearly eradiated polio worldwide.  
Given the above-mentioned concerns associated with oral vaccines, it is 
important to investigate alternative mucosal routes. In this context, it would be 
critical to perform head- to- tail- comparative studies of other routes (e.g. i.n., 
i.vag. and s.l.). Moreover, the compartmentalisation of the mucosal immune 
system makes that cells induced after oral vaccination will not necessarily home 
with equal efficiency to any given mucosal territory. For example, oral 
immunisation results in efficient local responses at the gut and mammary 
glands, but not in vagina [112], [118]. In contrast, protective immune responses 
can be elicited in the genital tract after immunisation by the i.n., i.vag. or s.l. 
route. Therefore, other mucosal routes of vaccination seem to be more 
promising in order to elicit protection against STDs.  
 
1.4.2. Intranasal route 
The i.n. route is of interest since the administered ag dose can be significantly 
reduced compared to oral administration, whereas preserving the easiness of 
administration [119]. The nasal mucosa is in constant contact with respiratory 
particles and offers the first line of defence against inhaled pathogens. It 
contains ciliated membranes and produces mucous that helps to clear foreign 
particles. The nasal lumen is lined by an epithelium containing M-cells, which 
are involved in the uptake of ag. The submucosal tissue underlies the M-cells 
and contains a layer are B-cell follicles and T-cell areas followed by the lamina 
propria [120]. 
 
Immunisation by the i.n. route stimulates humoral and cellular immune 
responses [121]. In murine studies, it has been shown that i.n. vaccination 
induces the NALT [122]. Humans have similar lymphoid follicles enriched 
mucosal area associated to the nose, which can be compared to the NALT 
[123]. In the submucosal tissue, ags are processed and presented to T- and B-
cells, which are then activated [121], [122], [124], [125]. After priming, the ag-
specific T- and B-cells drift from the NALT to the draining cervical lymph nodes 
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(cLN) and begin circulation in the lymphatic system. At this point, they are able 
to home to distant effector sites and exert their effector function [121]. For 
example, ag-specific IgA is produced, which then bind and neutralise the ag 
and/or enable their binding to receptors on phagocytes recognising the 
fragment-crystallisable (Fc) region of the Ig, thereby leading to ag or pathogen 
clearance. After i.n. vaccination, the compartmentalisation of the mucosal 
immune system results in the elicitation of IgA antibody responses in saliva, 
nasal secretions and in airway mucosa, as well as in the genital tract [115], 
[117], [112], [113], [114], [116]. Human studies have supported these finding by 
showing that after nasal vaccination with CTB, CTB-specific IgA can be found in 
the serum, vaginal secretions and the upper respiratory tract [91], [115].  
 
Given these robust and distant immune responses, the i.n. mucosa was long 
considered as a prime target site to induce mucosal immunity. In recent years, 
however, it has been shown that certain adjuvants included into the formulation 
(i.e. bacterial A-B moiety toxins and their derivates) can be redirected to the 
central nervous system (CNS) via retrograde axonal transport and become 
harmful to the host. Murine studies, for example, have shown that CT and CTB, 
when delivered i.n., are redirected to the olfactory epithelium with subsequent 
retrograde transport into the olfactory bulb (OB) of the CNS [126]. Furthermore, 
in 2000 Nasalflu, a very promising inactivated virosomal-subunit vaccine against 
influenza, was formulated into a spray and clinically tested in Switzerland. Like 
most subunit vaccines, an adjuvant was required to elicit protective immune 
responses; in this case Escherichia coli heat-labile toxin (HLT) was used. 
Alarmingly, however, the vaccine was shown to cause reversible Bell’s palsy 
(paralysis of the trigeminal ganglia). This can be explained by different potential 
mechanisms, such as toxicity resulting from the retrograde axonal transport of 
E. coli HLT caused by application via the i.n. route, or mechanic compression of 
the nerve as a result of the ensuing local inflammatory reaction, or inflammatory 
stress resulting in reactivation of persistent viral infection or increased 
susceptibility to infection by neurotropic viruses [127]. Subsequent clinical trials 
with genetically inactivated derivatives of the HLT further confirm the safety 
concerns associated with the use of A-B moiety toxins and/or their derivatives 
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[128]. Since these severe safety problems were discovered, the i.n. route is no 
longer considered a favourable mucosal vaccination route, at least for this class 
of adjuvants. Nevertheless, the immune responses and protective efficacy 
induced after i.n. can also serve as a gold standard when evaluating other 
mucosal routes. 
 
1.4.3. Intravaginal route 
Especially for STDs the delivery to the vaginal mucosa constitutes another 
possible mucosal application route. The i.vag. immunisation in female mice 
elicits mucosal humoral and systemic immune responses. After vaccination ags 
are processed by Langerhans cells and presented to T-cells, which migrate to 
the draining lymph nodes [the iliac lymph nodes (iLN)], where they differentiate 
into effector-T-cells [129]. When ags are co-administered with certain adjuvants, 
protective immune responses can be initiated, including IgA and CTL responses 
[90]. Unfortunately, studies have shown only marginal systemic immune 
responses after immunisation via this route, in contrast to what observed after 
i.n. vaccination [112], [113], [114], [115], [91, 116]. On the other hand, vaginal 
cell composition changes according to the hormonal status. For example, in 
rodents four stages can be distinguished in the oestrus cycle: diestrus, 
prooestrus, oestrus, and metoestrus. In this context, the success of i.vag. 
vaccination seems to depend on which stage of the oestrus cycle is 
implemented, being more efficient in the dioestrus. This can be explained, at 
least in part, by differences in the movement of particles across the epithelium 
according to the oestrus cycle [130]. Movement is most frequent in the 
dioestrus, less frequent in prooestrus and metoestrus, and almost negligible in 
the oestrus. This cycle dependent change in protein movement might be related 
to the change in the predominant cell populations and the thickness of the 
epithelium at the various stages of the oestrus cycle [131].  
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Figure 4: Hormonal changes in the female oestrus cycle in rats [132]. 
Graphical representation of the changes of serum levels of oestrogen (E2) and progesterone 
(P4) during the four stages of the oestrus cycle. 
 
In the figure from Edwards et al., the distribution of serum levels of progesterone 
(P4) and oestrogen (E2) is shown for rats, but the effects are comparable in mice 
[132], [133]. The prooestrus stage is characterised by increasing oestrogen 
levels that peak in this stage and then begin to decline. During prooestrus, the 
number of cell layers in the vagina increases. In vaginal smears, various nucleic 
epithelial cells are detected. The decline of oestrogen corresponds with 
increasing progesterone that peaks at the beginning of ovulation. This marks the 
beginning of the oestrus stage, characterised by proliferation of the basal layer 
resulting in a very thick epithelium and a large number of anucleated cells. The 
luteal phase occurs in metoestrus. Here, the oestrogen concentration in sera 
shows the same basal level as in the oestrus stage and serum concentration of 
progesterone continues to increase. This stage of the cycle is characterised by 
a thinner epithelium, anucleated epithelia cells, invading neutrophils and mucus 
production. Toward the end of dioestrus follicular development starts. Here, the 
serum levels of progesterone are very low, but the oestrogen concentration is 
increasing [132]. During dioestrus the epithelium is the thinnest, cornified 
epithelial cells as well as a high number of neutrophils are present, and mucus 
is produced. It is during this stage of the cycle, dioestrus, that successful 
immunisation can occur.  
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Figure 5: Histological section of vagina, cross section. 
The organ was removed from the genital tract and cryosections of ~10 µm thickness were 
performed. Finally, the section was stained with Diff Quik. In the centre of the picture, the lumen 
(blue) is visible, containing cornified epithelial cells indicating the oestrus stage of the female 
cycle. The morphology of the cells is visible, as well as the presence of mucus in the lumen and 
immune cells, like neutrophils. Merge of pictures, 100x magnification, microscope used: 
Axioplan, Zeiss. 
 
An obvious and probably the most important limitation of the vaginal 
immunisation route is that only females can be vaccinated through this route. 
However, i.vag. immunisation might still represent a valid vaccination route, 
particularly in the prevention of STDs caused by agents like HSV, HIV, 
Chlamydia spp. or HPV [134], [91], [88]. Thus, it is important to identify other 
vaccination strategies able to stimulate a similar response pattern to that 
achieve using the i.vag. route.  
 
1.4.4. Sublingual route 
Until recently, the s.l. route has rarely been investigated in vaccine formulations. 
However, this route is widely accepted for the treatment of allergy disorders 
[135]. A clinical technique used to induce tolerance is sublingual immunotherapy 
(SLIT), which has been of special interest for treating patients with certain 
allergic disorders. SLIT is used to re-develop tolerance to specific allergens. 
This therapy seems to induce Tregs that suppress T-cell responses in the early 
phase of treatment and anergy and clonal deletion of allergen-specific T-cells in 
the late phase of treatment [136]. It also seems that prior to SLIT treatment 
patients have more Th2 than Th1 circulating T-lymphocytes, but SLIT treatment 
also reverses this ratio of Th2 and Th1 in these patients [137], [135]. 
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Furthermore, no anaphylactic shock or other adverse side effects have been 
observed in human studies [138], [139]. Given these findings, the s.l. route 
might be a promising alternative for vaccine administration.  
 
Although s.l. immunisation has similarities to both SLIT and oral immunisation, 
these processes have crucial differences that must be outlined. On the one 
hand, both SLIT and s.l. immunisation are used for delivery of a vaccine 
formulation resulting in the elicitation of protective immune responses. SLIT, 
however, is used for treating certain allergies with the aim of blocking hyper- 
responsiveness and promoting suppression, thereby shifting the existing 
immune response pattern. This is not the case for s.l. immunisation, which is 
aimed at stimulating efficient adaptive immune responses able to protect against 
subsequent challenge. To achieve this aim, the ag should be co-formulated with 
an adjuvant.  
Tolerance induction can be prevented by selecting a correct dosage and time 
schedule. The s.l. immunisation results in the elicitation of high IgA titres locally 
as well as at distant mucosal compartments, like the genital tract [140].  
 
Histologically, the s.l. mucosa consists of keratinised stratified epithelium 
covering a lamina propria composed by capillary vessels, fibroblasts and 
mononuclear cells [141]. The oral mucosa is an immune privileged site with a 
compact immunological network containing local DCs. According to Cuburu et 
al. [119], the s.l. epithelium contains numerous DCs expressing CCR6, CD80, 
CD86 and CD40. These surface markers are similar to those of epidermal 
Langerhans cells. At cellular level, CCR7-CCL19/CCL21-regulated DCs activate 
T- and B-cells [141]. In the steady state, the epithelium and the lamina propria 
bears MHC class II+ and/or CD11b+ cells, which have been shown to increase 
after s.l. immunisation with CT [141]. The squamous stratified epithelium lines 
the oral cavity, which is characterised by a large degree of vascularisation and 
permeability. This in turn facilitates fast ag absorption and direct entry into the 
bloodstream, thereby circumventing the intestine [109], [142], [143], [144], [145].  
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Figure 6: Morphology of sublingual mucosa [138]. 
Longitudinal cut at the length of the tongue (paraffin-embedded) and stained with haematoxylin-
eosin. 
 
The immune response after s.l. immunisation is characterised by the production 
of sIgA at the port of entry of pathogens, namely the oral cavity. Additionally, 
due to the compartmentalisation and the “common mucosal immune system” 
antibody production can also be obtained at distant mucosal sites, such as the 
vagina [146], [118], [147]. The draining lymph nodes for the s.l. immunisation 
route are the cLN, where ag-specific T-cell proliferation occurs after vaccination 
[141]. It has also been reported that in addition to systemic and mucosal 
antibody responses, s.l. immunisation can also induce cytotoxic CD8+ T-cells in 
systemic lymphoid organs after vaccination with OVA + CTB [119]. Functional 
CTL responses have also been observed in the lungs after immunisation via the 
s.l. route [148]. 
 
Vaccination by the s.l. route prevents many of the problems/limitations 
associated with other mucosal routes, therefore arising considerable interest. 
For example, s.l. immunisation does not result in retrograde axonal transport, as 
tested by Song et al., who worked with inactivated and live A/PR/8 virus 
combined with mCTA/LTB, a chimeric adjuvant resulting from an inactive mutant 
of the CT A subunit (E112K) and a pentameric B subunit derived from LT [148]. 
It is important to mention that the receptor for CT, GM-1, is on the surface of 
cells like axons, which in turn promote the redirection to the CNS [149], [150]. 
Furthermore, vaccines delivered through this route are not transported across 
the intestine or liver. Therefore, it is of special interest in the vaccination against 
infectious diseases because the administered ag is well tolerated and enters 
directly into the blood stream [142], [143], [144], [145]. Taken together, s.l. 
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vaccination appears as a very promising vaccination route to elicit efficient 
protection after mucosal immunisation. 
 
1.5. Role of interleukin-17 in mucosal immune responses  
Park et al. were the first to describe the Th17 lineage as a T-helper line distinct 
from Th1 or Th2 cells, which is characterised by IL-17 production. Furthermore, 
Th17 cell development is independent of cytokines and transcription factors 
which normally regulate Th1/Th2 cells [151]. However, IL-17 was first 
characterised in 2005 by Harrington et al., who found that IL-23 induces IL-17 
secreting CD4+ T-cells [152]. Th17 cells are the primary producers of IL-17, but 
they are not the only cells [153]. The cytokines IL-17A and IL-17F are produced 
by various cell types, such as CD4+ T-cells, CD8+ T-cells, Th17 cells, NKT-cells, 
natural killer (NK)-cells, neutrophils, lymphoid-tissue inducer (LTI)-cells and γδ 
T-cells [154], [155]. The receptor for IL-17A and IL-17F is IL-17 RA, which is 
predominantly expressed on hematopoietic cells, endothelial cells, epithelial 
cells, fibroblasts and osteoblasts [156], [157], [158]. After stimulation of IL-17 
RA, these cells begin to produce granulocyte macrophage colony-stimulating 
factor (GM-CSF), IL-6, IL-8 and mediate granulopoiesis [159]. Th17 cells need 
three to five days to become induced, NK-cells produce IL-17 after several 
hours [160]. IL-17 is therefore able to link the innate and adaptive immune 
responses. IL-17 has pro-inflammatory properties and can act in immunity 
against extracellular pathogens, some intracellular pathogens and fungi [161], 
[162]. For example, in mice IL-17 can promote B-cell isotype class switching 
from IgG to IgG2a and IgG3, which further supports B-cell differentiation [163]. 
IL-17 also stimulates recruitment of neutrophils to the site of inflammation [159]. 
In humans, IL-17 leads to secretion of IL-6, IL-8 and granulocyte colony-
stimulating factor (G-CSF) in epithelial, endothelial and fibroblastic cells [164]. 
For example, during early infection (4-8 hours), IL-17 secretion is activated in 
cells from the innate immune system [160]. Generally, Th17 cells are 
characterised by expression of CD4 and they bear the transcription factor RAR-
related orphan receptor gamma (ROR-γt). Ivanov et al. described the orphan 
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nuclear receptor ROR-γt as the transcription factor for development of Th17 
cells from naїve precursor T-cells, which is encoded by the gene RAR-related 
orphan receptor C (RORC) [165]. The transcription factor RORα has a 
synergistic relationship, being also required for Th17 differentiation [166], [167]. 
ROR-γt transcribes the IL-17-encoding genes and RORα further supports Th17 
differentiation by promoting IL-17 expression on Th17 cells. The transcription 
factor RORα is controlled in a signal transducer and activator of transcription 
protein 3 (STAT-3)- dependent manner [168], [165], [167], [167]. STAT-3 is a 
protein regulating T-helper cell differentiation, its activation is necessary for 
induction of ROR-γt [159]. The anti-inflammatory cytokine transcription-growth-
factor-β (TGF-β) and IL-6 are responsible for successful stimulation of naïve T-
cells leading to Th-17 development by induction of ROR-γt expression and it 
also controls IL-17 gene expression [169], [170], [166]. In the absence of IL-6, 
the cytokine IL-21 (secreted by NK- and NKT- cells) can replace IL-6 in Th17 
development, i.e. IL-21 together with TGF-β is able to activate ROR-γt in cells 
that differentiate into Th17 cells [171]. IL-23, which is secreted by various APCs, 
supports Th17 lineage commitment and promotes further IL-17 secretion [166]. 
The receptor for IL-23, IL-23R, is only expressed by activated or memory CD4+ 
T-cells.  
 
Tregs are the antagonists of Th17 cells and keep the balance of the immune 
system. They are phenotypically characterised by CD4+ and CD25+ expression 
and the transcription factor forkhead-box-protein 3 (FoxP3). Tregs play a role in 
self-tolerance, autoimmunity and dampening immune responses [172]. Similar 
to Th17 cells, the differentiation of naïve T cells into Tregs depends on the 
presence of TGF-β. However, the main difference is that Treg differentiation is 
independent of the cytokine IL-6. In the initial stages of immune response, 
immune cells begin to secrete IL-6. This shifts the development of naïve T cells 
to Th17 cells in order to combat the infection. In the later phase, the production 
of IL-17 is reduced, thereby facilitating the differentiation of Tregs.  
These cells are also stimulated to differentiate after TGF-β contact, but only in 
the absence to IL-6. In the presence of IL-6 naïve T cells develop into Th17, 
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whereas in the absence of IL-6 naïve T cells develop into Tregs [173]. Bettelli et 
al. describes this as the reciprocal relationship of Th17 cells and Tregs [173]. 
 
The main role of Th17 cells is the clearance of pathogens, particularly in regards 
to pathogens resistant to the effector functions of Th1/Th2 cells [159]. Th17 are 
able to induce potent inflammation responses via secretion of cytokines like IL-
17 and IL-22. For example, IL-22 acting together with IL-17 (A or F) can induce 
antimicrobial peptides like β-defensins or several S100A proteins [174]. IL-22 
production by Th17 cells can be enhanced by IL-23. Liang et al. showed that 
these cytokines (IL-22 and IL-17A, F) are involved in gene regulation associated 
with the innate immunity of the skin [174]. IL-17A is also involved in host 
defence against Candida albicans infection [175]. This response is mainly 
mediated by neutrophil recruitment and by the antimicrobial peptides stimulated 
by IL-17 [176]. It has been shown that IL-17 also stimulates protective properties 
during lung infection, as it has been demonstrated in a murine model for 
Klebsiella pneumoniae infection [177]. Here, IL-17 contributes in enhancing 
secretion of G-CSF and chemokine production, resulting in improved clearance. 
The pro-inflammatory cytokine IL-17 also plays important roles in mucosal 
immune responses. It is known that it has an influence on providing defence 
through innate immune cells until adaptive immune cells are able to control 
infection [178]. In fact, previous studies indicate that IL-17 is involved in 
protection against extracellular bacterial infections (e.g. in the lung) by recruiting 
neutrophils and chemokines to the target site [179], [177]. 
Furthermore, IL-17 seemed also to play a role in HSV infection by promoting Th-
responses. Studies performed in a HSV-1 mouse corneal infection model it was 
observed high local amounts of IL-17 24 hours post-infection [180]. The main-
producers were γδ T-cells, being the effect transient. Interestingly, interferon-γ-
knockout (IFN-γ–KO) mice showed elevated IL-17 production and a faster rate 
of corneal opacity [180]. A likely explanation is that IFN-γ regulates the 
production of IL-17 in an inhibitory manner due to suppression of IL-23 [152]. 
Mouse corneal fibroblasts express IL-17R on their surface, which when 
stimulated by IL-17 induces the production of chemokines, such as IL-6 and 
 Introduction 
 
 
44 
 
macrophage-inflammatory protein 2 (MIP-2), thereby leading to an influx of 
neutrophils [180]. 
 
Additionally, IL-17 is often associated with autoimmune diseases like 
rheumatoid arthritis (RA) or inflammatory bowel disease (IBD) [181]. Patients 
suffering from RA show increased IL-17A levels in sera and synovial fluids 
[182], [183]. This in turn leads to increased neutrophil recruitment and increases 
inflammation by stimulating the secretion of pro-inflammatory cytokines [181]. In 
IBD increased amounts of IL-17 are also detected, though the mechanism is not 
completely understood [184].  
1.6. Aim of the thesis 
The major aim of this thesis was to investigate the potential of s.l. vaccination as 
alternative approach to the well described i.n. immunisation strategy to promote 
local and systemic immune responses, as well as protection at local and distant 
mucosal sites. In this context, IL-17 as well as Th17 cells seems to play a 
crucial role in mucosal host defence. However, little is known about these 
effectors and their function in the genital tract. Thus, a secondary aim was to 
asses the role of IL-17/Th-17 in protective immunity to vaginal infections.  
 
To this end, it was performed a head-to-head comparison of the immune 
responses stimulated following i.n., i.vag. and s.l. vaccination using different ags 
and adjuvants, as well as challenge studies using HSV as a mouse 
experimental infection model. By selecting the appropriate adjuvants, a strong 
humoral and cellular immune response can be induced. Vaccination via i.n. 
route using the potent adjuvant c-di-AMP stimulates mixed Th1/Th2/Th17 
humoral and cellular response, which seems to be inefficient in order to protect 
mice against HSV infection. However, responses can be tailored by using 
adjuvants which optimise the required responses according to the route of 
application. In this context, co-administration of α-GalCerMPEG allowed to tailor 
IL-17 responses following s.l. vaccination, thereby promoting protection against 
i.vag. challenge with HSV-1. The obtained results demonstrated that s.l. 
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vaccination in combination with the appropriate adjuvant is very promising 
approach to promote the elicitation of protective immunity. 
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2. Material 
2.1. Chemicals and reagents 
2.1.1. General 
 
2-Mercaptoethanol (50 mM) Gibco, Invitrogen GmbH, Darmstadt, 
Germany 
2,2’-azino-bis (3-ethylbenzthiazoline-6-
sulfonic) (ABTS) 
Sigma Aldrich, Chemie GmbH, 
Steinheim, Germany 
Albumine fraction V, 200 g (BSA) Carl Roth GmbH, Karslruhe, Germany 
Brefeldin A Sigma Aldrich, Chemie GmbH, 
Steinheim, Germany 
Citric acid 0.1 M (21 g added to 1l aqua dest) 
Collagenase D (from Chlostridium 
histolyticum) 
100 mg, Cat. No: 11088858001, 
Roche Diagnostics GmbH, Penzberg, 
Germany  
Concanavalin A (ConA) Sigma Aldrich, Chemie GmbH, 
Steinheim, Germany 
Dimethyl sulfoxide (DMSO) 100 ml, Euroclone, Euroclone S.p.A. 
Life Science Division, Pero, Italy 
Dispase II (from Bacillus polymyxa) Roche Diagnostics GmbH, Penzberg, 
Germany 
DNase I 100 mg, Cat. No: 11284932001, 
Roche Diagnostics GmbH, Penzberg, 
Germany 
Ethylendiamintetraacetat (EDTA) Fluka, Switzerland 
Foetal calf serum (FCS) Greiner Bio-One, USA 
L-Glutamine Gibco, Invitrogen GmbH, Darmstadt, 
Germany 
Paraformaldehyde Merck, Germany 
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Penicillin /Streptomycin Gibco, Invitrogen GmbH, Darmstadt, 
Germany 
Phenylmethanesulfony fluoride 
(PMSF) 
Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
Saponin Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
Trypsin-EDTA 100 ml, PAA, The cell culture 
company, PAA Laboratories GmbH, 
Pasching, Austria 
 
2.1.2. Enzyme-linked immunosorbant assay (ELISA) 
2,2’-azino-bis (3-ethylbenzthiazoline-6-
sulfonic) (ABTS) 
Sigma Aldrich Chemie GmbH, 
Seinheim, Germany; 
for stock preparation: 300 mg ABTS 
added to 1 l citric acid [0.1 M], pH= 
4.35 
ABTS working solution ABTS (stock) + H202 (30%) 
(1:1000 v/v) 
Blocking solution PBS + 3% BSA 
Carbonate buffer 1.59 g/l Na2CO3; 2.93 g/l NaHCO3; pH 
9.6 
Coating with antigen 2 µg/ml antigen (OVA or β-Gal) in 
carbonate buffer 
Detection antibody IgG 1 biotin conjugated, Cat. No: 1072-
08, Southern Biotech, USA; used 
dilution 1:5000 
 IgG 2a biotin conjugated, Cat. No: 
1082-08, Southern Biotech; used 
dilution 1:10.000 
 IgG 2b biotin conjugated, Cat. No: 
1092-08, Southern Biotech, USA; used 
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dilution 1:10.000 
 IgG 3 biotin conjugated, Cat. No: 1102-
08, Southern Biotech USA; used 
dilution 1:5000 
 IgA biotin conjugated, Cat. No: 1040-
08 Southern Biotech USA; used 
dilution 1:5000 
 IgM biotin conjugate, Cat. No: B-9265, 
Sigma Aldrich; used dilution 1:5000 
Hydrogen peroxide, 30% Fluka, Switzerland 
Standard curve and total IgA coating 
IgA 
Anti-mouse IgA (2 µg/ml working 
solution in carbonate buffer), Cat. No: 
M-8769, Sigma Aldrich Chemie GmbH; 
Steinheim, Germany 
Standard curve IgA Standard mouse IgA, kappa, Cat. No: 
M-1412, Sigma, beginning with 0.2 
µg/ml in PBS + 3% BSA 
Streptavidin-horseradish peroxidase 
(HRP) 
Cat. No: 554060, BD Pharmingen, 
USA, 1:1000 in PBS + 0.1% Tween 20 
+ 1% BSA 
ELISA plate, Microlon 96 well, flat 
bottomed, high binding 
Greiner bio one, Frickenhausen, 
Germany 
PS-coverplate for microplate Greiner bio one, Frickenhausen, 
Germany 
Tween 20  Greiner bio one, Frickenhausen, 
Germany 
 
2.1.3. Enzyme-linked immune spot technique (ELISPOT) 
Acetate solution (0.1 mM) 148 ml of 0.2 mM acetic acid to 352 ml 
of 0.2 mM sodium acetate; adjust 
volume to 1 l with water; pH 5.0 
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3-amino-9-ethylcarbozole (AEC)  For stock solution: 150 mg AEC +  
10 ml DMF 
Blocking solution Royal Park Memorial Institute (RPMI) 
complete 
Capture antibody IFN-γ (Cat. No: 51-2525KZ) 
IL-2 (Cat. No: 51-1816KZ) 
IL-4 (Cat. No: 51-1819KZ), all BD 
Biosciences 
IL-17 A (Cat. No: 16-7175-68), 
ebioscience 
Coating buffer 1x PBS 
Detection antibody IFN-γ (Cat. No: 51-1818KA) 
IL-2 (Cat. No: 51-1817KZ) 
IL-4 (Cat. No: 51-1804KZ), all BD 
Biosciences 
IL-17 A (Cat. No: 13-7177-68), 
ebioscience 
Di-methylformamide (DMF) Sigma-Aldrich, Chemie GmbH, 
Steinheim, Germany 
Hydrogen peroxide, 30% Fluka, Switzerland 
MultiScreen HTS filter plates, 96 well Millipore, USA 
Substrate solution 333.3 ml AEC stock solution + 10 ml 
0.1M Acetat solution, sterile filtrated, 5 
µl H202 (30%) are added immediately 
before use.  
Streptavidin-HRP BD Biosciences Pharmingen, USA 
Wash buffer I 1 x PBS containing 0.05% Tween 20 
Wash buffer II 1 x PBS 
Wash buffer III 1 x PBS + 10% FCS 
 
  
Material 
 
 
50 
 
2.1.4. Proliferation 
[methyl-3H]thymidine solution (5.0 
Ci/mmo 
Amersham, Germany 
Plate paper Perkin Elmer, USA 
Melt-on scintillation wax, Meltilex A  Wallac, Finland 
Cassette Filtermat Perkin Elmer, USA 
Filter cell harvester, Filtermat A PerkinElmer, USA 
 
2.2. Media and buffer 
 
2.2.1. General 
 
Ammonium chloride-potassium 
hydrogen carbonate (ACK)-buffer 
155 mM NH4CL 8.3 g/l (1 M= 53.49 
g/l) 
10 mM KHCO3     1 g/l (1 M= 100.1 g/l) 
1 mM ETDA   0.37 g/l (1 M 372.2 4 g/l) 
add 1l aqua dest. 
pH 7.3 with 1 M NaOH 
autoclave or sterile filtrate 
Ampuwa, 1000 ml Fresenius Kabi, Bad Homburg, 
Germany 
Coulter®Isoton® II Dilutent Beckman Coulter 
Dulbecco’s modified eagle medium 
(DMEM) 
Cat. No: 419657039, Gibco /Invitrogen 
GmbH, Darmstadt, Germany 
Freezing media FCS + 10% DMSO 
Ficoll Lympholyte®- M Cedarlane, USA 
MilliQ water filter Millipore, Germany 
Phosphate buffered saline (PBS) Dulbeccos, 1x /10x, PAA, Pasching, 
Austria 
PBS/BSA 1x PBS + 3% BSA 
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PBS/FCS (Lavage buffer) 1x PBS + 5% FCS 
PBS + paraformaldehyde (PFA)  1x PBS + 2% PFA 
Permeabilisation buffer 1 x PBS + 0.5% BSA + 0.5% Saponin 
RPMI 1640, with L-Glutamine Cat. No: E15-840, PAA, Pasching, 
Austria; also used: Cat. No: 31870, 
Gibco Invitrogen; 
L-glutamin, penicilline/streptomycine 
and 10% FCS are added; called then 
RPMI complete 
 
2.3. FACS-analysis 
2.3.1. Antibodies against murine antigens 
Carboxyfluorescein diacetate 
succinimidyl ester (CFDA-SE) 
Carboxyfluorescein diacetate 
succinimidyl ester, stock: 10 mM in 
DMSO, Invitrogen, Darmstadt, 
Germany 
Fc-Block Purified rat anti-mouse CD16/CD32, 
0.5 mg/ml, Cat. No: 553142, BD 
Biosciences, USA 
CD3 Clone: 145-2C11, BD Biosciences, 
USA 
CD4 Clone: L3T4, RM4-5, BD Biosciences, 
USA 
CD8 Clone: 53-6.7, BD Biosciences, USA 
 
2.3.2. Reagents and chemicals/-iterative chip based cytometry 
(ICBC) chips.. 
Histofix Carl Roth, Karlsruhe, Germany 
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Axioimager M1, motorised Carl Zeiss, Goettingen, Germany 
Permeabilisation buffer Ebioscience, USA 
Cell adhesive microfluidic chips Special preparation technique by Dr 
Christian Hennig, Department of 
Pneumology, Allergy and Neonatology, 
Hannover Medical School, Germany 
Parafilm Laboratory film, American National 
Can™, Neenah, USA 
Glass slides for sections 18 x 18 mm, Menzel-glasses, Menzel 
GmbH & Co KG, Braunschweig, 
Germany 
CD4 Clone: RM4-5, BD Biosciences, USA 
CD8a Clone: Ly-2, BD Biosciences, USA 
CD11b Clone: M1/70, BD Biosciences, USA 
CD11c Clone: HL3, BD Biosciences, USA 
CD19 Clone: 1D3, BD Biosciences, USA 
CD45 Clone: (LCA Ly5) (30-F11), BD 
Biosciences, USA 
TCR-γδ Clone: GL3, BD Biosciences, USA 
F4/80 Clone: BM8, BD Biosciences, USA 
FoxP3 Clone: FJK-16F, BD Biosciences, USA 
Gr-1 Clone: LyC/G RB6-8C5, BD 
Biosciences, USA 
IL-17 EBIO17B7, ebiosciences, USA 
RORγt/RORC2/NR1F3 Clone: 600380, R&D Systems, USA 
 
2.3.3. Histological staining 
Diff-Quik staining kit Cat. No: 130832, Medion Diagnostics, 
Duedingen, Switzerland 
Giemsa Fluka, Switzerland 
May-Grünwald Merck, Darmstadt, Germany 
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2.3.4. Kits 
HEK-BLUETM LPS Detection Kit InvivoGen, USA 
Mouse Th1/Th2 10 plex FLOW 
Cytokine kit 
Bender Med Systems, USA 
2.4. Antigens and peptides 
β-D-Galactosidase galactohydrolase from Escherichia coli, Roche 
Diagnostics GmbH, Mannheim, 
Germany 
β-Gal peptide Synthesised by Dr Tegge, Helmholtz-
Zentrum für Infektionsforschung, 
Braunschweig, Germany 
OVA Endograde, lypophylised, Hyglos, 
Bernried am Starnberger See, 
Germany 
OVA peptide Synthesised by Dr Tegge, Helmholtz-
Zentrum für Infektionsforschung, 
Braunschweig, Germany 
 
2.5. Adjuvants 
α-Galactosylceramide MPEG Synthesised at Helmholtz-Zentrum für 
Infektionsforschung, Braunschweig, 
Germany 
BPPcysMPEG Synthesised at Helmholtz-Zentrum für 
Infektionsforschung, Braunschweig, 
Germany 
c-di-AMP Synthesised at Helmholtz-Zentrum für 
Infektionsforschung, Braunschweig, 
Germany 
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CTB CTB subunit from Vibrio cholerae, Cat. 
No: C9903-1MG, Sigma-Aldrich 
Lipopolysaccharide from E.coli E. coli 026:B6, L2651-1MG, 
107K4046, Sigma-Aldrich 
 
2.6. Cell lines 
Vero cells are a cell line were originally isolated from kidneys of green monkeys 
[185]. 
 
2.7. Virus 
The Herpes simplex virus 1 strains LV (large variant) LacZ and LV wild type 
were obtained from our cooperation partner, Dr Peggy Marconi, University of 
Ferrara, Italy. The LV wild type is a HSV-1 strain Kos without mutations and was 
originally isolated of a patient [186]. The LVLacZ is strain LV with lacZ 
integrated into the unique long (UL) 41 that codify for virion-host shut off protein 
(VHS), this gene is consequently interrupted. Also the stains 
17SynIGR20HE/gJZ and 17SynIGR20Luc were provided from the cooperation 
partner. The 17SynIGR20HE/gJZ is a HSV-1 strain 17 with luciferase into the 
intergenetic region 20 (IGR20) and green fluorescent protein (GFP) into unique 
short 5 sequence locus (Us5) that codify for glycoprotein J. The 
17SynIGR20Luc has luciferase into IGR20.  
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2.7.1. Stock preparation reagents 
Solutions:  
Optiprep™ Cat. No: 1030061, Axis-Shield, 
Heidelberg, Germany 
Solution B 2.8 ml 5 M NaCl; 6 ml HEPES 1 M, pH 
7; 1.2 ml EDTA 0.5 M, pH 8.0; bring to 
100 ml and sterile filtrate, keep at 4°C 
Solution C 2.8 ml 5 M NaCl; 1 ml HEPES 1 M, pH 
7; 200 µl EDTA 0.5 M, pH 8.0; bring to 
100 ml and sterile filtrate, keep at 4°C 
Solution D 5 volume Optiprep + 1 volume solution 
B; fresh preparation before use 
Solution E Virus (4 ml) + solution C, total 4.8 ml 
Solution F Top-up solution; 1.27 ml solution C + 1 
ml solution D. Equals the final 
concentration of 22% Optiprep that the 
gradient will have; fresh preparation 
before use 
(4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
(Hepes)  
Sigma-Aldrich, Chemie GmbH, 
Steinheim, Germany 
NaCl Merck, Darmstadt, Germany 
EDTA Sigma-Aldrich, Chemie GmbH, 
Steinheim, Germany 
 
2.7.2. Material and instruments for virus stock preparation 
Cell scraper 30 cm  TPP, Switzerland 
Centrifugation tubes Oak Ridge tubes; Nalgene, USA 
Ultracentrifugation tubes  Cat. No: 344059, Beckman Coulter, 
USA 
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Crystal violet-methanol crystal violet, Serva, Heidelberg, 
Germany; solution was used as: 5% 
crystal violet in 100% ethanol + 25ml 
H2O + 25 ml methanol 
Methanol Sigma-Aldrich, Chemie GmbH, 
Steinheim, Germany  
Carboxymethylcellulose Sigma-Aldrich, Chemie GmbH, 
Steinheim, Germany Germany 
Rotor SS34, T875, Th-641 Sorvall; Thermo Scientific 
Ultracentrifuge OTD combi Sorvall; Thermo Scientific 
 
2.8. Mice 
The female BALB/c H-2d and C57BL/6 H-2b mice, 6-8 weeks of age, were 
purchased from Harlan (Harlan-Winkelmann GmbH, Horst, Netherlands). The 
mice were housed under specific pathogen free (SPF)-conditions and according 
to local and European community guidelines. The permission numbers for 
animal experiments are 33.42502-084/06 and 33.11.42502-04-017/08/2007. A 
maximum of five mice were kept in each cage with water and food ad libitum. 
Also BALB/c from the company Janvier were used and kept as described for 
BALB/c mice from Harlan.  
 
C57BL/6J-IL-17a IL17ftm1Prnz knock-out-mice on C57BL/6 background were 
kindly provided by PD Dr Immo Prinz, Institute for Immunology, Hannover 
Medical School. These mice are not able to produce IL17A and IL17F. 
The mice were then breed in the animal facility of the Helmholtz-Zentrum für 
Infektionsforschung, Braunschweig. 
 
OT II transgenic mice were bred and maintained at the animal facility of the HZI, 
Braunschweig. They have a transgenic TCR on CD4+ T cells recognising OVA-
peptide (323-339) [187].  
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2.9. Chemicals 
2.9.1. Chemicals for murine application 
Depo-Clinovir Depo-Clinovir, 150 mg, 
medroxyprogesteronacetat (pregn-4-
ene-3,20- 
dione, 17-(acetyloxy)-6-methyl-, (6α-)), 
1 single-use syringe to 1 ml, N3, sterile 
aqueous suspension for intramusculary 
injection, PHARMACIA GmbH a 
company of the Pfizer-Gruppe, 
Karlsruhe, Germany 
Isofluorane Baxter Deutschland GmbH; 
Unterschleißheim, Germany 
Ketamine Ketamin Inresa, 50 mg/ml injection 
solution, 10 ml, Inresa Arzneimittelwerk 
GmbH, Freiburg, Germany 
Ketamine/Rompun Used for i.p. application as: 1 ml 
Ketamine + 0.5 ml Rompun + 8.5 ml 
NaCl, 100 µl working solution per 10 
mg bodyweight 
Pilocarpine hydrochloride Sigma-Aldrich, Chemie GmbH, 
Steinheim, Germany, used at a 
concentration of 500 µg/kg mouse; 100 
µl/mouse were injected i.p. 
Rompun 2% injection solution Xylazin (as 
Xylazinhydrochloride), 25 ml, Bayer 
Health Care, Bayer Vital Gmbh 
Geschäftsbereich Tiergesundheit, 
Leverkusen, Germany 
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2.10. Consumables 
15 ml Cellstar® tubes Greiner bio-one, Frickenhausen, 
Germany 
50 ml Cellstar® tubes Greiner bio-one, Frickenhausen, 
Germany 
6-well flat bottomed plates TPP, Switzerland 
96-well flat bottomed plates TPP, Switzerland 
96-well round bottomed plates TPP, Switzerland 
Buttoned cannula Laboratory equipment 
Cell strainer 100 µm Nylon BD Falcon BD Bioscience, USA 
Combitips, 2.5 ml, 5 ml, 10 ml Eppendorf, Germany 
Container for cryo-cooling Nalgene® Mr.Frosty™ Cryo 1°C 
Freezing Container, USA 
Cotton swab For taking vaginal smears; Cat. No: 
1032648, Heinz Herenz, 
Medizinalbedarf GmbH, Hamburg, 
Germany 
CryoTubeTM Vials 1.8 ml Nunc, Denmark 
Cytobrush medex Medesign I.C. GmbH, Dietramszell, 
Germany 
FACS-PE 5 ml tubes BD Biosciences, USA 
Glass slide Menzel-Gläser, Super-Frost, 
geschliffen, 76x26 mm, Menzel GmbH 
& Co KG, Braunschweig, Germany (for 
smears) 
Injection needle 1ml 30G x ½” Omnican F, B Braun, Melsungen, 
Germany 
Injection needle 1 ml, 5 ml, 10 ml B Braun, Melsungen, Germany 
Micro haematocrit tubes for sera 
collection, 75 µl 
Brand GmbH+ Co. KG, Wertheim, 
Germany 
Multistepper Matrix Thermo Scientific, Karlsruhe, Germany 
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Parafilm Laboratory film, American National 
Can™, Neenah, USA 
Pasteur pipettes (glass) Brand GmbH + Co. KG, Wertheim, 
Germany 
Petri dishes Greiner bio-one, Frickenhausen, 
Germany 
Pipet tips 200 µl Easy load, Greiner bio-one, 
Frickenhausen, Germany 
Pipet tips 10 µl, 100 µl, 200 µl, 1000 µl Thermo Scientific, Karlsruhe, Germany 
Pipettes Eppendorf Eppendorf, Hamburg, Germany 
Pipettes Fintip Thermo Scientific, Karlsruhe, Germany 
Plastic pipettes, 5 ml, 10 ml, 25 ml Serological pipette, Roth, Karlsruhe, 
Germany 
Safe lock reaction tube 0.5 ml, 1 ml,  
2 ml 
Eppendorf, Hamburg, Germany 
Scissors Aesculap, B Braun, Melsungen, 
Germany 
Serological pipette Roth, Karlsruhe, Germany 
Syringe for lung lavage Winged needle infusion, 18G/ 1 ¾ “ 
Interocan, Luer Lock, B Braun, 
Melsungen, Germany 
Syringe for spleen 2 ml Luer Solo, Inject®, B Braun, 
Melsungen, Germany 
Tissue culture flask 75 cm2, 150 cm2 TPP, Switzerland 
Cytobrush medex Medesign I.C. GmbH, Dietramszell, 
Germany 
 
2.11. Instruments 
Biostack Bio-Tek, BioTek Laboratories GmbH, 
Bad Friedrichshall, Germany 
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Cell counter Z2 Coulter Particle Count 
and Size analyser 
Beckman Coulter, USA 
Ultracentrifuge OTD combi Sorvall 
Centrifuge Biofuge pico Heraeus Instruments, Osterode, 
Germany 
Centrifuge Megafuge R 40 Heraeus Instruments, Osterode, 
Germany 
Centrifuge Multifuge 3 S-r Heraeus Instruments, Osterode, 
Germany 
Cryotom Rotation microtom, Thermo Scientific 
CTL Immunospot® analyser CTL-Europe GmbH 
ELISA Reader Synergy 2, Bio-Tek, BioTek 
Laboratories GmbH, Bad 
Friedrichshall, Germany 
ELISPOT Reader, ImmunoSpot, 
Series 3A 
Cellular Technology Ldt., USA 
Flow Cytometer FACSCanto BD Biosciences, USA 
Freezer -20°C, Liebherr 
Freezer -80°C, Thermo Scientific Karlsruhe, 
Germany 
Fridge 4°C, Liebherr 
Cell harvester, ICH-110 INOTECH, Switzerland 
Handystep Brand, Germany 
Heating stirrer IKA Labortechnik, Braunschweiger 
Laborbedarf 
Incubator Heraeus Instruments, Osterode, 
Germany 
Micropipettor Hirschmann Laborgeräte GmbH & Co. 
KG, Eberstadt, Germany 
Microscope, Axioplan + Axiocam Zeiss, Jena, Germany 
Microscope Axioimager M1 Zeiss, Jena, Germany 
Microscope Motic AE 20 Motic Instruments, Germany 
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Microscope Nicon Eclipse E200 Nicon, Duesseldorf, Germany 
Microwave Sharp, Germany 
pH-meter Hannah Instruments Deutschland 
GmbH, Kehl am Rhein, Germany 
Pipetboy Thermo Scientific, Karlsruhe, Germany 
Plate pipetting system Precision 2000, 96/384 well automated 
microplate pipetting system, Bio-Tek, 
BioTek Laboratories GmbH, Bad 
Friedrichshall, Germany 
Plate washer ELx 405, Bio-Tek, BioTek Laboratories 
GmbH, Bad Friedrichshall, Germany 
Scale TE 1502S Satorius, Goettingen, Germany 
Scintillation Counter Wallac 1450 
MicroBeta TriLux 
PerkinElmer, Finland 
Shaker Janke & Kunkel, IKA Labbortechnik, 
Staufen, Germany 
Sonicator Elmasonic one, 35kHz, Elma GmbH & 
Co. KG, Singen, Germany 
Sterile hood Hera Safe Thermo Scientific, Karlsruhe, 
Deutschland 
Vortex Vortex Genie-2, Scientific Industries, 
Omnilab 
Water bath Köttermann, Braunschweiger 
Laborbedarf, Braunschweig, Germany 
2.12. Software 
CellhopperX, IR-engine 3.1 Software of Dr. Christian Hennig, 
Hannover Medical School, Germany 
FACSDIVA Becton Dickinson, USA 
Endnote X4 EndNote X4, Thomson Reuters 
FlowCytomix Pro software Bender MedSystems, Vienna, Austria 
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Gen5 version 1.06 
 
Bio-Tek Instruments, Inc., Bad 
Friedrichshall, Germany 
Graph Pad Prism version 5.04 Prism 5 for Windows, Version 5.04, 
GraphPad Software, Inc., La Jolla, 
USA 
ImmunoSpot image analyzer v3.2 Bio-Tek Instruments, Inc., Bad 
Friedrichshall, Germany 
Multi32 Coulter Z2 Accu Comp Version 
3.01, 2000 
Beckman-Coulter, USA 
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3. Methods 
3.1. Methods for cell culture/in vitro experiments 
3.1.1. Isolation of mouse vaginal immune cells 
First, mice were killed by either CO2 asphyxiation or cervical dislocation. Then, 
with the mouse on its back and using a tiny pair of scissors, deep vertical cuts 
were made around the vagina. The vagina was then removed by pulling with 
rounded tweezers. It was important that the uterus was visible, thereby 
indicating that the vagina had been completely removed. The organ was then 
placed in a 1.5 ml Eppendorf tube containing 500 µl of dispase (4 mg/ml) in PBS 
and incubated for one hour at 37°C. The organ was then cut into 0.5-2 mm 
fragments using scissors and incubated in 1 ml of a solution containing DNAse I 
(30 µg/ml), collagenase D (0.425 mg/ml), and dispase (4 mg/ml) in PBS for 45 
minutes, shaking at 300 rounds per minute (rpm). After incubation, the digested 
organ was pushed through a 100 µm mesh screen and into a 50 ml reaction 
tube containing 10 ml RPMI complete (containing additives, see 2.2.1), which 
was then centrifuged for eight minutes at 314 g. The supernatant was further 
discarded and the cells were washed a second time in 1 ml PBS. The final pellet 
was ready for analysis (e.g. FACS staining or Cytospot). 
 
3.1.2. Determination of cell number and vitality test 
Cell number was determined by an automated cell counter (BC). First, a 
counting cuvette was filled with 10 ml Coulter®Isoton® II Dilutent, then 10 µl of 
cells were added (~1:1000 dilution). Before analysis, the cuvette was carefully 
inverted three times and the counting parameters were entered into the 
system’s software (dilution factor, cell size). After counting, a histogram of 
counted cells appears.  
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From the histogram, cell number was determined by gating based on its size, 
which excludes cell debris from the cell count. Cell vitality could be further 
determined using trypan blue. For this, a Neubauer cell chamber was used and 
a cell solution containing 10 µl (10 µl cell solution + 10 µl of trypan blue) was 
added to the chamber. Trypan blue is an acidic staining substance and its anion 
is binding to cell proteins. It can only enter through destroyed membranes and 
therefore only dead cells become blue. The percentage of dead cells is 
determined by counting the number of dead cells per 100 cells.  
 
3.1.3. Lysis, freezing, and thawing of cells 
Erythrocytes (e.g. spleen erythrocytes) in samples were lysed by adding 3 ml of 
ACK-buffer and pipetting up and down with a 5 ml pipette constantly for one 
minute. During lysis, the solution changed from dark red to cherry-red. Lysis 
was stopped by adding 30 ml RPMI complete and centrifuging at 4°C for ten 
minutes at 314 g. The supernatant was then discarded and the cells were 
washed a second time in 10 ml PBS. The final pellet was then ready to be 
counted or frozen. 
 
To freeze the cells, the pellets were resuspended in 900 µl of FCS with 20% 
DMSO and placed in cryo vials. The vials were then placed in special 1°C 
freezing containers, Nalgene® Mr.Frosty™ Cryo 1°C, which were stored at        
-80°C for 24-48 hours. After 24-48 hours, the vials were placed in liquid nitrogen 
(-196°C) and stored until processing.  
 
To thaw the cells, the vials were first removed from liquid nitrogen and briefly 
placed on ice. They were then rapidly thawed by gentle agitation in a 37°C 
water bath. Once thawed, the toxic DMSO was quickly removed by washing the 
cells with 5 ml of RPMI complete and centrifugation for five minutes at 314 g, 
4°C. The DMSO containing supernatant was then discarded and the cells were 
washed a second time before being added to the appropriate growth media. 
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3.1.4. In-vivo-CFSE-proliferation 
The donor animals for the adoptive transfer are OT-II mice, which have a 
transgenic T-cell-receptor on CD4+ T-cells recognising the OVA323-339 epitope. 
The spleen and various lymph nodes were extracted from these transgenic 
animals and a single-cell suspension was prepared (see 3.3.6.1). Then, the 
cells resuspended at a concentration of 2x107 cells/ml were stained with CFSE. 
To this end, an equal volume of CFDA-SE (20 µM) in PBS was added to the cell 
suspensions, which were then incubated for five minutes at room temperature 
(RT) in the dark. Next, an equal volume of heat-inactivated FCS was added to 
stop the reaction. After incubating for another five minutes at RT in the dark, 
cells were centrifuged at 314 g, washed with RPMI complete media, and 
resuspended in PBS at a concentration of 1x108 cells/ml.  
Before immunising, the stage of the cycle was determined in C57BL/6 recipient 
mice by vaginal smears stained with Pappenheim-staining. A total amount of 
1x107 cells in 100 µl were then injected intravenously (i.v.) to the recipients. 
After injecting the donor cells, the animals were immunised by i.vag. route using 
OVA-protein (50 µg) + BppCysMPEG (0.5 µg) according to each stage of the 
oestrus cycle. On day five after transfer, animals were sacrificed. The spleens 
were removed, single cell suspensions were prepared (see 3.3.6.1) and cells 
were stained for CD4 (see 3.2.1). Finally, cell suspensions of spleen cells were 
analysed on FACSCanto, gating on CD4+ T-cells. Because CFSE stains plasma 
proteins in cells, the fluorescence intensity is reduced by 50% each time that 
cells are divided following proliferation in response to the OVA-protein. 
 
3.1.5. HEK-BlueTM LPS detection 
To determine if the adjuvants used in this study were contaminated with LPS, 
the HEK-BLUETM LPS detection kit was used, according to manufacturer’s 
instructions. The endotoxin LPS is the major cell wall component of Gram-
negative bacteria which is sensed by PRRs and can induce the activation of NF-
κB and the production of pro-inflammatory cytokines (i.e. IL-1 or TNFα) by 
binding to the TLR 4 receptor. The HEK-Blue™ LPS Detection Kit enables the 
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detection of the contamination level of LPS in the used stock solutions. HEK-
BlueTM-4 cells are engineered HEK293 (Human Embryonic Kidney cells) cells 
stably transfected with multiple genes involved in TLR 4 recognition that include 
TLR 4 and the co-receptors MD2 and CD14. The kit is very sensitive for the 
detection of very low LPS concentrations (0.3 ng/ml). As positive control, LPS 
derived from E.coli K12 strain was used in different concentrations in the range 
of 0.1 ng/ml up to 100 µg/ml. The ag stock solutions (e.g. β-Gal, OVA) were 
tested at three different concentrations (2.5, 0.25, and 0.025 µg/µl) in triplicates 
and had a LPS contamination of 5 ng/ml at a concentration of 50 µg/ml. Also the 
synthetic adjuvant stock solutions were analysed, α-GalCerMPEG or c-di-
nucleotides (i.e. c-di-AMP), which were used for our in vivo experiments and 
showed that even in 5 to 10-fold higher concentrated samples (50 µg) no LPS 
contamination was observed, respectively. 
 
3.2. Flow Cytometry 
3.2.1. Direct surface staining 
The cells to be stained were initially resuspended at a concentration of 5x106 
cells/ml in PBS. Then, 100 µl of this cell suspension were added to a 5 ml-
FACS-tube, to which 1 µl of Fc-block was added, being the solution further 
incubated for five minutes at 4°C. The antibody was then added according to the 
required dilution and incubated for 20-30 minutes at 4°C in the dark. A small 
volume of cells were left unstained (~ 200 µl) and used as a negative control for 
setting the fluorescence activated cell sorter (FACS) gating parameters. After 
staining, the cells were washed by adding 3 ml PBS and subsequent 
centrifugation for five minutes at 314 g (4°C). The washing step was then 
repeated and the supernatant decanted. The sample was ready for analysis on 
FACSCanto.  
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3.2.2. Intracellular phenotyping and cytokine determination 
Restimulated cells were used for intracellular phenotyping. The restimulation of 
cells was carried out as it is described for the proliferation test (see 3.7.3) in 96-
U-bottom plates. In the case that surface markers must also be stained, direct 
surface staining was performed in advance. After washing restimulated cells in 
PBS (see 3.2.1), cells were fixed with 200 µl of PBS + PFA (2%) per well. Cells 
were then incubated for 30 minutes to 24 hours at 4°C, followed by 
centrifugation for five minutes at 314 g. The supernatants were then decanted 
and the cells were washed by adding 200 µl of permeabilisation buffer (PBS + 
0.5% BSA + 0.5% Saponin) to each well. This was followed by incubation for 45 
minutes at 4°C. The cells were then centrifuged again and the supernatant was 
decanted. Next, 50 µl of the titrated antibody was added according to the 
required dilution in permeabilisation buffer and incubated for 30 minutes at 4°C. 
After incubation, 200 µl of perm buffer were added to the cells, which were then 
centrifuged for five minutes at 314 g (4°C) and the supernatant was decanted. 
This step was then repeated two more times: once again with permeabilisation 
buffer and a second time with PBS. Finally, 100 µl of PBS were added to each 
well and the cells were transferred to FACS tubes. The samples were then 
ready for FACS analysis on FACSCanto.  
 
3.2.3. Chipcytometry 
An iterative chip-based cytometry (ICBC) method was used that allows analysis 
at single cell level with a virtually unlimited set of markers per cell. This concept 
was developed by Dr Christian Hennig, Department of Pneumology, Allergology 
and Neonatology (laboratory of Professor Gesine Hansen, Hannover Medical 
School), who also analysed the chips used in this study. The method is 
described by Hennig et al. in 2009 [188]. Briefly, cells were resuspended in 5 µl 
PBS and applied to cell-adhesive microfluidic chips. Cells were allowed to self-
immobilise for five minutes on the chip surface, followed by fixation of the cells 
using Histofix. Thereafter, markers were analysed in a cyclic staining-imaging-
bleaching process by automated quantitative microscopy on a motorised 
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Axioimager M1 (Zeiss). After analysis of the surface markers, cells were 
permeabilised using permeabilisation buffer for measuring intracellular markers. 
For surface markers, antibodies were diluted 1:10 in PBS and incubated on the 
cells inside the chip for five minutes at RT, followed by washing the channels 
with 200 µl PBS. For intracellular markers, antibodies were diluted in 
permeabilisation buffer and incubated for one h at RT, again followed by a 
washing step using 200 µl of permeabilisation buffer. The imaging process, 
image-recognition and image-processing, as well as data visualization were 
controlled by an in-house developed software (CellhopperX, IR-engine 3.1). 
To visualise the complexity of the resulting marker-cell combinations and cell-
populations, as generated by chipcytometry, hierarchical clustering of cytometric 
data was used. Before clustering, the fluorescence values of different markers 
were normalised to each other in order to minimise the influence of different 
antibody labellings and stains. Agglomerative average-linkage clustering was 
used as clustering algorithm. 
 
3.2.3.1. Sample preparation for chipcytometry 
Chipcytometry was used to analyse spleen cells of immunised mice. In brief, the 
spleens were extracted and a single cell suspension was prepared with lysis of 
erythrocytes (as described in 3.1.3 and 3.3.6.1). Cells were seeded in 96-well-
U-bottom plates at a concentration of 5x105 cells/well for restimulation. The cells 
were then restimulated with the appropriate ag (e.g. β-Gal) at a concentration of 
40 µg/ml for 48 hours at 37°C, 5% CO2. After 44 hours, Brefeldin A (1 µg/ml) 
was added to prevent further cytokine secretion. This step is necessary to 
detect cytokines at the intracellular level of the cell. Finally, the cells were 
washed with PBS (10 min, 300 g, 4°C) and filtered through a 35 µm cell-strainer 
and 2x106 cells contained in 10 µl were loaded on the chip. A staining procedure 
was then conducted, as described by Hennig et al. [188]. 
Chipcytometry is also valid for histological sections of tissues. Here, the method 
was applied to cryo-sections of vaginas isolated from immunised mice. The 
sections were 4 to 6 µm thick and they were placed onto 18 mm x 18 mm glass 
slides with two 2 mm parallel bars of parafilm affixed to the backside of the slide. 
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This slide was then placed on a larger (26 mm x 76 mm) glass slide with a chip-
specific channel, sandwiching the vagina in a flow chamber between the glass 
slides.  
The markers investigated were listed in 2.3.2. 
 
3.2.4. Cytokine array (Mouse Th1/Th2 10-plex Flow Cytomix) 
The cytokine array was performed according to the manufacturer’s instructions. 
The system is comparable to a sandwich-ELISA. The kit contains beads coated 
with antibodies binding to certain cytokines and also beads which are coated 
with a biotinylated detection antibody. These beads bind to each other and the 
cytokines from the sample is bound to the antibody-coated bead, consequently 
the sample is sandwiched. Then the complexes are stained with streptavidin-
phycoerythrin (PE) and can be analysed in the FACS. A standard is inserted in 
the kit allowing quantitatively determination of cytokines.  
 
3.2.5. Acquisition of samples using FACS 
The FACS allows analysis of single cell suspensions stained with fluorescent 
colours. The cells are aspirated by the nozzle and in fluid sheath covered. In this 
flow, they pass through different lasers. The forward- and side scatter 
discriminate cells according to their size and granularity. With the staining of 
cells by antibodies conjugated with fluorescent dyes, the molecules of interest 
according to cells can be analysed.  
 
3.3. Methods with laboratory animals and handling of mice 
3.3.1. Marking of mice 
Mice were marked by cutting a fragment of their earlobe(s). Generally, no 
marking indicated “Mouse 1”, a marking on the right ear indicated “Mouse 2”, a 
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marking on the left ear indicated “Mouse 3”, a marking on both ears indicated 
“Mouse 4”, and a triangular notch on one ear indicated “Mouse 5”.  
 
3.3.2. Taking blood and serum preparation 
To collect blood, mice were tightly held behind their neck causing an 
accumulation blood in this region. The retro-orbital venous plexus was then 
punctured using a glass capillary. Bleeding was stopped by removing the 
capillary and releasing the mouse. Using a micropipetter, the blood was 
transferred to an Eppendorf tube and allowed to stand first for 60 minutes at 
37°C and then for 60 minutes at 4°C for agglutination. To ensure proper sera 
separation, the tube was centrifuged for five minutes at 3000 g, 4°C. The serum 
was then collected and stored at -20°C until it was processed. 
 
3.3.3. Strategies to synchronise the murine oestrus cycle 
3.3.3.1. DEPO-treatment 
For synchronising the oestrus cycle of mice, 2 mg of DEPO-Clinovir was 
injected subcutaneously (s.c.). After five days, the mice’s hormone levels were 
synchronised. Their cycles were then arrested for a period of about two weeks 
in the dioestrus stage, which is characterised by a high amount of mucus, 
neutrophil granulocytes, and keratinised epithelia cells in the vagina. To make 
sure that cycles had been successfully arrested, vaginal smears were stained 
with Diff-Quik and then viewed under a light microscope (20x, Nicon Eclipse). 
 
3.3.3.2. Whitten-effect for synchronisation of the oestrus cycle 
To mimic the most natural synchronisation process of their hormonal cycles, 
female mice were housed in cages originally used by male mice. This type of 
synchronisation via the odour of hormones, however, was not successful.  
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3.3.4. Immunisation/challenge strategies 
3.3.4.1. Intranasal immunisation 
For intranasal immunisation, mice were anesthetised by inhalation of Isoflurane 
to prevent antigen loss by sneezing. After being anesthetised, mice were gently 
held at the neck with their body hanging vertically and 10 µl of solution were 
then pipetted into each nostril.  
 
3.3.4.2. Sublingual immunisation 
For sublingual immunisation, mice were first anesthetized with 
Ketamine/Rompun (i.p.; 100 µl per 10 mg of bodyweight). Then, the vaccine 
formulation was gently delivered under the tongue using a 10 µl pipette. During 
administration, the mouse was fixed in a vertical position with its head at a 90° 
angle to its body, which helped to ensure that the formulation was delivered 
sublingually and not oro-gastrically. To further ensure that the vaccine was not 
ingested, the mice were returned to their cages in a sitting position with their 
head lying onto their stomach (see photos below).  
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Figure 7: Mice were under narcosis and placed in this position, sitting head in ante 
flexion as long as narcosis is lasting. 
The top picture represents how the animals are placed in their cage. In bottom picture, the arrow 
indicated where the formulation is administered, under the tongue. 
 
3.3.4.3. Oral immunisation 
For administration of formulations into the gastrointestinal tract, a feeding 
needle was used. Mice were held in a position which allows a head tilt-chin lift 
manoeuvre, so that the feeding needle can be easily inserted into the stomach. 
Then, the formulation was released with the help of a syringe. 
 
3.3.4.4. Intravaginal immunisation 
The i.vag. immunisation is a non-invasive manoeuvre. During this procedure, 
mice were held with their tail in the air. The palmar reflex kept the mice 
immobilised. A pipette with a 200 µl tip was used to gently pipette 10 µl of 
solution into the outer part of the vagina. The position was maintained for 
several minutes to ensure that the drop was absorbed and not pressed out by 
the mouse’s muscles. 
  
3.3.4.5. Subcutaneous injection
For administration of formulations under the skin, the mice were first shaved on 
their backs close to the tail. Then, using a needle of 30Gx1/2”, 100 µl of s
were injected into this area. 
 
3.3.4.6. Immunisation schedule
Immunisations were given on day 0, 14 and 28, and the sampling (animals were 
sacrificed and the organs processed) was done at day 49. For the i.vag. 
immunisation DEPO
at day 0. Consequently, the immunisation protocol for these mice starts at day 
five respect to the immunisation.
 
Figure 8: Immunisation strategy under DEPO treatment.
Diagram illustrating the 
further studies. DEPO is included for i.vag. immunisation
 
3.3.5. Health and constitution monitoring
3.3.5.1. Measurement of weight 
Using a balance, the weight of each mouse was monitored during th
immunisation protocol at days 0, 2, 4, 9, 14, 16, 18, 23, 28, 30, 32, 37, 42 and 
49. The mice were placed in a plastic container while they are weighed.
 
3.3.5.2. Health monitoring expressed in scores
Mice infected with HSV were monitored and a daily health score was assigned. 
Score = 0: very healthy, no sign of illness
 
 
 
 
-treatment occurred 5 days prior to the immunisation given 
 
 
experimental design for identifying the optimal vaccine formulation for 
.  
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Score = 1: minimal weight loss  
Score = 2: minimal weight loss and ruffled hair 
Score = 3: mouse less vital, hair loss and weight loss 
Score = 4: mouse lost 20% of its weight, eat rarely, possible hind limb paralysis, 
ruffled hair, signs of tissue inflammation 
Score = 5: mouse is dead 
 
3.3.5.3. Killing 
Mice were either killed by CO2 asphyxiation or cervical dislocation. Death was 
confirmed by pinching between the toes of both feet to test for reflexes and by 
feeling for a heartbeat.  
 
3.3.5.4. Narcosis 
Isofluorane narcotises mice for around 30 seconds. For this method, 1 ml of 
Isofluorane was pipetted into a plastic container with a closable lid containing 
paper tissues. The mouse was then placed into the container and removed once 
its breathing and movement slowed. 
 
3.3.5.5. Anaesthesia 
For deep anaesthesia, Ketamine/Rompun was used. The mouse to be 
anesthetised was fixed on its back and 100 µl of working solution per 10 mg 
bodyweight were administered intraperitoneal (i.p.). After a few minutes, the 
mouse was anesthetised and remained this way for about 30 minutes. 
 
3.3.6. Collection of organs 
3.3.6.1. Spleen resection 
After removing the spleens from each mouse, they were pooled based on the 
vaccine group and placed in Petri dishes containing RPMI. Then, they were 
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mechanically pushed through 100 µm sterile filters using a syringe plunger. The 
resulting cell suspension was then centrifuged for 10 min at 314 g, 4°C. Next, 
the erythrocytes were lysed in ACK-buffer by pipetting up and down 
continuously for 1-2 minutes. Lysis was stopped by adding 15 ml of RPMI. After 
another centrifugation step, the pellet was again mechanically pushed into a 100 
µm mesh filter. At this point, the cell number could be determined and analysis 
could begin. 
 
3.3.6.2. Resection of vagina 
With the mouse on its back, deep vertical cuts were made around the vagina, 
using a tiny pair of scissors. The vagina was removed by pulling with rounded 
tweezers. The organ was completely removed once the uterus could be seen. 
The vagina was then cut into 1-5 mm fragments and digested with enzymes.  
 
3.3.6.3. Resection of lymph nodes 
For lymph node extraction, the mouse was completely opened. The sublingual 
lymph nodes are positioned in the fatty tissue surrounding the cervix and below 
the mandible and they are the draining lymph nodes for sublingual 
immunisation. The iliac lymph nodes are located next to the vena cava near the 
hind legs and they are the draining lymph nodes for i.vag. immunisation. These 
lymph nodes were extracted with tweezers and placed into a 100 µm cell-
strainer in a Petri dish containing RPMI complete media. A single cell 
suspension was prepared using a method similar to the one described for 
spleen cells (see 3.3.6.1) without lysing the erythrocytes.  
These lymph nodes can be used to determine cell proliferation via thymidine 
incorporation (3.7.3).  
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Figure 9: Lymph nodes of a mouse. Lymph nodes 1-3 are here named sublingual lymph 
nodes and lymph nodes no. 21 are the iliac lymph nodes extracted in this study [189] 
Fig. 4a. 
 
3.3.7. Collection and processing of lavages 
3.3.7.1. Nasal lavage (NL) 
With the mouse lying on its back and its head down, the nasal lavage was 
performed by first opening the mouth and disconnecting the upper and lower 
parts of the jaw. Then, from inside of the jaw, the choanae was flushed out 
through the nostrils and the droplets were collected in a 1.5 ml Eppendorf 
reaction tube containing 10 µl PMSF (40 µM). Centrifugation and storage were 
performed as described for vaginal lavage.  
 
3.3.7.2. Saliva 
For saliva collection, mice were first narcotised with Ketamine/Rompun i.p. and 
then injected with pilocarpine (500 µg/kg mouse; i.p.). After the animal began to 
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salivate, the sample was collected using a pipette and transferred to a vial 
containing 10 µl PMSF (40 µM). Centrifugation and storage were performed as 
described for vaginal lavage. 
 
3.3.7.3. Bronchoalveolar lavage (BAL) 
The bronchoalveolar lavage (also called lung lavage (LL)) was conducted by 
opening and flaying the mice. With the thoracic and abdominal wall completely 
open, a small incision was made between two rings of the trachea in order to 
insert a long pipette. The pipette was connected to a syringe containing 500 µl 
lavage buffer. The lavage was flushed twice and directly transferred to a 1.5 ml 
Eppendorf reaction tube containing 10 µl PMSF (40 µM). Centrifugation and 
storage were carried out as described for vaginal lavage.  
 
3.3.7.4. Vaginal lavage (VL) 
The vagina was flushed twice with 250 µl of lavage buffer (PBS + 5% FCS) and 
the lavage was transferred to a vial containing 10 µl PMSF (40 µM). The vial 
was then centrifuged for five minutes at 3000 g, 4°C. After centrifugation, the 
supernatant was collected and placed into a new vial containing 10 µl PMSF (40 
µM) and stored at -20°C until it was processed.  
 
 
3.4. Vaginal smears 
3.4.1. Vaginal smears with swabs 
The upper part of the vagina was gently swabbed using a thin cotton swab 
(150x0.9-1.0 mm, Heinz Herenz, Germany). The swab was then rolled onto an 
object slide and allowed to air dry. At this point, it was possible to stain the slide. 
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3.4.2. Vaginal treatment with cytobrush 
Before the mice could be infected with HSV-1 virus by i.vag. route, a cytobrush 
(medex, Medesign) had to be used to cause microtrauma to the vaginal 
epithelium. This trauma prepared the tissue to fully resorb the virus. Therefore, 
the cytobrush was inserted into the vagina and rotated five times to the right 
side and five times to the other side. 
 
3.5. HSV-1  
3.5.1. 17SynIGR20Luc and 17SynIGR20GFPgJZ virus stock 
preparation 
The 17SynIGR20GFPgJZ and 17SynIGR20 Luc stocks were prepared at 
University of Ferrara, Italy. One additional stock of 17SynIGR20GFPgJZ and 
stocks of LVwt and LVLacZ were prepared at HZI, Braunschweig.  
To propagate the virus, Vero cells were infected. In brief, Vero cells were 
seeded into 20x150 cm2 tissue culture flasks at a concentration of 8-10x106 
cells for each flask in 20-25 ml high glucose DMEM growth media (completed 
with 10% FCS, 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml 
streptomycin). The cells were then incubated at 37°C, 5% CO2 for 24 hours and 
reached confluence. Next, the media was removed from the flasks and the 
adherent Vero cells (about 24x106 cells/flask) were infected with the virus at a 
multiplicity of infection (MOI) of 0.01. Calculating the MOI from the virus stock 
concentration, 96 µl of virus (e.g. 17SynIGR20GFPgJZ) were used and diluted 
in 100 ml DMEM (without FCS). For a homogenous distribution of the virus, the 
virus was sonicated for several seconds and then cooled on ice. 5 ml of this 
virus dilution was then added to each flask and incubated for 1 hour at 37°C, 5% 
CO2 and gently shaken every 10 minutes. This ensured viral contact for each 
cell and guaranteed the highest rate of infection of the Vero cells monolayer. 
After incubation, the supernatant containing excess virus was removed and 25 
ml of DMEM complete media was added to each flask. Incubation followed for 
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the next 24 hours. During this time the virus was replicated inside Vero cells. 
Under the microscope, it was observed that the cells change their appearance 
by becoming rounded and begin to come off the flasks. This indicated 
successful infection. With a cell scraper, adherent cells were disconnected from 
each flask and transferred into 50 ml tubes with lids. These suspensions were 
then centrifuged at 1251 g for 15 minutes, 4°C. The supernatants were then 
decanted and saved on ice. The pellets were resuspended in the small 
remaining volume of supernatant in each tube, then combined into one tube and 
centrifuged again. The final pellet was resuspended in 3 ml supernatant, 
transferred to a 15 ml tube and shortly frozen in liquid nitrogen and stored over 
night at -80°C. The decanted supernatants were also stored over night at -80°C. 
The next day the pellet was thawed and re-frozen three times by cycling 
between liquid nitrogen and a 37°C water bath, vortexing between each cycle 
for a few seconds. After the final thaw, the virus was sonicated three times for 
10-20 seconds with a 10 seconds pause in ice between each sonication cycle 
(35 kHz). This ensured that the cell membranes of the Vero cells were 
destroyed and all viral particles were released. The cell debris was centrifuged 
two times at 1501 g for 15 minutes, 4°C. The pellet was discarded and the virus 
containing supernatant was put into Oak Ridge tubes for ultracentrifugation 
along with the original virus supernatant which was still frozen at -80°C from the 
day before. With a Sorvall centrifuge and a SS34 rotor, the supernatants were 
centrifuged at 43667 g for 30 minutes at 4°C. Next, the supernatant was 
discarded and the pellets were resuspended by adding 1 ml growth media 
(without FCS). All resuspended pellets were combined and centrifuged again at 
43667 g for 30 minutes at 4°C. The final pellet was then kept on ice for one hour 
before the purification.  
For purification, solutions B-F were prepared and kept at 4°C (see Material 
section). Next, 2.6 ml of solution D was pipetted into ultracentrifugation tubes 
and 2.1 ml of solution E was slowly added. Finally, 1 ml of solution F was added 
almost completely filling each tube. To ensure the tubes are exactly balanced 
with each other, they were weighed and solution F was added where necessary. 
Each tube was then sealed with a cap and loaded into a Sorvall-ultracentrifuge 
using a T 875 rotor or TH-641 swinging rotor and centrifuged for 9-16 hours at 
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63580 g at 4°C in vacuum at maximum acceleration and no brake in 
deceleration. After centrifugation, the tubes were placed on ice. The virus band 
appeared as a result of density gradient formation. This band was extracted by 
puncturing the tube with a syringe placed 2 mm under the band and carefully 
collecting only the virus band. To concentrate the virus, the collected virus band 
was put into ultracentrifugation tubes and diluted (1:2) with PBS and centrifuged 
again using a Sorvall-ultracentrifuge, this time using a SS34 rotor at 43667 g for 
30 minutes at 4°C. The final pellet was resuspended in 1 ml of PBS and 
sonicated for 15 seconds three times. The viral solution was placed on ice 
between each sonication step. Finally, the purified virus was aliquoted into 20 µl 
aliquots and stored at -80°C until usage. In addition, the viral stocks were 
titrated by determining the cell number of plaque-forming units (PFU)/ml, using a 
Plaque-assay. 
 
3.5.2. Plaque-assay 
The plaque-assay was used to determine the PFU/ml of the viral stock. First, 
Vero cells were seeded into a 6-well-plate and grown to confluence. Next, the 
virus was diluted in RPMI media to reach 10-4 to 10-9. The media was then 
aspirated from the Vero cells and 200 µl of the dilutions were added to each well 
of Vero cells. This was followed by incubation for one hour at 37°C and 5% CO2 
with gently shaking every 10 minutes. Finally, the viral solution was removed 
and each well was covered with 2 ml of methylcellulose and incubated for four 
days. The methylcellulose was then removed and each well was washed with 2 
ml of PBS, and then stained with 2 ml of crystal violet–methanol solution and air 
dried. Finally, the titre of the viral stock was determined by counting the plaques. 
Here, 21 plaques at a dilution of 10-7 were counted. The titre of the prepared 
stock 17SynIGR20GFPgJZ was therefore determined to be 1.05x109 PFU/ml.  
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3.6. Technics of staining cells in liquid and in sections 
3.6.1. Cryosections 
To create cryosections of the vaginal tissue the organ was directly extracted, put 
into cryosection tubes, frozen in liquid nitrogen and stored at -80°C until it was 
processed. The organ was cut using a cryotome into 4-6 µm slices at -25°C. 
The slices were then placed onto glass slides and air dried. At this point the 
slides could be stained. For ICBC, the sections were frozen again at -80°C, and 
then stained and scanned by Dr Christian Hennig at Hannover Medical School.  
 
3.6.2. Staining of vaginal smears 
3.6.2.1. Diff-Quik staining 
Using the Diff-Quik staining solution, it was possible to differentiate between cell 
subsets quickly. After the sample to be stained had air dried, it was dipped three 
times, for five seconds each time, into Diff Quik fixing solution. This procedure 
was performed identically when using DQ Solution I and Solution II. The slides 
were then rinsed carefully with distilled water and allowed to air dry.  
 
3.6.2.2. Pappenheim staining 
First, the slides were kept in May-Grünwald staining solution for five minutes. 
Then, they were washed with PBS for two minutes and subsequently stained for 
20 minutes with Giemsa staining solution, diluted 1:20 in distilled water. Finally, 
the slides were washed with normal water and air-dried. The entire staining 
procedure took place at RT.  
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3.7. Immunological methods 
3.7.1. ELISA 
3.7.1.1. Detection of antigen-specific IgG in sera 
The determination of antigen-specific IgG or IgG subclasses in sera was done 
by substrate reaction measured with ELISA reader Synergy 2 (Bio-Tek) by 
detection of optical density at 405 nm. The 96-well-plates were coated with 2 
µg/ml antigen diluted in coating buffer and left overnight at 4°C or for one hour 
at 37°C. Plates were then washed with PBS (+ 0.1% Tween 20) using an ELISA 
washer (ELx 405, Bio-Tek) on a 6-cycle program. To avoid unspecific binding, 
the plates were blocked with PBS/BSA (3%) for 1-2 hours at 37°C. The serum 
was diluted 1:1000 in PBS /BSA. Next, the liquid from the plates was discharged 
and the diluted serum was pipetted into the first well (200 µl) of each row, 100 µl 
PBS/BSA had already been pipetted into the other wells for performing a serial 
dilution (1:2) using a plate pipetting system robot (Precision 2000, Bio-Tek). The 
last well of each row was left empty. Then, the plates were incubated for one 
hour at 37°C, followed by washing. The detection antibodies were given at an 
appropriated dilution, and the plates were further incubated for 1 hour at 37°C. 
After additional washing, streptavidin-HRP solution (1:1000 in PBS+ Tween + 
BSA) was added to the plates, which were incubated for 30 minutes. After 
washing, the substrate solution ABTS plus H2O2 (30%) (1:1000 v/v) was 
pipetted on the plates (100 µl/well). Finally, the plates were read using an ELISA 
reader after 5, 15 and 30 minutes at 405 nm. For final results, always the value 
measured after 30 minutes was regarded. Sera of single animals were used for 
analysis. 
 
3.7.1.2. Detection of antigen-specific IgA in mucosal lavages 
To assess the amount of IgA in the sera and lavages, an ELISA for IgA 
detection was performed. As in the IgG ELISA, the plates were coated over 
night at 4°C. For the standard and the total IgA, the plates were coated with 100 
µl of anti-mouse IgA antibody (2 µg/ml) diluted in carbonate buffer. For specific 
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detection of IgA, the plates were coated with antigen (2 µg/µl) diluted in 
carbonate buffer. Following incubation, plates were washed as described for 
IgG ELISA and blocked for two hours by pipetting 200 µl of blocking solution into 
the wells. After incubation for 1-2 hours at 37°C, the solution was discharged 
and the samples were transferred to the plate. For a standard curve, 
standardised mouse IgA antibody was diluted in PBS + BSA (3%) starting with a 
concentration of 0.2 µg/ml. The serial dilution (1:2) was completed by a plate 
pipetting system robot (Precision 2000, Bio-Tek). For this, 200 µl of the starting 
dilution were pipetted into the first well of each row and 100 µl of the dilution 
buffer were pipetted into all other wells, which were then diluted 1:2 by the 
robot. The first half of the plate was filled with a 1:20 dilution from the vaginal, 
nasal and lung lavages, and a 1:250 dilution for saliva, respectively. Similar to 
the standards, serial 1:2 dilution was completed by the robot, up to a 1:640 
dilution for VL, NL and BAL; and 1:8000 for saliva. The other half of the plate 
was used for antigen-specific IgA detection. For this, the VL, NL and BAL 
samples were diluted 1:4 and the saliva samples 1:50. Here, a 1:2 serial dilution 
was completed by the robot, which continued to a dilution of 1:128 for the VL, 
NL, and BAL samples; and up to 1:1600 for the saliva samples. The samples 
were then incubated for 1-2 hours at 37°C and then washed using an ELISA 
washer (ELx 405, Bio-Tek) on a 6-cycle program. The IgA detection antibody 
was diluted 1:5000 in PBS + 0.1% Tween 20 + 1% BSA, and 100 µl of this 
dilution was placed in each well and allowed to incubate for another hour. This 
was followed by a washing step and the plates were then filled with Streptavidin-
HRP at a 1:1000 dilution in PBS + 0.1% Tween 20 + 1% BSA. After a 30 
minutes incubation and a washing step, ABTS plus H2O2 (30%) (1:1000 v/v) 
was added to the plates. Using the ELISA reader, the colour reaction of 
enzyme-substrate-solution was analysed after 5, 15 and 30 minutes at 405 nm. 
For final calculation of results, always the value measured after 30 minutes was 
regarded. Lavages of single animals were used for analysis. 
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3.7.2. Enzyme-linked immune spot technique (ELISPOT) 
The ELISPOT is done to detect individual cytokine secreting cells. The 
multiscreen plates were coated with 100 µl capture antibody diluted in coating 
buffer. The plates were stored at 4°C over-night. Next, the coating solution was 
discarded and the plates filled in with blocking solution (200 µl/well) and further 
incubated for two hours at RT. After that, the solution was discarded and the 
plates were loaded with protein or peptide, media, ConA and spleen cells. The 
final concentration of antigen or ConA was 5 mg/ml. After preparing the plates 
with the antigen, mitogen and media, cell solutions were prepared. Pooled 
spleen cells were given at a concentration of 5x105 cells/well and 2x105 
cells/well. The plates for detection of IFN-γ were incubated for 24 hours, 
whereas those for IL-2, IL-4 and IL-17 detection were incubated for 48 hours 
(37°C, 5% CO2). After incubation, the cell suspension was removed and the 
plates were washed twice with deionised water. The wells were soaked for 3-5 
minutes between the washing steps. The wells were washed three times with 
200 µl/well of wash buffer I and they were then loaded with 100 µl of detection 
antibody (1:250 in dilution buffer). The plates were incubated for two hours at 
room temperature. After removing the solution, plates were washed three times 
with wash buffer I. Then, 100 µl of avidin-HRP-solution was added to the plates, 
which were incubated for one hour at room temperature. Further, the plates 
were washed four times with wash buffer I and two times with wash buffer II. 
Then, 100 µl of the substrate solution was added to each well and spot 
development was observed and stopped by adding deionised water. The plates 
were air dried over-night and the next day they were automatically read using 
the ELISPOT reader (program Image Acquisition 4). This information was 
necessary for the program Immunospot 3, which counted the number of spots in 
each well, with each spot being created by a distinct cytokine secreting cell. 
 
3.7.3. Proliferation assay 
Splenocytes or lymph node cells were used for the proliferation assays. The 
organs from each group were pooled to perform the assay. Single cell 
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suspensions were prepared on the sampling days and given to the wells at a 
final concentration of 5x105 cells/well. Before adding the cells to a particular 
well, either media, ConA or the antigen at concentrations of 40 µg/ml, 20 µg/ml, 
10 µg/ml or 5 µg/ml were added. The final volume of each well was 200 µl. After 
72 hours of incubation in 5% CO2  at 37°C, 1 µCi 3H-thymidine in 50 µl media 
was added to each well and incubation continued for an additional 16 hours. 
Cells were harvested on glass fibre filters by using the Inotech® cell harvester. 
The principle underlying this method is that proliferating cells will incorporate 3H-
thymidine into their DNA and be immobilised on the filter plate, with unused 3H-
thymidine simply washing away. The filter plate was marked with a pencil and 
positioned into the machine and humidified with autoclaved water. The 
harvester was also rinsed. Then, the samples were put into position and a 
vacuum was used to remove the cell suspension. The cells remained on the 
filter and everything else was discarded into the radioactive waste tray. The 
wells were washed twice with sterile water and vacuum filtered once again, 
allowing the vacuum to run 30 seconds longer than necessary to dry the filter. 
The 96-well plate was then discarded and the filter was dried for 30 seconds in 
the microwave. Next, the filter was placed on a heater using tweezers and 
covered with scintillation wax. The wax was allowed to melt completely and then 
to air dry. To assess the radioactivity, the filter was placed into the cassette 
1450-104 Filtermat of the scintillation counter. The counts appeared as a cell 
number in an excel file. These counts per minute were used to determine the 
amount of proliferating cells. First, the mean of the quadruplicates for each 
group and antigen or mitogen concentration were calculated. Then, the 
background (media alone) was subtracted and the standard deviation 
calculated. The stimulation index was calculated by dividing the mean of the 
quadruplicate of each sample by the mean of the media.  
 
3.7.4. Cytokine secretion 
As during the proliferation, the single cell suspensions of spleen or lymph node 
cells were restimulated with antigen concentrations of 40 µg/ml, 20 µg/ml, 10 
µg/ml or 5 µg/ml, media or ConA. The cells had a concentration of 5x105 in each 
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well of the 96-flat bottomed plate. After incubation for 90 hours, plates were 
centrifuged for five minutes at 314 g and the supernatant, which contained the 
released cytokines, was collected in 1.5 ml Eppendorf tubes. The samples were 
stored at -80°C until they were processed using a Th1 /Th2 10-plex Flow 
cytokine kit (Bender Med Systems).  
 
3.7.5. Statistical analysis 
For analysing statistical significant differences occurring between the different 
groups, was analysed with Graph Pad Prism software using analysis of variance 
(One-way Bonferronis multiple comparison test and Two-way Anova). 
Probability (p) values of p<0.05 (*), p<0.01 (**), p<0.001 (***) and p<0.00001 
(****) indicating differences were considered significant. 
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4. Results 
4.1. Establishment of a synchronisation strategy for the 
murine oestrus cycle 
The female oestrus cycle is defined by four different stages regulated by varying 
hormone profiles (see 1.3.3). The prooestrus stage is dominated oestrogens, 
whereas in the oestrus progesterone is the main hormone. Changes in the 
concentrations of these hormones are responsible for the restructuration of cell 
layers and mucus production, which result in a cycle of about four days for 
female mice. The dioestrus is the stage of the cycle in which the epithelial layers 
are the thinnest and ags and vaccines can successfully penetrate the mucosa. 
Thus, to immunise animals the oestrus cycle must be synchronised in order to 
obtain meaningful and comparable data. It is essential that all animals receive 
the vaccination on the same day in dioestrus stage to avoid huge variations in 
the obtained responses. One of the common methods to synchronise the 
oestrus of female mice is based on hormone treatment. However, since the 
amount given to the animals is usually above physiological values, the immune 
responses stimulated following vaccination might not reflect the natural 
situation. Thus, it was first tested if the cycle could be also regulated by a 
natural method. 
 
4.1.1. Whitten-effect for oestrus cycle synchronisation 
In an attempt to synchronise the oestrus cycle of female mice using a natural 
method, female mice were housed in cages which had previously been used by 
male mice. This could be effective because male mice leave the odour of their 
urine and hormones, and female mice are responsive to them. This results in 
the so-called Whitten-effect [190], [191]. However, in the present study this 
method did not provide robust and reproducible results. When the stage of the 
oestrus cycle was accessed by Diff-Quik staining of vaginal smears, the 
obtained results showed that both the period of time until the mice reached 
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synchronisation and the length of time during which synchronisation was 
maintained significantly varied. This strategy was therefore excluded for 
subsequent studies, shifting to hormone-based synchronisation methods. 
 
4.1.2. DEPO-treatment 
To synchronise the oestrus cycle of female mice a s.c. treatment with DEPO, a 
medroxyprogesterone acetate (pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-
methyl-, (6α-)) solution, was carried out (Fig. 10). This hormone is normally used 
as a three-month treatment to prevent pregnancy in humans. In mice, the 
administration of 2 mg of DEPO five days before i.vag. immunisation leads to a 
successful synchronisation at the dioestrus stage. Accordingly to our 
observations, this effect lasts for about ten days and must be repeated prior to 
each immunisation/boost. Figure 10 gives an overview of the oestrogen and 
progesterone levels during the oestrus cycle and the corresponding phenotype 
of the vaginal smears. It shows pictures of vaginal smears taken with a cotton 
swab in the vagina at 400x magnification using a Nikon Eclipse microscope. The 
staining makes cells and mucus clearly distinguishable. The prooestrus is 
characterised by cornified epithelial cells with nuclei in the centre and by small 
quantities of mucus in the vagina (Fig. 10B). During the oestrus, cornified 
epithelial cells are still visible, but they are already anucleated, the mucus 
disappeared and cell layers are in the process of conversion (Fig. 10C). Figure 
10D shows the metoestrus, which is characterised by mucus production and 
infiltration of granulocytes. There are still cornified epithelial cells in the smears 
and the tissue degradation continues. In the dioestrus, cornified epithelial cells 
are regenerating, as indicated by the presence of a nucleus in these cells, and 
neutrophils are still infiltrating the tissue (Fig. 10A). This is the point of the cycle 
at which the cell layers are the thinnest. Therefore, animals are immunised at 
this stage of the oestrus cycle when the penetration of the vaccine ag through 
the skin barrier is most efficient. Figure 10A, lower picture, shows the dioestrus 
stage as it appeared when induced by DEPO-treatment, which is in turn 
indistinguishable from naturally-occurring dioestrus. Taken together our results, 
the hormone treatment represents the only successful synchronisation strategy. 
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However, one needs to keep in mind that the non-physiological hormone values 
might have a direct or indirect impact on the stimulated immune responses. 
There is a clear integration of the neuro-endocrine-immune axes [192]. For 
example, it has been shown that progesterone has immune modulatory effects, 
making also mice more susceptible to HSV-infection as a result of an impaired 
immune response [193]. On the other hand, NK-cell and CTL activity is 
decreased following progesterone treatment [194]. 
 
 
 
Figure 10: Stages of the murine oestrus cycle. 
Overview of oestrogen and progesterone levels during the oestrus cycle and the corresponding 
phenotype of the vaginal smears, as modified from the original [132]. (A) Dioestrus with many 
leukocytes and few nucleated epithelial cells (lower panel shows dioestrus after synchronisation 
with DEPO), (B) prooestrus with few cornified but many nucleated epithelia cells, (C) oestrus 
with many cornified cells with degenerated nuclei, (D) metoestrus with many leukocytes and few 
cornified cells. Vaginal smears of female mice stained with Diff-Quik staining observed at a 
magnification of 400x.  
 
4.1.3. Identification of the phase of the oestrus cycle allowing to 
obtain the most efficient immune responses following 
immunisation 
Using an adoptive transfer model, proliferation of spleen cells was used as read-
out to conclude in which stage of the oestrus cycle cells are maximally 
stimulated following i.vag. immunisation. For this experiment, OVA-protein co-
administered with the adjuvant BPPcysMPEG was used for immunisation. Then, 
the transferred cells were CFSE stained to assess their proliferation after 
specific stimulation following the i.vag. administration of the ag. Consequently, 
each peak in a histogram (or cloud in dot plot) represents a successive 
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generation in which the intensity of the labelling was reduced by 50% (see Fig. 
11 and 12). In figure 11, the gating strategy and the proliferated cells from 
animals immunised in dioestrus are shown (n=4).  
 
 
Figure 11: In vivo proliferation of spleen and lymph node cells following i.vag. 
immunisation. 
C57BL/6 female mice which received CFSE-stained cells recovered from spleens and LN from 
OT-II animals were then immunised by i.vag. route during the dioestrus with OVA-protein co-
administered with BPPcysMPEG. (A) All cells detected in the forward scatter–area (FSC-A) 
against side scatter–area (SSC-A) were gated on leukocytes, (B) doublet discrimination by 
gating on singlets in FSC-A against FSC-H gated on leukocytes, (C) doublet discrimination by 
gating on singlets in SSC-A against SSC-W gated on leukocytes,(D) CFSE-stained cells in 
FITC-channel against CD4-cells in the APC-channel.  
 
In figure 11A, the total amount of cells detected in the forward-and side scatter 
are shown, the gate one is set on the leukocyte population. In figure 11B and 
11C, singlets are chosen by doublet discrimination. In figure 11D, the CFSE-
stained transferred cells are detected in the fluorescein isothiocyanate (FITC)-
channel and CD4-cells are detected in the APC-channel, including only the cells 
from gate three. The CFSElow CD4+ cells represent the cells that have 
proliferated due to the immunisation stimulus, whereas CFSEhigh cells are 
Gate 3 
A B
C D
Gate 1 
Gate 2 
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undivided. The proliferation of these cells is plotted in a histogram and 
percentages of the divided, parent cells are indicated (Fig. 12).  
 
Figure 12: Proliferation of CD4+ spleen cells after adoptive transfer. 
CFSE-stained transgenic OT-II-cells were transferred i.v. to C57BL/6 wild type mice which were 
afterwards immunised by i.vag. route during different phases of the oestrus cycle. Five days 
61.7% 
7.5% 
7.6% 
20.7% 
A 
B 
C 
D 
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after immunisation, spleens were removed and analysed. Immunisation during the (A) dioestrus 
(n=4), (B) prooestrus (n=2), (C) oestrus (n=4) and (D) metoestrus (n=2). 
 
As shown in figure 12, stimulation of strong proliferative responses (i.e. 
activation of ag-specific T cells) following immunisation by i.vag. route depends 
on the stage of the oestrus cycle. While i.vag. immunisation during prooestrus, 
oestrus or metoestrus is not resulting in proliferation of CD4+ OT-II-spleen cells, 
strong proliferative responses have been obtained when mice were immunised 
during the dioestrus stage (Fig. 12A). This can be explained by improved ag 
uptake, as a result of high number of neutrophils and thinner vaginal cell layers 
in dioestrus, as compared to the other stages of the oestrus cycle. In contrast, 
the increased thickness of the vaginal cell layer and specific cellular composition 
in other stages of the cycle might not allow efficient uptake of the vaccine 
formulation, thereby resulting in very weak cell activation. To conclude, these 
results confirm that successful i.vag. immunisation requires ag administration 
during the dioestrus as it is mostly described in the literature.  
 
4.2. Defining the optimal immunisation protocol 
4.2.1. Identification of the most potent adjuvant stimulating the 
strongest immune response after i.n. and i.vag. 
immunisation 
After identification of the most efficient strategy for obtaining the synchronisation 
of the cycle, it was critical to find the most suitable i.vag. immunisation protocol 
determining the most promising model ag and adjuvant. To this end, 
comparative immunisation studies were performed in which C57BL/6 female 
mice (n=5/group) received a model ag co-administered with different adjuvants 
by i.n. and i.vag. routes. The groups that received the formulation via the i.vag. 
route were DEPO-treated five days prior to each immunisation to synchronise 
their cycles (see Methods, Fig. 8).  
OVA was given at 50 µg/dose, whereas the dosage for the adjuvants was as 
follows: c-di-AMP 1.5 µg/dose, LPS 10 µg/dose, α-GalCerMPEG 5 µg/dose and 
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BPPcysMPEG 5 µg/dose. (C-di-AMP and α-GalCerMPEG were tested to be 
LPS free with HEK-blue test, levels were below the detection level [195].) At day 
49, animals were sacrificed, blood and VL were taken and the spleens were 
removed.  
Immunisation of OVA co-administered with c-di-AMP (OVA + c-di-AMP) by 
i.vag. route resulted in the elicitation of the highest serum IgG titres (Fig. 13A). 
Similar results were obtained when OVA was co-administered with either LPS or 
c-di-AMP as adjuvant by the i.n. route. Cellular responses were investigated by 
assessing the production of cytokines by spleen cells. To this end, we evaluated 
the expression of the Th1-cytokines IFN-γ and IL-2, as well as the Th2 cytokine 
IL-4 and the Th17 cytokine IL-17. The Th17- cytokine was strongly produced by 
spleen cells of mice immunised with OVA + c-di-AMP by i.n. route, whereas Th1 
responses were comparatively weaker (Fig. 13B). IL-4 was mainly induced in 
the groups where α-GalCerMPEG or c-di-AMP was co-administered as 
adjuvants. Based on these preliminary data, c-di-AMP was selected as most 
suitable mucosal adjuvant for further comparative studies following vaccination 
by different mucosal routes.  
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Figure 13: Identification of the optimal formulation for further studies. 
C57BL/6 (n=5 per group) were immunised by i.n. or i.vag. route with OVA co-administered with 
different adjuvants. (A) Black and white bars indicate groups immunised by i.n. and i.vag. route, 
respectively. The displayed results correspond to OVA-specific antibody titres obtained using 
pooled sera. (B) Cellular response measured in spleen cells.  
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4.2.2. Identification of the most suitable model ag for stimulating 
immune responses after i.n. and i.vag. immunisation 
In order to identify the optimal ag able to stimulate the strongest immune 
responses following immunisation by the two selected mucosal routes (i.n. and 
i.vag.), mice were immunised with either OVA (50 µg/dose) + c-di-AMP (5 
µg/dose) or β-Gal (15 µg/dose) + c-di-AMP (5 µg/dose). (β-Gal was tested with 
HEK-blue test for LPS, at a concentration of 2.5 µg/µl β-Gal, 5 ng/ml LPS were 
detected [195].) 
4.2.2.1. Induction of local and systemic humoral immune responses in 
C57BL/6 mice after immunisation by i.n. and i.vag. route 
In general, i.n. immunisation resulted in the elicitation of higher IgG titres in sera 
of vaccinated mice, as compared to the responses triggered after i.vag. 
immunisation (Fig. 14A). 
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Figure 14: Humoral immune response elicited in C57BL/6 mice immunised with OVA + c-
di-AMP or β-Gal + c-di-AMP by i.n. or i.vag. route.  
(A) Analysis of ag-specific IgG titre in sera and (B) IgA titre in VL of C57BL/6 mice (n=3) 
immunised on days 0, 14 and 28. The black bars (left part) indicate the Ig titres of i.n. immunised 
animals, whereas the white bars (right part) represent the titres of i.vag. immunised mice. 
Standard error of the mean (SEM) is indicated by vertical lines. Differences were statistically 
significant at p<0.05 (*), p<0.01 (**), p<0.0001 (****) using the One-way ANOVA.  
 
Moreover, formulations including β-Gal raised statistically significant higher 
humoral responses compared to OVA, as demonstrated by the levels of Igs in 
sera and VL (Fig. 14). Immunisation of mice using OVA + c-di-AMP induced 
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only marginal IgA production in the genital tract (Fig. 14B). On the other hand, 
immunisation of animals with β-Gal + c-di-AMP by i.n. route resulted in 
significant higher IgA titres in VLs, as compared to controls or groups receiving 
OVA + c-di-AMP (p<0.01), whereas i.vag. vaccination failed to induce high titres 
of ag-specific IgA in the vaginal mucosa. Taken together, in our experimental 
model β-Gal + c-di-AMP was the formulation inducing more robust immune 
responses. 
 
The IgG subclass pattern analysed in these studies indicates if a Th1 or Th2-
biased immune response is favoured. Thus, higher titres of IgG2a, IgG2b and 
IgG2c indicate Th1-dominated immune response, whereas IgG1 is specific for 
Th2-biased responses. Analysis of the IgG subclass pattern stimulated after i.n. 
immunisation with OVA alone showed a Th2 dominated response (IgG1), 
whereas a mixed Th1-Th2 response (increased levels of IgG1 and IgG2b) was 
observed in animals receiving OVA + c-di-AMP (Fig. 15). Immunisation via the 
i.vag. route favours the IgG2c rather than the IgG2b subclass (Th1 response) 
(Fig. 15). Immunisation via the i.vag. route seems to favour the stimulation of 
IgG2c rather than the IgG2b subclass (Th1 response) (Fig. 15). On the other 
hand, immunisation with β-Gal + c-di-AMP via the i.n. route resulted in the 
elicitation of similar IgG1, 2a and 2b titres, whereas administration of this 
formulation via i.vag. route stimulated stronger IgG2c titres followed by IgG2a 
and IgG1 (Fig. 15). However, mice immunised with β-Gal + c-di-AMP showed 
significantly higher ag-specific Ig titres in sera as compared to the titres induced 
in control groups receiving either PBS or OVA alone. This formulation also 
elicited significantly higher titres as compared to OVA + c-di-AMP given by 
either i.n. or i.vag. route (p<0.0001) (Fig. 15). Moreover, β-Gal + c-di-AMP 
elicited significant higher levels of IgG1 and IgG2b in sera after immunisation by 
i.n. route, as compared to the i.vag. route. Again the i.vag. delivered formulation 
induced significantly higher titres of IgG2b and 2c, as compared to control 
groups and groups receiving OVA as ag (IgG2a p<0.001, IgG2b p<0.0001) 
(Fig.15). 
Taken together, i.n. administration of β-Gal + c-di-AMP induced strongest IgG 
subclass titres, characterised by a mixed Th1/Th2 response pattern.  
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Figure 15: Pattern of IgG subclass titres induced in mice immunised with OVA + c-di-AMP 
or β-Gal + c-di-AMP by i.n. or i.vag. route.  
Induction of ag-specific IgG subclass titres in sera of C57BL/6 mice (n=3) immunised on days 0, 
14 and 28 by i.n. (left part) or i.vag. route (right part). SEM is indicated by vertical lines. The 
observed differences were statistically significant at p<0.01 (**), p<0.0001 (****), calculated 
using Two-way ANOVA, in comparison to the PBS group (●), the group receiving OVA alone (□) 
or the groups receiving OVA + c-di-AMP (■ i.n., ◙ i.vag) or β-Gal + c-di-AMP (◊ i.n., ⌂ i.vag.)  
 
4.2.2.2. Stimulation of cellular immune responses in C57BL/6 mice after i.n. 
and i.vag. immunisation 
 
The stimulation of efficient immune responses results also in the induction of 
cellular immunity, such as Th and cytotoxic T cell responses. Thus, proliferation 
of spleen derived immune cells was assessed by determination of 3H-thymidine-
incorporation (Fig. 16). For this assay, splenocytes were restimulated with OVA 
or β-Gal at concentrations of 0 µg/ml, 5 µg/ml, 20 µg/ml, 40 µg/ml. ConA (10 
µg/ml) served as positive control. 
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Figure 16: Evaluation of cellular immune responses in C57BL/6 mice immunised with 
OVA or β-Gal + c-di-AMP by mucosal routes. 
Splenocytes derived from mice immunised by (A) i.n. or (B) i.vag. route were analysed for their 
proliferation. Spleen cells were in vitro restimulated with different concentrations of the 
corresponding ag. Results are expressed as the ratio between values (average of 
quadruplicates) from stimulated and non-stimulated samples (stimulation index). The standard 
deviation (SD) is indicated by vertical lines. The observed differences were statistically 
significant in comparison with the PBS group (●), the groups receiving ag alone (□) or the 
groups receiving OVA + c-di-AMP (■) or β-Gal + c-di-AMP (◊) at p<0.05 (*) and p<0.0001 (****) 
using the Two-way ANOVA.  
 
The strongest spleen cell proliferation was stimulated in mice immunised with β-
Gal + c-di-AMP via the i.vag. route. Here, the stimulation index of 28 was 
statistically different to that of splenocytes derived from mice receiving OVA + c-
di-AMP or PBS alone (p<0.0001 (****)) (Fig. 16B). Lower differences in the 
proliferation rates of spleen cells were observed in mice immunised with OVA or 
β-Gal + adjuvant by i.n. route (p<0.005 (*)) (Fig. 16A). Nevertheless, for these 
groups stimulation was significantly higher as compared to the PBS group or 
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mice receiving ag alone with p<0.0001 (****). Mice immunised with OVA + c-di-
AMP via i.vag. route showed marginal proliferative responses of spleen cells 
(Fig. 16B). 
 
Cytokine secretion after restimulation of spleen cells with the corresponding ag 
was then assessed by an ELISPOT assay (section 3.7.4). Restimulation of 
spleen cells derived from mice receiving β-Gal + c-di-AMP resulted in increased 
numbers of cytokine secreting cells independently of the immunisation route, as 
compared to the results observed in mice receiving ag alone (Fig. 17). The 
highest levels of cytokine producing cells were obtained in mice immunised with 
β-Gal + c-di-AMP by the i.vag. route. Here, the higher numbers of cells 
produced IFN-γ, followed by those secreting IL-17 and IL-2. In all cases the 
secretion levels were significantly higher as compared to those observed in the 
control groups (p<0.05). Few IL-4 producing cells were detected (Fig. 17B). IFN-
γ production was similar in spleen cells of mice immunised with β-Gal + c-di-
AMP by i.vag. route as compared to that of mice immunised by the i.n. route 
(Fig. 17). IL-17 was significantly strongly produced after i.vag. immunisation 
using β-Gal + c-di-AMP than OVA + c-di-AMP (p<0.05). A similar profile, 
although with lower values, was observed in splenocytes derived from mice 
immunised with β-Gal + c-di-AMP and OVA + c-di-AMP by the i.n. route (Fig. 
17A). In contrast, administration of OVA + c-di-AMP by the i.vag. route also 
elicited increased numbers of IFN-γ, IL-2 and IL-4 producing cells, but did not 
stimulate IL-17 production (Fig. 17B). Taken together, β-Gal was the most 
potent ag for stimulating strong cellular immune responses by either the i.n. or, 
more pronounced, the i.vag. route. OVA and β-Gal induced a mixed 
Th1/Th2/Th17 immune response after i.n. immunisation in combination with c-
di-AMP. However, the cytokine profiles detected after vaccination seems to 
depend not only on the adjuvant but also on the ag used, since OVA + c-di-AMP 
was not able to stimulate strong IL-17 production when delivered by the i.vag. 
route. 
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Figure 17: Secretion profile of cytokines of spleen cells after ag-restimulation.  
Spleen cells from C57BL/6 mice immunised with OVA + c-di-AMP or β-Gal + c-di-AMP by (A) i.n 
or (B) i.vag route were analysed for their cytokine profile. Splenocytes were cultured for 24 h 
(IFN-γ) or 48 h (IL-2, IL-4, IL-17) with the corresponding ag. Cytokine production was 
determined by ELISPOT. The SEM is indicated by vertical lines. Results are expressed as spot 
forming units per 106 cells with subtracted background. Differences were statistically significant 
at p<0.05 (*) analysed by the Two-way ANOVA test with respect to values in C57BL/6 mice 
receiving OVA + c-di-AMP.  
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4.2.3. Comparative studies of ag-specific immune responses in 
C57BL/6 and BALB/c mouse strains  
As described in section 4.2.2, β-Gal + c-di-AMP induced stronger humoral and 
cellular responses at systemic and mucosal levels in C57BL/6 mice, as 
compared to OVA + c-di-AMP. However, it has been shown that the genetic 
background of the immunised animal can influence the polarisation of the 
stimulated immune responses. For example, infection of C57BL/6 mice with 
Leishmania induces a protective Th1 response, whereas in BALB/c mice an 
ineffective Th2 response is elicited [196]. Furthermore, even independently of 
the stimulated Th response pattern, genetic differences influence the 
susceptibility of the animals to certain pathogens, as shown before for the HSV-
1 [197]. Another aspect is that C57BL/6 mice are able to develop a fast IFN type 
I response and therefore are less susceptible than BALB/c mice [198], [199]. 
Hence, studies have been performed to investigate the potential of the studied 
immunisation approaches in mice strains of different genetic background. 
Most experiments in BALB/c mice were performed with β-Gal as ag. Here it was 
tested if and to which extent immune response of BALB/c mice immunised with 
β-Gal + c-di-AMP would vary from that of C57BL/6 mice. The i.n. route served 
as a golden standard and was compared to i.vag. administration. Animals 
received the formulations according to the usual immunisation protocol. At day 
49 post priming the stimulated immune responses were evaluated. In this 
experiment the influence of DEPO-treatment on the immune responses 
stimulated after i.n. immunisation was also analysed. Therefore, all animals 
were DEPO-treated five days before each immunisation. From the literature, the 
levels of a-specific serum IgG, proliferation and cytokine secretion were in the 
same range in DEPO-treated and untreat mice following a similar i.n. 
immunisation protocol [68]. 
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4.2.3.1. Induction of efficient local and systemic humoral immune responses 
in BALB/c mice after i.n. and i.vag. immunisation  
Immunisation with β-Gal + c-di-AMP via the i.n. route induced the highest IgG 
titre in sera of BALB/c mice, followed by titre observed in mice receiving the 
same vaccine formulation by i.vag. route (p<0.05) (Fig. 18). In both experimental 
settings β-Gal + c-di-AMP induced statistically significant stronger IgG 
production as compared to OVA + c-di-AMP via the same route (p<0.001) 
(Fig.18). Concluding, β-Gal constitutes the most immunogenic ag to elicit 
humoral immune responses when co-administered with c-di-AMP. In contrast, in 
mice receiving PBS or ag alone only weak IgG titres have been stimulated if any 
at all. 
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Figure 18: Induction of efficient systemic humoral immune responses in sera of BALB/c 
mice immunised with OVA + c-di-AMP or β-Gal + c-di-AMP by i.n. or i.vag. route. 
Analysis of ag-specific IgG titres in sera of BALB/c mice (n=4/group) immunised by i.n. (black 
bars) or i.vag. (white bars) route. SEM is indicated by vertical lines. Differences were statistically 
significant at p<0.005 (*), p<0.001 (***) and p<0.0001 (****) shown by analysis with One-way 
ANOVA test. 
 
When analysing the IgG subclass pattern stimulated in the different mouse 
strains, immunisation with ag + c-di-AMP via the i.n. or i.vag. route elicited 
similar profiles in BALB/c and C57BL/6 mice (Fig.15 and 19), respectively.  
 
*** 
**** 
* 
i.n. i.vag. 
Results 
 
 
103 
 
Ag
-
sp
ec
ifi
c 
Ig
G
 
su
bc
la
ss
tit
re
 
in
 
se
ra
PB
S
OV
A 
-
Ga
l
β
OV
A +
 
c-
di-
AM
P
-
Ga
l +
 
c-
di-
AM
P
β
0
5.0×105
1.0×106
1.5×106
IgG1
IgG2a
IgG2b
IgG3
Ag
-
sp
ec
ifi
c 
Ig
G
 
su
bc
la
ss
tit
re
 
in
 
se
ra
PB
S 
OV
A +
 
c-
di-
AM
P
-
Ga
l +
 
c-
di-
AM
P
β
0
5.0×105
1.0×106
1.5×106
 
Figure 19: Distribution of IgG subclass titres in sera of BALB/c mice immunised with OVA 
+ c-di-AMP or β-Gal + c-di-AMP by i.n. or i.vag. route. 
Analysis of IgG subclass titres in sera stimulated in BALB/c mice after two booster 
immunisations (n=4/group) given by (A) i.n. or (B) i.vag. route. The SEM is indicated by vertical 
lines. Differences were statistically significant at p<0.05 (*), p<0.0001 (****) shown by Two-way 
ANOVA.  
 
The IgG subclass distribution indicates similarities in groups immunised with β-
Gal + c-di-AMP via i.n. and i.vag. route (Fig. 19). Significant higher IgG2a and 
2b titres (p<0.0001) were observed in mice after immunisation with β-Gal with 
respect to animals receiving OVA + c-di-AMP. In animals immunised via the 
i.vag. route using β-Gal + c-di-AMP (Fig. 19), also IgG1 production was induced 
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significantly stronger, as compared to what observed using OVA + c-di-AMP by 
the same route (p<0.05). In all cases the levels of IgG3 were very low. 
Interestingly, while OVA co-administered with adjuvant delivered via the i.n. 
route stimulated increased levels of IgG1 and 2b but only weak IgG2a titres, 
immunisation via the i.vag. route stimulated similar levels of IgG1, 2a and 2b 
(Fig. 19). In none of the control groups β-Gal-specific IgG titres have been 
detected. Only i.n. immunisation with β-Gal alone stimulated an IgG1 titre of 
1:352000. To sum up, immunisation with ag + c-di-AMP stimulated mixed 
Th1/Th2 responses, as indicated by the mixed IgG subclass pattern observed. 
However, stronger humoral responses have been elicited in BALB/c mice using 
β-Gal as model ag (Fig.15 and 19). 
 
Beside the stimulation of antibody production at systemic level, we also 
analysed the differences in the level of IgA production in BALB/c and C57BL/6 
mice. Again, β-Gal + c-di-AMP administered via i.n. route elicited the strongest 
titres of ag-specific IgA in VL, which were statistically significant different to titres 
obtained following OVA + adjuvant administration via i.n. or i.vag. route 
(p<0.001) (Fig. 20). Immunisation through the i.vag. route using β-Gal + 
adjuvant also induced strong IgA responses. However, these titres were not 
significantly higher, as compared to those obtained using OVA as ag. 
Comparing the levels of ag-specific IgA elicited after i.n. and i.vag. 
immunisation, i.n. delivery of β-Gal + c-di-AMP raised similar titres in VL of 
BALB/c and C57BL/6 mice, whereas i.vag. administration stimulated stronger 
IgA production in BALB/c mice (Fig.14 and Fig. 20). Groups receiving OVA 
alone showed only poor induction of IgA production in VL. 
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Figure 20: Local humoral IgA immune response of immunised BALB/c mice in VL. 
Analysis of ag-specific IgA titres in lavage samples of BALB/c mice (n=4) after i.n. (black bars) 
or i.vag. immunisation (white bars). SEM is indicated by vertical lines. Differences were 
statistically significant at p<0.001 (***), p<0.0001 (****) and analysed by One-way ANOVA. 
 
Thus, in order to achieve strong humoral immune responses at local as well as 
at systemic level, immunisation of BALB/c mice using β-Gal + c-di-AMP is the 
most efficient vaccination protocol tested here. 
 
 
4.2.3.2. Stimulation of ag-specific cellular responses in BALB/c mice 
immunised by i.n. or i.vag. route 
The proliferation of spleen cells after ex vivo restimulation was measured by 3H-
thymidine incorporation, which was evaluated as CPM and expressed as 
stimulation index. The strongest lymphocyte proliferation was observed in cells 
of mice immunised with β-Gal + c-di-AMP by either i.vag. (SI of 100) or i.n. (SI 
of 70) route (Fig. 21). However, the values obtained in mice immunised with β-
Gal + c-di-AMP were also significantly different as those observed in groups 
receiving OVA + c-di-AMP following restimulation with 20 µg/ml (i.n.) or 40 µg/ml 
(i.vag.) of the corresponding ag (p<0.001 for i.n. and p<0.01 for i.vag. route, Fig. 
21). 
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Figure 21: Proliferation of restimulated spleen cells of mice immunised with OVA + c-di-
AMP or β-Gal + c-di-AMP by i.n. or i.vag. route. 
Analysis of the proliferative capacity of spleen cells derived from BALB/c mice (n=4) immunised 
with OVA + c-di-AMP or β-Gal + c-di-AMP by either (A) i.n. or (B) i.vag. route. SD is indicated by 
vertical lines. For the statistical analysis Two-way ANOVA was used and showed that 
differences were statistically significant at p<0.01 (**), p<0.001 (***), p<0.0001 (****), in 
comparison with the PBS control (●), the groups receiving OVA (□) or β-Gal alone (▲) or mice 
receiving OVA + c-di-AMP (■). 
 
Splenocytes derived from BALB/c mice showed up to four times increased 
proliferative capacities as compared to those of C57BL/6 mice (Fig. 16 and 21). 
Interestingly, comparing the proliferative capacities of spleen cells from mice 
immunised with β-Gal + c-di-AMP via i.n. by i.vag. route, i.vag. application 
stimulated significantly higher proliferation rates than i.n. application (p<0.0001) 
(Fig.21). However, maximal proliferation rate of splenocytes was already 
reached after restimulation of splenocytes with 5 µg/ml of the corresponding ag 
(Fig. 21). 
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The strong immune-stimulatory capacity of β-Gal + c-di-AMP indicated by high 
stimulation index was further confirmed by the enhanced number of cytokine 
producing spleen cells.  
Again, administration of this vaccine formulation promoted stronger cytokine 
production than the formulation containing OVA as ag (Fig. 22). In addition, as 
in the case of the immunisation studies using C57BL/6 mice, i.vag. 
immunisation stimulated higher numbers of cytokine secreting cells with respect 
to the i.n. application strategy (Fig. 22). This was also consistent with the results 
obtained immunising C57BL/6 mice (Fig. 17). However, the distribution pattern 
of the produced cytokines was similar when comparing values obtained 
following the i.n. and i.vag. immunisation protocols (Fig. 22).  
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Figure 22: Cytokine secretion profile of splenocytes derived from BALB/c mice 
immunised with OVA/c-di-AMP or β-Gal/c-di-AMP by the i.n. or i.vag. route. 
Cytokine production after (A) i.n. or (B) i.vag. immunisation. SEM is indicated by vertical lines.  
 
Thus, the numbers of IFN-γ, IL-2 and IL-17 secreting cells were significantly 
different to those obtained in all control groups (p<0.05). Nevertheless, similar to 
what was observed immunising C57BL/6 mice, the results obtained using β-Gal 
were not significantly different as compared to those using OVA as model ag 
(Fig. 22). Remarkably, in contrast to the results obtained after immunising 
C57BL/6 mice, vaccination of BALB/c mice with β-Gal + c-di-AMP stimulated 
increased numbers of IL-2 producing splenocytes. In addition, vaccination via 
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the i.vag. route using OVA + c-di-AMP resulted in increased numbers of IL-17 
producing spleen cells, which was also in contrast to what observed in C57BL/6 
mice (Fig. 17B and 22B).  
As in the case of C57BL/6 mice, i.n. immunisation of BALB/c mice with β-Gal + 
c-di-AMP stimulated the same pattern of cytokine secretion as immunisation via 
the i.vag. route. Here, only 65% of the spleen cells isolated after i.vag. 
immunisation have been detected to be IL-17 producing cells, followed by IFN-γ 
(50%), IL-2 (50%) and IL-4 (42%) producing cells (Fig. 22A). The same was true 
after immunisation of mice with OVA + c-di-AMP, with similar cytokine secretion 
profiles observed following i.n. and i.vag. vaccination. Moreover, higher 
numbers of cytokine producing cells were elicited after i.vag. immunisation, as 
compared to those obtained following i.n. immunisation. 
 
In conclusion, β-Gal + c-di-AMP stimulated spleen cells to a stronger cytokine 
production than OVA did, with i.vag. immunisation triggering higher cytokine 
levels as compared to i.n. immunisation. The observed Th response pattern was 
similar, with ag + c-di-AMP promoting a mixed Th1/Th2/Th17 response.  
 
4.2.4. Influence of mucosal adjuvants on the production of IL-17  
Th17 cells are a pivotal component for mucosal immunity. In this context, the 
cytokine IL-17 seems to be important for protection against pathogens such as 
Klebsiella pneumonia or Candida spp. and can be induced by certain microbial 
peptides [200], [201], [202]. Since IL-17 is known to play a role in mucosal 
immune responses, it was of special interest in the context of this work. 
Therefore, the following experiments were conducted to characterise the 
influence of different adjuvants on the outcome of the stimulated immune 
responses. To this end, animals were immunised following the vaccination 
protocol which was identified to stimulate the strongest immune responses by 
the above-described studies.  
BALB/c mice were immunised with β-Gal (15 µg/dose) co-administered with 
adjuvant c-di-AMP (5 µg/dose) by the i.n. route. In addition, another vaccine 
formulation was implemented based on the use of α-GalCerMPEG (5 µg/dose) 
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as adjuvant. The adjuvant α-GalCerMPEG has been chosen for the 
investigation of the role of IL-17 in host defence since it was shown to inhibit the 
IL-17 production in later phases of the immune response [203]. In contrast, c-di-
AMP enhances IL-17 production at late phase of the immune response (three 
weeks after the last boost) [68].  
Furthermore, a side-by-side comparison of the responses stimulated after i.n. 
and i.vag. immunisation of BALB/c mice has been performed, in order to 
investigate the impact of the immunisation route on the resulting immune 
responses. Vaccination followed the usual immunisation protocol, as described 
in 3.3.4.6. Animals immunised via the i.vag. route were DEPO-treated five days 
before each immunisation. As expected, immunisation with β-Gal + c-di-AMP 
stimulated high numbers of IL-17-producing splenocytes, whereas no IL-17 
secreting cells have been observed following vaccination with β-Gal + α-
GalCerMPEG (Fig. 23). 
 
4.2.4.1. Stimulation of efficient local and systemic humoral immune 
responses in BALB/c mice immunised with β-Gal co-administered 
with mucosal adjuvants by i.n. or i.vag. route 
Both tested adjuvants stimulated increased ag-specific IgG titres in sera of 
immunised mice, as compared to those observed in mice receiving the ag 
alone, independent of the administration route (p<0.0001) (Fig. 23). 
Furthermore, immunisation with β-Gal + c-di-AMP resulted in significantly higher 
IgG titres in sera of mice (n=5/group) than those observed in mice immunised 
with β-Gal + α-GalCerMPEG (p<0.0001) (Fig. 23).  
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Figure 23: Induction of efficient systemic humoral immune responses in sera of BALB/c 
mice immunised with β-Gal + c-di-AMP or β-Gal + α-GalCerMPEG. 
Ag-specific IgG titres in sera of BALB/c mice (n=5/group) stimulated after three immunisations 
through (A) i.n. or (B) i.vag. route. SEM is indicated by vertical lines. Differences were 
statistically significant at p<0.0001 (****) analysed by One-way ANOVA test. 
 
Consequently, the adjuvant α-GalCerMPEG seems to be less potent than c-di-
AMP at eliciting IgG responses in sera, independently of the route of 
immunisation.  
 
Beside the strength of the humoral immune responses stimulated by α-
GalCerMPEG also its immunomodulatory properties have been investigated. To 
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this end, the IgG subclass profiles stimulated after i.n. and i.vag. vaccination 
were evaluated. While c-di-AMP co-administered with ag elicited a mixed 
Th1/Th2 IgG response, as indicated by similar levels of IgG1, 2a and 2b, α-
GalCerMPEG stimulated a IgG1 dominated Th2 immune response (Fig. 24). In 
fact, significantly lower IgG2a and 2b titres were elicited, as compared to those 
obtained using c-di-AMP as adjuvant (p<0.0001) (Fig. 24). In fact, significantly 
lower IgG2a and 2b titres were elicited, as compared to those obtained using c-
di-AMP as adjuvant (p<0.0001) (Fig. 24). Interestingly, while administration of β-
Gal + α-GalCerMPEG via i.n. route also stimulated increased levels of IgG2a 
and IgG2b, almost no production of these IgG subtypes have been observed 
when β-Gal + α-GalCerMPEG was administered via i.vag. route (Fig. 24).  
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Figure 24: Distribution of IgG subclass titres in sera of BALB/c mice immunised with β-
Gal + c-di-AMP or β-Gal + α-GalCerMPEG. 
Analysis of the different IgG subclass titres in sera derived from BALB/c mice (n=5/group) 
immunised on days 0, 14 and 28 with β-Gal + c-di-AMP or β-Gal + α-GalCerMPEG by (A) i.n. or 
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(B) i.vag. route. SEM is indicated by vertical lines. Differences were statistically significant at 
p<0.0001 (****) analysed by Two-way ANOVA test. 
 
It is known that i.n. vaccination stimulates immune responses not only in the 
respiratory tract but also at distant mucosal territories, such as the genital tract 
[204], [205], [206]. The stimulation of mucosal immune responses at areas 
distant to the site of infection or vaccine application is based on the 
compartmentalisation of the mucosal immune system. Furthermore, recent 
studies showed, that i.n. immunisation of mice with ag + c-di-AMP is able to 
stimulate increased IgA titres in different mucosal areas [68]. However, unlike to 
i.n. vaccination, immunisation via i.vag. route has been reported to stimulate 
immune responses mainly at the site of vaccine application [112]. Thus, the 
stimulation of efficient mucosal immune responses at local and distant territories 
using c-di-AMP and α-GalCerMPEG as adjuvant has been investigated in a 
side-by-side comparison. 
When animals were immunised by the i.n. route, administration of β-Gal + c-di-
AMP stimulated significantly increased levels of IgA in VL, as compared to those 
observed in animals receiving β-Gal + α-GalCerMPEG or in the control groups 
(p<0.001) (Fig.25). 
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Figure 25: Induction of local humoral immune response in VL of BALB/c mice. 
Ag-specific IgA titre in VL induced in BALB/c mice immunised three times with β-Gal + c-di-AMP 
or β-Gal + α-GalCerMPEG by i.n. route. SEM is indicated by vertical lines. Differences were 
statistically significant at p<0.001 (***) analysed by One-way ANOVA test.  
 
Furthermore, i.vag. immunisation with β-Gal + c-di-AMP elicited significantly 
higher IgA titres in VL, as compared to immune responses stimulated after 
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administration of β-Gal + α-GalCerMPEG and in all control groups (p<0.0001) 
(Fig. 26A). As expected, no differences in the levels of ag-specific IgA were 
observed in saliva, NL and LL, when samples obtained from animals in the PBS 
control group and groups receiving ag + adjuvant were compared (Fig. 26B). 
This confirms that there is not efficient homing to distant mucosal territories 
following i.vag. vaccination [112].  
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Figure 26: Induction of mucosal immune responses in VL samples of BALB/c mice 
immunised with β-Gal + c-di-AMP or β-Gal + α-GalCerMPEG by i.vag. route.  
(A) The ag-specific IgA titre elicited was tested in VL derived from immunised mice. (B) Ag-
specific IgA titre detected in saliva, NL and LL of immunised mice. SEM is indicated by vertical 
lines. Differences were statistically significant at p<0.0001 (****) and analysed by Two-way 
ANOVA test.  
 
4.2.4.2. Induction of enhanced cellular proliferation and cytokine production 
in BALB/c mice immunised with β-Gal co-administered with 
adjuvants by i.n. or i.vag. route 
Besides the stimulation of humoral immune responses, α-GalCerMPEG is also 
known to stimulate strong cellular responses when administered via the i.n. 
route [207]. Here, co-administration of β-Gal + α-GalCerMPEG also stimulated 
increased cellular responses, as compared to those of mice receiving β-Gal 
alone (p<0.0001). However, the proliferative capacity of spleen cells derived 
from mice immunised i.n. with β-Gal + α-GalCerMPEG was significantly weaker, 
as compared to that observed using c-di-AMP as adjuvant (p<0.01) (Fig. 27A). 
Similar results have been obtained following i.vag. immunisation (Fig. 27B). 
Again, vaccination with β-Gal + c-di-AMP stimulated significantly stronger 
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cellular proliferation (stimulation index of about 22) as compared to all other 
groups immunised by i.vag. route (p<0.0001) (Fig. 27B). Interestingly, while c-di-
AMP seemed to stimulate stronger responses in mice immunised via the i.vag. 
than the i.n. route, the route of application seems to play a minor role when 
using α-GalCerMPEG as adjuvant (Fig. 27). 
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Figure 27: Cellular proliferation of ex vivo ag-restimulated spleen cells. 
The proliferation of spleen cells derived from BALB/c mice immunised by (A) i.n. or (B) i.vag. 
route was tested. SD is indicated by vertical lines. Differences were statistically significant at 
p<0.01 (**) and p<0.0001 (****) and analysed by the Two-way ANOVA test with respect to the 
PBS control group (●), the groups receiving β-Gal (▲), c-di-AMP alone (►), α-GalCerMPEG 
alone (○) or β-Gal + α-GalCerMPEG (◘). 
 
 
Then, the cytokine profiles stimulated in mice following vaccination with β-Gal + 
α-GalCerMPEG via the i.n. and i.vag. routes were investigated and compared 
with those stimulated using c-di-AMP as adjuvant (Fig. 28).  
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As expected, immunisation with β-Gal + α-GalCerMPEG stimulated significant 
lower levels of cytokine secreting cells, as compared to those observed in the 
group immunised with β-Gal + c-di-AMP, independently of the route of 
application (Fig. 28). However, the main sub-population stimulated by c-di-AMP 
was IL-17 secreting cells, followed by IFN-γ, IL-2 and IL-4 expressing 
splenocytes (Fig. 28). In contrast, groups immunised with the β-Gal + α-
GalCerMPEG showed no IL-17 producing cells and only marginal numbers of 
IFN-γ and IL-2 secreting cells. Here, mainly IL-4 secreting cells were induced 
(Fig. 28). However, despite the clear trend, the detected numbers of cytokine 
secreting cells did not differ significantly from those observed in control groups. 
As seen for the proliferative capacities of the splenocytes derived from 
immunised mice, also the levels of cytokine producing cells were higher after 
i.vag. immunisation than following vaccination by i.n. route (Fig. 28). Thus, the 
number of IL-2 producing cells stimulated after i.vag. immunisation with β-Gal + 
c-di-AMP was three-fold higher than in the i.n. group (p<0.01) (Fig. 28). The 
same was true in case of the number of IL-17 producing cells. Again, the values 
observed following i.vag. immunisation with β-Gal + c-di-AMP were significantly 
higher as compared to those following i.n. vaccination (p<0.05) (Fig. 28).  
In parallel experiments, it was tested if i.n. vaccination using β-Gal + c-di-AMP 
induced CD8+ IFN-γ secreting cells in spleens after restimulation with the CD8-
peptide (Fig. 28C left bar). Interestingly, i.vag. immunisation does not resulted in 
the stimulation of CD8+ IFN-γ secreting cells in spleens (Fig. 28C right bar). In 
conclusion, the i.n. immunisation using the above-mentioned formulation 
stimulates CD4+- and CD8+-cells to secrete IFN-γ, which was tested by 
restimulation of spleen cells with ag-peptide (Fig. 28C) and ag-protein (Fig. 
28A), whereas vaginal immunisation mainly stimulates CD4+-cells to secrete 
IFN-γ after restimulation with the ag-protein (Fig. 28B). 
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Figure 28: Cytokine profile of ag-restimulated spleen cells derived from BALB/c mice 
immunised with β-Gal + c-di-AMP or β-Gal + α-GalCerMPEG.  
Cytokines secreted by ex vivo ag-restimulated spleen cells from BALB/c mice immunised three 
times by (A, C left bar) i.n or (B, C right bar) i.vag. route. Cells were incubated for 24 or 48 h in 
the presence of a peptide encompassing the immunodominant Ld-restricted epitope of β-Gal 
(TPHPARIGL), which is specific for MHC class I presentation (for IFN-γ i.n. and i.vag. Fig 28C), 
or the β-Gal protein for IFN-γ, IL-2, IL-4 and IL-17 (Fig. 28 A + B). SEM is indicated by vertical 
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lines. The differences were statistically significant tested with the Two-way ANOVA at p<0.05 (*), 
p<0.01 (**), p<0.0001 (****) with respect to the group receiving β-Gal + α-GalCerMPEG (◘).  
 
 
To test if the compartmentalisation of the mucosal immune system allows also 
IL-17 secretion in the distant vaginal draining LN (iliac LN (iLN)) following i.n. 
vaccination, the stimulation of local cellular responses has been analysed. As 
shown in figure 29, β-Gal + c-di-AMP elicited also high numbers of IL-17 
secreting cells in iLN, as compared to all other groups (p<0.05) (Fig. 29). In 
contrast, ag + α-GalCerMPEG was not able to stimulate IL-17 producing cells in 
the iLN (Fig. 29).  
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Figure 29: Cytokine secretion of IL-17 produced by iLN cells following i.n. immunisation. 
Cellular responses stimulated after ag-specific restimulation following three i.n. immunisations 
using β-Gal + c-di-AMP or β-Gal + α-GalCerMPEG. SD is indicated by vertical lines. Differences 
were statistically significant tested with the One-way ANOVA at p<0.0001 (****) with respect to 
the PBS control group (●), and the groups receiving β-Gal (▲), c-di-AMP (►), α-GalCerMPEG 
(○), or β-Gal + α-GalCerMPEG (◘). 
 
 
The cytokine IL-17 and Th17 cells seem to play an important role in mucosal 
host defence. Thus, due to their capacity to specifically induce or block Th17 
polarisation, the two adjuvants c-di-AMP and α-GalCerMPEG constitute 
powerful tools to gain a more in depth knowledge of the underlying processes. 
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4.3. Evaluation of the s.l. immunisation strategy as alternative 
approach for i.n. immunisation 
Immunisation via the i.n. route is a very prominent and powerful vaccination 
strategy. As shown above, vaccine formulations applied by this route stimulate 
strong humoral and cellular immune responses not only at systemic but also at 
local mucosal areas [121]. However, it has been shown that there is the risk of 
vaccine redirection to the central nervous system (CNS) via retrograde axonal 
transport, as well as an association to neurological side effects, such as Bell’s 
palsy, after i.n. vaccination with formulations based in A-B moiety toxins and 
their derivatives [127]. Thus, alternative strategies need to be developed 
combining the advantages of i.n. vaccination with an improved safety profile. 
Immunisation via the s.l. route seems to be one of such approaches. Therefore, 
comparative studies were performed among formulations administered by other 
traditional mucosal routes and sublingually. 
 
4.3.1. Immunisation via s.l. route differs from oro-gastric 
application 
In order to confirm that in our experimental setting s.l. administration did not 
result in deglutition and subsequent oral immunisation, a side-by-side 
comparison of both administration routes was performed. To this end, BALB/c 
mice were immunised with β-Gal (30 µg/dose) + c-di-AMP (10 µg/dose) via s.l., 
oral and, as a golden standard, i.n. routes (n=4/group). The oral immunisation 
was performed using a feeding needle. Parts of the results in chapter 4.3.1. 
were pre-published [195].  
 
4.3.1.1. Immune responses stimulated following s.l. and oral immunisation 
differ in strength and shape 
Immunisation via s.l. route stimulated significant higher IgG titres in sera 
compared to oral immunisation (p<0.0001) (Fig. 30). However, the ag-specific 
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IgG titres stimulated following s.l. immunisation were similar to those detected 
after i.n. immunisation (Fig. 30). 
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Figure 30: IgG titre in sera of BALB/c mice immunised by s.l., i.n. or oral route. 
Analysis of ag-specific IgG titre in sera derived of BALB/c (n=4) immunised with β-Gal + c-di-
AMP by s.l., oral or i.n route. SEM is indicated by vertical lines. Differences were statistically 
significant tested with One-way ANOVA at p<0.0001 (****). 
 
Furthermore, as in the case of i.n. immunisation, vaccination via the s.l. route 
also stimulates a mixed Th1/Th2 response (Fig. 31). In both cases the observed 
IgG1, 2a and 2b titres were significantly higher, as compared to those occurring 
after oral immunisation (p<0.05). However, oral immunisation did not elicit 
significantly higher titres in sera, as compared to the titres induced in the control 
group (Fig. 31). 
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Figure 31: IgG subclass pattern in sera of BALB/c mice after immunisation via s.l. or i.n. 
or oral route. 
Humoral immune responses of BALB/c immunised with β-Gal + c-di-AMP via the s.l., oral or i.n 
route. SEM is indicated by vertical lines. Differences were statistically significant, as tested by 
Two-way ANOVA, p<0.05 (*), p<0.01 (**), p<0.0001 (****), with respect to the PBS group (●), 
and the groups receiving β-Gal + c-di-AMP via s.l. (♦) or oral (∩) or i.n. (◊) route 
 
 
These results confirmed that the responses obtained after s.l. vaccination are 
truly due to locally initiated process rather than by a trivial passage of ag and 
adjuvant to the gut. Furthermore, the obtained local humoral immune responses 
support the assumption that responses stimulated by s.l. administration differ 
qualitatively from those obtained after oral or i.n. immunisation. Nevertheless, in 
order to further validate this, the stimulated local immune responses were also 
analysed. Similar titres of ag-specific IgA were detected in mucosal samples of 
mice immunised via s.l. and i.n. route, respectively. While in both vaccination 
groups the highest titres were detected in saliva followed by VL, NL and LL, s.l. 
immunisation stimulated less IgA production in LL as compared to i.n. 
immunisation (Fig. 32). However, significant higher IgA titres were stimulated in 
saliva after s.l. and i.n. immunisation, as compared to the titres induced 
following immunisation by oral route (p<0.001) (Fig. 32).  
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Figure 32: Elicitation of humoral immune responses at distinct mucosal sites following 
s.l., oral and i.n. immunisation. 
BALB/c (n=4) were immunised with β-Gal + c-di-AMP via s.l., oral or i.n route. SEM is indicated 
by vertical lines. Differences were statistically significant as tested by Two-way ANOVA [p<0.001 
(***), p<0.0001 (****)] with respect to the PBS control group (●) and the groups receiving β-Gal + 
c-di-AMP via oral (∩) or i.n. (◊) route. 
 
 
4.3.1.2. Determination of the cellular immune responses elicited after s.l., 
oral and i.n. immunisation 
After providing a clear proof that immunisation via s.l. route differs from oral 
administration of vaccines in terms of the capacity to stimulate humoral 
immunity, cellular responses were evaluated.  
Immunisation with β-Gal + c-di-AMP via the s.l. route stimulated similar strong 
proliferative responses as i.n. immunisation (Fig. 33). Furthermore, both routes 
stimulate significantly higher spleen cell proliferation rates than oral 
immunisation (p<0.0001) (Fig. 33). 
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Figure 33: Cellular proliferation of ex vivo ag-restimulated spleen cells derived from 
BALB/c mice immunised by s.l., oral or i.n. route. 
BALB/c mice were immunised three times with β-Gal + c-di-AMP. SD is indicated by vertical 
lines. Differences were statistically significant when tested with Two-way ANOVA at p<0.001 
(***) and p<0.0001 (****) with respect to the PBS control group (●), and the groups receiving β-
Gal + c-di-AMP via s.l. (♦) or oral (∩) route. 
 
 
The same trend was observed analysing the stimulated cytokine response. 
Similar numbers of IL-2, IL-4 and IL-17 secreting spleen cells were stimulated 
following i.n. and s.l. immunisation (Fig. 34). Interestingly, while immunisation of 
mice with β-Gal + c-di-AMP via the i.n. route stimulated high numbers of IFN-γ 
producing cells, the same vaccine formulation administered via the s.l. route 
elicited only low numbers of IFN-γ secreting splenocytes (Fig. 34). However, 
both routes promoted significantly higher numbers of cytokine secreting cells, as 
compared to those observed following oral immunisation (p<0.0001). Again, oral 
immunisation elicited only very weak cellular immune responses (Fig. 34). 
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Figure 34: Effect of vaccination by different routes in the secretion of cytokines by ex 
vivo ag-restimulated spleen cells. 
BALB/c mice were immunised three times with β-Gal + c-di-AMP by s.l., oral or i.n. route. Cells 
were incubated for 24 or 48 h in the presence of a peptide encompassing the immunodominant 
Ld-restricted epitope of β-Gal (TPHPARIGL), which is specific for MHC class I presentation (for 
IFN-γ), or the β-Gal protein (for IL-2, IL-4 and IL-17). SEM is indicated by vertical lines. 
Differences were statistically significant when tested with Two-way ANOVA at p<0.0001 (****).  
 
 
4.3.2. Immunisation via s.l. route requires increased vaccine 
dosages as compared to the i.vag. and i.n. route 
When comparing the i.n. and i.vag. immunisation routes 15 µg β-Gal and 5 µg c-
di-AMP per dose were used. The optimal dose of β-Gal and c-di-AMP for s.l. 
immunisation turned out to be 30 µg and 10 µg per dose, respectively (data not 
shown). Thus, in order to allow a side-by-side comparison of the s.l. and i.vag. 
route studies were performed immunising BALB/c with the two different vaccine 
concentrations.  
4.3.2.1. Humoral immune responses  
Immunisation of mice via i.vag. route using the double amount of antigen and 
adjuvant, respectively, seemed to have only marginal effects on the stimulation 
of ag-specific IgG production if any at all (Fig. 35). 
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Figure 35: Humoral immune responses stimulated in vaccinated BALB/c mice using c-di-
AMP as mucosal adjuvant. 
The groups were immunised with dosages of 30 and 15 µg of ag, and 5 and 10 µg of 
adjuvant/dose. SEM is indicated by vertical lines.  
 
 
Furthermore, no effect has been observed in terms of the stimulated IgG 
subclasses. Both dosages of ag co-administered with the adjuvant strongly 
elicited a mixed Th1/Th2 response characterised by the presence of ag-specific 
IgG1, IgG2a and IgG2b significantly higher to those observed for the control 
groups (p<0.01 to p<0.001).  
However, when analysing the stimulated mucosal responses, administration of 
the high-dose vaccine formulation resulted in a similar stimulation of IgA 
responses in VL as compared to the low-dosage regimen (Fig. 36B).  
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Figure 36: Humoral immune responses after i.vag. immunisation with low and high dose 
formulations of the ag and adjuvant. 
(A) Systemic immune responses in BALB/c after three i.vag. immunisations, (B) Analysis of ag-
specific IgA in lavage samples of vagina (VL) of immunised mice. Local immune response in 
BALB/c after three i.vag. immunisations. The animals were immunised using either 30 or 15 µg 
of ag and 10 or 5 µg of adjuvant per dose. SEM is indicated by vertical lines. The statistic 
analysis was performed using two-way ANOVA, p<0.01 (**), p<0.001 (***). The differences were 
statistically significant in comparison with the PBS control group (●), and the groups receiving β-
Gal (▲), c-di-AMP (►) or β-Gal co-administered with c-di-AMP 15/5. 
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4.3.2.2. Cellular immune responses 
At the cellular level, the high dose vaccine formulation using β-Gal + c-di-AMP 
seemed to stimulate stronger proliferative responses of splenocytes (Fig. 37). 
However, the obtained values only differ significantly as compared to the low 
dose formulation when splenocytes were restimulated ex vivo with high ag 
concentration [20 µg/ml] (p<0.0001) (Fig. 37).  
 
 
Figure 37: Cellular immune responses after i.vag. immunisation with low and high dose 
formulations of the ag and adjuvant.  
SD is indicated by vertical lines. The statistical analysis was performed using Two-way ANOVA, 
p<0.0001 (****). The differences were statistically significant in comparison with the PBS control 
group (●), and the groups receiving β-Gal (▲), c-di-AMP (►) or β-Gal co-administered with c-di-
AMP 15/5 (◊). 
 
When analysing the stimulated cytokine profiles, no significant differences were 
observed comparing the low and high dose formulations administered by i.vag. 
route (Fig. 38). IL-17 producing splenocytes were stimulated by both vaccine 
formulations, followed by IL-2 and IL-4 secreting cells (Fig. 38). Interestingly, no 
IFN-γ producing cells were detected in both groups after stimulation with a 
peptide encompassing a MHC class I restricted epitope (Fig. 38). 
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Figure 38: Cytokine secreting cells stimulated after i.vag. immunisation with low and high 
dose formulations.  
Spleen cells were incubated for 24 or 48 h in the presence of a peptide encompassing the 
immunodominant Ld-restricted epitope of β-Gal (TPHPARIGL), which is specific for MHC class I 
presentation (for IFN-γ), or the β-Gal protein (for IL-2, IL-4 and IL-17). SEM is indicated by 
vertical lines.  
 
 
Taken together, when mice were immunised by i.vag. route with the optimal ag-
adjuvant dose for s.l. immunisation of 30 µg and 10 µg, respectively, no further 
increase in the stimulated immune responses was observed compared to those 
obtained using the optimal dose for i.n. immunisation of 15 µg and 5 µg.  
 
 
4.3.3. Side-by-side comparison of immune responses stimulated 
following immunisation by s.l. and i.vag. routes 
The formulation β-Gal + c-di-AMP stimulated most efficiently local and systemic 
immune responses in BALB/c mice. Thus, comparative studies for s.l. and i.vag. 
immunisations were performed using this vaccine formulation. However, in order 
to investigate the impact of the s.l. administration route on the stimulation of IL-
17 production, α-GalCerMPEG was again used for down-modulation of the 
triggered IL-17 responses, as opposite to the IL-17 response obtained after 
immunisation using c-di-AMP.  
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To this end, BALB/c mice (n= 5/group) were vaccinated with β-Gal + c-di-AMP 
and β-Gal + α-GalCerMPEG, applied through the i.vag. or s.l. route. I.n. 
immunisation was used as a golden standard to ascertain if the s.l. route 
represents a valid alternative for mucosal responses at the level of the genital 
tract, which are similar to those obtained following i.vag. exposure to the ag.  
 
4.3.3.1. Immunisation by the s.l. route elicits efficient mucosal, humoral 
immune responses  
Administration of β-Gal + c-di-AMP through the s.l. route stimulated as strong 
IgG titres as application via either i.n. or i.vag. route (Fig. 39). The obtained 
values were significantly higher as compared to the control groups receiving 
PBS, ag or adjuvant alone (p<0.0001). Immunisation with β-Gal + α-
GalCerMPEG also stimulated significant higher antibody titres in sera, as 
compared to those of animals in the control groups (p<0.001) (Fig. 39). 
However, α-GalCerMPEG was less efficient at stimulating humoral immune 
responses following vaccination via the s.l. and i.vag. routes than c-di-AMP (Fig. 
39). 
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Figure 39: Ag-specific IgG titre in sera of BALB/c mice immunised by i.n., s.l. and i.vag. 
routes.  
BALB/c mice were immunised three times with β-Gal alone or adjuvant by (A) s.l. or i.n. route, 
and (B) i.vag. route. The i.n. immunisation was used as golden standard. SEM is indicated by 
vertical lines. The differences were statistically significant when tested with One-way ANOVA at 
p<0.001 (***) and p<0.0001 (****) with respect to PBS group (●), the control groups receiving β-
Gal (▲), c-di-AMP (►) or α-GalCerMPEG (○) alone, or the group receiving β-Gal + α-
GalCerMPEG (◘) or β-Gal + c-di-AMP by i.n. route (◊). 
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To investigate the potential impact of s.l. immunisation the quality of the 
stimulated immune responses, the distribution of ag-specific IgG subclasses 
was analysed (Fig. 40).  
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Figure 40: Distribution of IgG subclass titres in sera derived from BALB/c mice 
immunised by i.vag., s.l. and i.n. route.  
BALB/c mice were immunised three times with PBS, β-Gal alone or co-administered with 
adjuvant by (A) s.l. or (B) i.vag. route. As positive control the i.n. administration strategy was 
used. SEM is indicated by vertical lines. The differences were statistically significant when 
tested with Two-way ANOVA at p<0.05 (*), p<0.001 (***) and p<0.0001 (****) with respect to to 
control groups receiving PBS (●), β-Gal (▲), c-di-AMP (►) or α-GalCerMPEG (○) alone, or 
groups receiving β-Gal co-administered with α-GalCerMPEG (◘) or with c-di-AMP by i.vag. (⌂) 
or s.l. (∩) route. 
 
 
No significant differences in the distribution of IgG subclasses in sera have been 
observed, when comparing the values obtained following vaccination with β-Gal 
+ c-di-AMP by the different immunisation routes (Fig. 40). Thus, in all of these 
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groups a mixed Th1/Th2 response has been stimulated as indicated by similar 
titres of IgG1, 2a and 2b subclasses. In addition, the obtained titres were 
significantly higher as compared to those observed in the control groups, and 
the groups receiving β-Gal + α-GalCerMPEG (p<0.0001) (Fig. 40). 
Nevertheless, statistically significant higher IgG1, 2a and 2b titres in sera were 
stimulated after i.n. immunisation, as compared to those observed after s.l. 
(p<0.05) and i.vag. immunisation (p<0.0001) (Fig. 40). The amount of IgG3 
detected after vaccination via s.l. or i.vag. route was negligible (Fig. 40). 
 
To investigate the potential of the s.l. immunisation strategy to stimulate 
mucosal immune responses not only at local level but also at distant mucosal 
areas, ag-specific IgA levels in different mucosal lavages were determined (Fig. 
41). Comparing the IgA titres stimulated following vaccination of mice with β-Gal 
+ c-di-AMP, s.l. immunisation strongly increased the IgA production in the 
mucosa, whereas immunisation via the i.vag. route elicited only weaker ag-
specific IgA in VL (Fig. 41). Furthermore, co-administration of β-Gal + c-di-AMP 
was the most efficient approach for stimulating IgA production, whereby the 
highest titres were observed in saliva of immunised mice, followed by VL, LL 
and NL (Fig. 41A). However, only in saliva statistically significant differences 
have been observed when comparing the IgA titres obtained following 
immunisation of mice with β-Gal + c-di-AMP by either s.l. or i.n. route 
(p<0.0001) (Fig. 41). In any case, immunisation of mice with this vaccine 
formulation stimulated significantly higher IgA titres, as compared to the 
formulation including α-GalCerMPEG as adjuvant (p<0.0001) (Fig. 41). 
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Figure 41: Ag-specific IgA titre in lavage samples derived from BALB/c mice immunised 
with β-Gal + c-di-AMP or β-Gal + α-GalCerMPEG by s.l., i.n. or i.vag. route.  
The ag-specifiic IgA titres were tested in saliva, VL, NL and LL derived from mice immunised by 
(A) s.l. or (B) i.vag. route. As positive control mice were immunised by i.n. route. SEM is 
indicated by vertical lines. Differences were analysed by Two-way ANOVA test and statistically 
significant at p<0.01 (**) and p<0.0001 (****) with respect to groups receiving PBS (●), β-Gal 
(▲), c-di-AMP (►) or α-GalCerMPEG (○) alone, or groups vaccinated with β-Gal + α-
GalCerMPEG (◘) or β-Gal + c-di-AMP by i.vag., s.l. (⌂) or i.n. (◊) route. 
 
As indicated by this data, s.l. immunisation efficiently triggers high IgA levels in 
local as well as in distant mucosal territories, to a similar extent to those 
obtained after i.n. immunisation. Thus, vaccination via s.l. route constitutes 
indeed a valid alternative to the i.n. immunisation strategy, particularly when 
responses at the level of the genital tract. 
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4.3.3.2. Effects resulting from s.l. immunisation on cellular immune 
responses 
After evaluating the capacity of s.l. immunisation to stimulate efficient humoral 
immune responses, the impact on cellular responses was investigated. The 
highest proliferation of spleen cells was induced in mice immunised with β-Gal + 
c-di-AMP via the i.vag. route (SI around 10) and the s.l. route (SI between 6-12) 
(Fig. 42). After i.n. immunisation, a stimulation index of about five was 
calculated. However, proliferation rates of splenocytes derived from mice 
immunised via s.l. route were not significantly different to those obtained after 
i.n. immunisation (Fig. 42A). Administration of β-Gal + c-di-AMP via the i.vag. 
route again stimulated significantly stronger proliferative capacities of spleen 
cells, as compared to the group receiving β-Gal + c-di-AMP by i.n. route 
(p<0.0001) (Fig. 42B). In contrast, the adjuvant α-GalCerMPEG stimulated only 
weak cellular responses after i.vag. or i.n. vaccination. The obtained indexes are 
rarely different compared to the control groups receiving PBS, ag or adjuvant 
alone.  
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Figure 42: Evaluation of the cellular responses stimulated in mice vaccinated by different 
mucosal routes.  
BALB/c mice were immunised three times with β-Gal + c-di-AMP via (A) s.l. or (B) i.vag. route. 
Results are averages of quadruplicates and they are expressed as stimulation index. SD is 
indicated by vertical lines. Differences were statistically significant when tested with Two-way 
ANOVA at p<0.001 (***) and p<0.0001 (****) with respect to the control groups receiving PBS 
(●), β-Gal (▲), c-di-AMP (►) or α-GalCerMPEG (○) alone, and groups receiving β-Gal + α-
GalCerMPEG (◘) or β-Gal + c-di-AMP (◊) by the i.n. route. 
 
 
Then, the proliferative capacity of lymphocytes derived from the draining LN was 
evaluated, to assess the local cellular immune responses stimulated by different 
formulations and routes. To this end, iLN (draining the vagina) and cLN 
(draining the sublingual tissue and the nose) were collected from immunised 
mice and proliferation assays were performed (Fig. 43). 
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Figure 43: Evaluation of the cellular responses of LN cells derived from BALB/c mice 
vaccinated by different routes using c-di-AMP as adjuvant.  
Spleen cells from vaccinated animals were restimulated with different concentrations of β-Gal for 
96 h. Cellular proliferation was then assessed by determination of the [3H] thymidine 
incorporated into the DNA of replicating cells. iLN and cLN cells were derived from mice 
immunised by (A+C) i.vag. or (B+D) s.l. route. Results are averages of quadruplicates and they 
are expressed as stimulation indexes. SD is indicated by vertical lines. The differences were 
statistically significant when tested by Two-way ANOVA at p<0.0001 (****) with respect to those 
from control groups receiving PBS (●), β-Gal (▲), c-di-AMP (►) or α-GalCerMPEG (○) alone, or 
groups immunised with β-Gal co-administered with α-GalCerMPEG (◘) or with c-di-AMP by the 
i.n. (◊) route. 
 
 
Cells isolated from iLN of mice immunised with β-Gal + c-di-AMP via i.vag. route 
showed the highest proliferation rates (SI between 25-99), which were 
significantly stronger as compared to those values observed in all other groups 
(p<0.0001) (Fig. 43 A). Efficient proliferative responses were also observed after 
s.l. immunisation with β-Gal + c-di-AMP (SI between 4-7; p<0.0001) (Fig. 43D). 
Only marginal proliferation rates were observed for cells derived from mice 
immunised with α-GalCerMPEG (Fig. 43). Thus, analogue to what was 
observed for the humoral immune responses, s.l. immunisation with β-Gal + c-
di-AMP stimulated increased proliferative capacities at both systemic and local 
levels (Fig. 42 and 43). 
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These results were further validated by analysing the stimulated cytokine 
profiles (Fig. 44). 
Again, co-administration of ag + c-di-AMP via i.vag. route stimulated most 
efficient cytokine production, as compared to those stimulated using α-
GalCerMPEG as adjuvant (Fig. 44). The detected values of IL-2 and IL-17 
producing cells were significantly higher than those observed in mice immunised 
via s.l. route (p<0.001) and all control groups (p<0.0001) (Fig. 44). Interestingly, 
while c-di-AMP was able to stimulate IFN-γ production by CD8+ cells when 
administered via either s.l. or i.n. route, no IFN-γ secreting cells were observed 
in spleens of mice immunised via the i.vag. route (Fig. 44). Using α-
GalCerMPEG as adjuvant, only low numbers of cytokine producing cells were 
stimulated following immunisation, with similar levels of IFN-γ and IL-4 secreting 
cells (Fig. 44).  
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Figure 44: Analysis of the cytokine producing cells from vaccinated mice.  
Spleen cells recovered from BALB/c mice immunised via (A) s.l. or (B) i.vag. route were 
incubated for 24 or 48 h in the presence of a peptide encompassing the immunodominant Ld-
restricted epitope of β-Gal (TPHPARIGL), which is specific for MHC class I presentation (for 
IFN-γ), or the β-Gal protein (for IL-2, IL-4 and IL-17). Then, the numbers of cytokine producing 
cells were determined by ELISPOT. As golden standard, responses stimulated after i.n. 
administration were analysed. SEM is indicated by vertical lines. The differences were 
statistically significant when tested with Two-way ANOVA at p<0.05 (*), p<0.01 (**), p<0.001 
(***), p<0.0001 (****) with respect to values from control groups receiving PBS (●), β-Gal (▲), c-
di-AMP (►) or α-GalCerMPEG (○), or vaccinated with β-Gal co-administered with α-
GalCerMPEG (◘) or c-di-AMP by i.n. (◊), s.l. (∩) or i.vag. (⌂) route. 
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In conclusion, similar patterns of cytokine secreting cells have been observed 
when the different immunisation routes were compared. Moreover, the highest 
levels of cytokine producing splenocytes were stimulated by i.vag. 
immunisation, followed by s.l. and i.n. immunisation. 
Interestingly, while s.l. immunisation seems to elicit superior immune responses 
at humoral level as compared to i.vag. immunisation, exactly the opposite was 
observed when comparing the stimulated cellular responses. Here, i.vag. 
immunisation led to the stimulation of stronger cellular responses than s.l. 
vaccination. 
 
4.3.4. Combination of i.vag. and s.l. immunisation does not result 
in a further increase of humoral and cellular immune 
responses 
As mentioned above, i.vag. immunisation with β-Gal + c-di-AMP elicits stronger 
cellular immune responses than s.l. immunisation, which in turn promotes 
stronger humoral responses. Thus, it was investigated if the combination of both 
immunisation strategies would lead to optimal humoral and cellular immune 
responses. 
 
4.3.4.1. Humoral immune responses stimulated following immunisation via 
i.vag. and s.l. route  
The analysis of the ag-specific IgG titres in sera of mice immunised following a 
combined vaccination strategy (i.e. simultaneous administration of formulations 
via s.l. and i.vag. route; 30 µg of ag and 10 µg of adjuvant divided in two 
aliquots) showed that there is no further increase in antibody production 
observed (Fig. 45). In fact, the combination regime stimulated similar ag-specific 
IgG titres to the conventional approach when using c-di-AMP as adjuvant. In the 
groups in which α-GalCerMPEG was used as adjuvant, even less efficient ag-
specific IgG responses were observed following the combined strategy (Fig. 45). 
However, in all cases animals immunised with β-Gal + c-di-AMP showed 
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significant higher IgG titre in sera compared to groups immunised with β-Gal + 
α-GalCerMPEG (p<0.0001 for i.vag. and i.vag. + s.l., p<0.001 for s.l.).  
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Figure 45: Ag-specific IgG in sera of BALB/c stimulated following single and combined 
vaccination strategies.  
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Humoral immune responses of BALB/c immunised three times with β-Gal + c-di-AMP via the (A) 
i.vag., (B) s.l or (C) combination (simultaneous administration of formulation to both routes) 
route. SEM is indicated by vertical lines. The statistic significance of the observed differences 
was evaluated using Two-way ANOVA, p<0.001 (***), p<0.0001 (****). 
 
When the IgG subclass pattern stimulated by the combined vaccine formulation 
encompassing β-Gal + c-di-AMP was analysed, a mix of the subclass pattern 
stimulated by the individual regimens was detected. Thus, while β-Gal + c-di-
AMP administered via the i.vag. route stimulated similar titres of IgG1, 2a and 
2b, and administration of the same formulation via s.l. route stimulated high 
titres of IgG2b followed by IgG2a and IgG1, simultaneous immunisation by both 
routes stimulated high titres of IgG2a followed to IgG2b and IgG1 (Fig. 46). In 
contrast, no effect on the stimulated IgG subclass profiles has been observed 
when α-GalCerMPEG was used as adjuvant (Fig. 46). However, the IgG2a and 
IgG2b titres stimulated following vaccination with β-Gal + c-di-AMP were 
significantly higher with respect to those of mice receiving β-Gal + α-
GalCerMPEG (p<0.0001), independently of the vaccination strategy (Fig. 46). 
No differences in the values of IgG1 have been observed comparing the titres 
stimulated by c-di-AMP and α-GalCerMPEG when administered by i.vag. route 
alone or by both routes together (Fig. 46A + C). In fact, s.l. immunisation of mice 
with β-Gal + α-GalCerMPEG following the combined vaccination protocol 
stimulated significantly higher IgG1 titres, as compared to those obtained using 
c-di-AMP as adjuvant (p<0.001) (Fig. 46B). However, while β-Gal + c-di-AMP 
stimulated a mixed Th1/Th2 response, as indicated by similar values of IgG1, 2a 
and 2b, β-Gal + α-GalCerMPEG stimulated a Th2 dominated response, as 
indicated by high levels of IgG1 (Fig. 46). 
 
Results 
 
 
142 
 
Ag
-
sp
ec
ifi
c 
Ig
G
-
su
bc
la
ss
 
tit
re
 
in
 
se
ra
1 2 3 4 5
0
1.0×104
2.0×104
3.0×104
5.0×105
1.0×106
1.5×106
IgG1
IgG2a
IgG2b
IgG3
Ag
-
sp
ec
ifi
c 
Ig
G
-
su
bc
la
ss
tit
re
 
in
 
se
ra
-
Ga
l 
β
c-
di-
AM
P
-
Ga
lCe
rM
PE
G
α
 
-
Ga
l +
 
c-
di-
AM
P
β -
Ga
lCe
rM
PE
G 
α
-
Ga
l +
 
β
0
5.0×105
1.0×106
1.5×106
Ag
-
sp
ec
ifi
c 
Ig
G
-
s
u
bc
la
ss
 
tit
re
 
in
 
se
ra
-
Ga
l 
β
-
Ga
l +
 
c-
di-
AM
P 
β
-
Ga
lCe
rM
PE
G 
α
-
Ga
l +
 
β
0
5.0×105
1.0×106
1.5×106
 
 
Figure 46: Humoral immune responses in sera after i.vag and s.l. immunisation and a 
combination of these routes.  
Humoral immune responses of BALB/c immunised three times with β-Gal + c-di-AMP via the (A) 
i.vag., (B) s.l or (C) combination of the routes. SD is indicated by vertical lines. The statistic 
significance of the observed differences was evaluated by Two-way ANOVA, p<0.001 (***), 
p<0.0001 (****). 
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4.3.4.2. Humoral local immune responses following combined immunisation 
via i.vag. and s.l. route 
As in the case for the observed IgG titres in sera of vaccinated mice, by and 
large the combination of both immunisation routes did not result in a further 
increase of the amount of ag-specific IgA in the different mucosal secretions of 
vaccinated animals (Fig. 47). Only in VL of mice immunised with β-Gal + c-di-
AMP following the combined vaccination strategy, significantly higher IgA titres 
were observed, as compared to those obtained following the individual 
immunisation protocol (Fig. 47A + B). Interestingly, when α-GalCerMPEG was 
used as adjuvant for the combined strategy, even a decreased IgA titre was 
detected (Fig. 47).  
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Figure 47: Humoral immune responses in mucosal lavages after i.vag and s.l. 
immunisation, alone and in combination.  
Humoral mucosal immune responses of BALB/c mice immunised three times with β-Gal + c-di-
AMP via the (A) i.vag., (B) s.l or (C) combination of the routes. SEM is indicated by vertical lines. 
The statistic significance of the observed differences was evaluated by Two-way ANOVA, 
p<0.0001 (****), p<0.01 (**). 
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4.3.4.3. Systemic and local cellular immune responses stimulated following 
combined immunisation via i.vag. and s.l. route 
The cellular immune responses stimulated following i.vag., s.l. and combined 
vaccination strategies were compared analysing the proliferative capacities of 
cells derived from spleen and the corresponding draining LNs. The only vaccine 
formulation stimulating strong proliferative immune responses at systemic level 
was β-Gal + c-di-AMP, independently of the application route (Fig. 48). In any 
case, the stimulated proliferation rates were significantly stronger as compared 
to those observed using PBS and adjuvant alone, respectively, or α-
GalCerMPEG in combination with β-Gal (p<0.0001) (Fig. 48). The strongest 
proliferation rates were stimulated after s.l. immunisation (Fig. 48B). Thus, 
combination of both immunisation routes did not further increase the cellular 
responses at systemic level (Fig. 48B and C). 
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Figure 48: Cellular immune responses from spleen cells after i.vag and s.l. immunisation 
and a combination of these routes.  
The groups received β-Gal and c-di-AMP via the (A) i.vag., (B) s.l. and (C) a combination of both 
routes. SD is indicated by vertical lines. The statistic analysis was performed using Two-way 
ANOVA, p<0.0001 (****).The differences were statistically significant in comparison with the 
control groups receiving PBS (●), β-Gal (▲), c-di-AMP (►), and α-GalCerMPEG (○), and the 
group receiving β-Gal + α-GalCerMPEG (◘). 
 
Evaluation of the cellular responses stimulated at local level showed that only 
immunisation with β-Gal + c-di-AMP resulted in strong cellular responses (Fig. 
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49 + 50). Nevertheless, the observed differences in the proliferative capacities 
of cells derived from iLN were only significant following i.vag. immunisation 
(p<0.01) (Fig. 49A). When investigating cells derived from cLN, immunisation 
via s.l. route stimulated the strongest proliferation rates which were significantly 
higher as compared to all other vaccination groups (p<0.0001) (Fig. 50B). 
Neither i.vag. immunisation stimulated strong local responses in cLN, nor did s.l. 
immunisation in iLN (Fig. 49B + 50A). In any case, the combined vaccination 
strategy was demonstrated to be unefficient to further increase the proliferative 
capacities of LN derived cells (Fig. 49C + 50C). 
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Figure 49: Cellular immune in iLN after i.vag and s.l. immunisation and a combination of 
these routes.  
The immunisation groups received β-Gal + c-di-AMP via the (A) i.vag., (B) s.l. and (C) a 
combination of both routes. SD is indicated by vertical lines. The statistic analysis was 
performed using Two-way ANOVA, p<0.01 (**).The differences were statistically significant in 
comparison with the control groups receiving PBS (●), β-Gal (▲), c-di-AMP (►), and α-
GalCerMPEG (○), and the groups receiving β-Gal + α-GalCerMPEG (◘). 
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Figure 50: Cellular immune responses in cLN after i.vag and s.l. immunisation and a 
combination of these routes. 
The groups were immunised with β-Gal and c-di-AMP and α-GalCerMPEG, respectively, via the 
(A) i.vag., (B) s.l. and (C) after combination of i.vag. and s.l. immunisation route. SD is indicated 
by vertical lines. Statistical test is Two-way ANOVA, p<0.005 (*), p<0.0001 (****).The differences 
were statistically significant in comparison with the PBS group (●), β-Gal (▲), c-di-AMP (►), α-
GalCerMPEG (○), and the groups receiving β-Gal + α-GalCerMPEG (◘). 
 
Interestingly, no significant differences in the values of cytokine producing cells 
have been observed when comparing the combined vaccination strategy with 
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the individual immunisation protocols (Fig. 51). Again, only vaccination with β-
Gal + c-di-AMP stimulated strong values of cytokine producing cells (Fig. 51). In 
addition, IL-17 secreting splenocytes were stimulated the most, followed by 
those secreting IL-4 (Fig. 51). In contrast, only low levels of IFN-γ secreting cells 
were observed (Fig. 51). As shown before, only low levels of IFN-γ and IL-4 
secreting splenocytes have been stimulated using α-GalCerMPEG as adjuvant 
(Fig. 51). 
 
Results 
 
 
151 
 
Sp
o
t F
o
rm
in
g 
Un
its
/
1x
10
6  
ce
lls
 
(S
FU
)
0
100
200
300
600
700
800
900
1000
1100
1200
IFN-γ
IL-2
IL-4
IL-17
Sp
o
t F
o
rm
in
g 
Un
its
/
1x
10
6  
ce
lls
 
(S
FU
)
-
Ga
l 
β
c-
di-
AM
P
-
Ga
lCe
rM
PE
G
α
 
-
Ga
l +
 
c-
di-
AM
P
β -
Ga
lCe
rM
PE
G 
α
-
Ga
l +
 
β
0
100
200
600
800
1000
1200
Sp
o
t F
o
rm
in
g 
Un
its
/
1x
10
6  
ce
lls
 
(S
FU
)
-
Ga
l 
β
-
Ga
l +
 
c-
di-
AM
P 
β
-
Ga
lCe
rM
PE
G 
α
-
Ga
l +
 
β
0
100
200
300
400
600
700
800
900
1000
1100
1200
 
Figure 51: Cytokine profile of spleen cells stimulated following i.vag and s.l. 
immunisation and a combination of these routes.  
The groups of mice were vaccinated via (A) i.vag., (B) s.l. and (C) a combination of both routes. 
Cells were incubated for 24 or 48 h in the presence of a peptide encompassing the 
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B 
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immunodominant Ld-restricted epitope of β-Gal (TPHPARIGL), which is specific for MHC class I 
presentation (for IFN-γ ), or the β-Gal protein (for IL-2, IL-4 and IL-17). SEM is indicated by 
vertical lines. The statistic analysis was performed using Two-way ANOVA, p<0.0001 (****). The 
differences were statistically significant in comparison with the control groups receiving PBS (●), 
β-Gal (▲), c-di-AMP (►) and α-GalCerMPEG (○), and the test group receiving β-Gal + α-
GalCerMPEG (◘). 
 
 
In conclusion, combination of the i.vag. and s.l. immunisation routes in a single 
vaccination protocol did not further increase the efficiency of the single route 
vaccination strategies.  
 
 
 
In order to characterise more in detail the source of IL-17 in mice immunised 
with β-Gal + c-di-AMP via i.vag. or s.l. route, spleen cells of vaccinated animals 
were restimulated with 40 µg/ml of ag and subsequently characterised by 
specific T-cell marker (CD4, CD8, γδ-TCR) based on iterative chip cytometry 
(ICBC). In brief, splenocytes of immunised mice were pooled and transferred to 
the chip. After fixation, cells were stained by fluorochrome-conjugated marker-
specific antibody, and the type and number of cells were evaluated. About 1% of 
spleen cells were IL-17+ cells (Fig. 52). While no clusters of IL-17 producing 
cells could be detected in splenocytes isolated from mice receiving PBS, 40% of 
the IL-17 producing cells isolated from spleens of mice immunised with β-Gal + 
c-di-AMP via the i.vag. route were CD4+, followed by 2.7% of CD8+ and 0.9% of 
γδ T-cells (Fig. 52A + B). However, more than half of the analysed cells were 
not specified, but it is likely that most of them were CD4- NKT cells (Fig. 52B) 
[208]. In contrast, when analysing spleen cells derived from mice immunised 
with β-Gal + c-di-AMP via the s.l. route, 15% of the IL-17 producing splenocytes 
were characterised by the expression of γδ-TCR and the number of CD4+ cells 
was increased by 10% (Fig. 52B+C). The amount of non specified IL-17 
producing cells was reduced by 20%. 
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Figure 52: Analysis of the IL-17 producing cells stimulated following immunisation with 
β-Gal + c-di-AMP.  
Cluster of IL-17 producing cells isolated from spleen of mice immunised by i.vag. route with (A) 
PBS, β-Gal + c-di-AMP by (B) i.vag. and (C) s.l. route. Results are given as percentage of IL-17 
producing splenocytes.  
 
Taken together, the main populations producing IL-17 following immunisation 
with β-Gal + c-di-AMP seemed to be CD4+ and perhaps NKT cells. However, 
also γδ T-cells were found to produce IL-17, whereby higher numbers of these 
cells were found in spleen of mice immunised via s.l. route compared to those 
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obtained following i.vag. vaccination. If this result is rooted in a different 
stimulation capacity of c-di-AMP depending on the route of application or in a 
different functionality of the γδ T-cells activated at different mucosal territories 
needs to be further investigated [209], [210]. 
 
4.4. Summary of the humoral and cellular responses obtained 
following different immunisation strategies 
The obtained results demonstrated that s.l. immunisation is an efficient 
alternative to i.n. immunisation (Table 1). Vaccination by both routes stimulated 
similarly strong humoral and cellular immune responses. In addition, 
administration of vaccine formulations by the s.l. route promoted as strong 
mucosal immune responses as administration by i.n. route, showing the same 
compartmentalisation profile. Thus, s.l. vaccination stimulated strong production 
of ag-specific IgA not only at local level but also at distant mucosal areas, such 
as the genital tract. Furthermore, the titres obtained at distant territories were 
even higher, as compared to those obtained following i.vag. immunisation. 
However, although immunisation via s.l. and i.n. route stimulated the strongest 
humoral immune responses using the adjuvant c-di-AMP, immunisation via the 
i.vag. and i.n. routes promoted the strongest cellular immune responses. An 
approach to stimulate optimal humoral and cellular immune responses based on 
the combination of these two vaccination strategies was not proven 
efficicacious. 
 
 
Table 1: Immune responses stimulated according to adjuvant and route of administration. 
 
Humoral immune response Cellular immune 
response 
Route of 
immunisation 
c-di-AMP α-GalCerMPEG c-di-
AMP 
α-
GalCerMPEG 
 
mucosal systemic mucosal systemic   
i.n. +++ +++ o + + + 
i.vag. ++ +++ + +/o ++ +/o 
s.l. +++ +++ + +/o + o 
i.vag. + s.l. ++ +++ + +/o + o 
No induction (o); low responses (+), intermediate responses (++), strong responses (+++). 
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4.5. Immunisation strategies to protect against mucosal 
challenge with HSV-1 
4.5.1. Protection against β-Gal expressing HSV-1 after s.l. 
vaccination with β-Gal 
The results obtained until now were based on subunit vaccine formulations 
using the model-ag β-Gal in combination with different adjuvants. However, it is 
essential to assess if the adjuvants administered by s.l. route would be able to 
stimulate a protective immune response. Thus, the potential of the used 
adjuvants co-administered with β-Gal by s.l. route to protect mice against a 
lethal viral challenge was investigated. To this end, a challenge model was 
implemented based on a HSV-1 strain expressing β-Gal, which operationally 
acts as viral ag [211], [212]. BALB/c mice (n=10) were immunised using either 
β-Gal + c-di-AMP or β-Gal + α-GalCerMPEG administered via the s.l. route. 
After three immunisations on day 0, 14 and 28, animals were challenged on day 
42 with 7.4x106 PFU of LVLacZ via i.vag. route. The weight loss and vitality of 
infected mice indicated that a certain degree of protection can be achieved by 
using the α-GalCerMPEG-based formulation. However, despite the trend, the 
differences were not statistically significant and no virus could be determined in 
plaque-assay of VL after day 7 post challenge in all groups. This suggests that 
the level of viral expression of β-Gal is not sufficient to measure a clear 
protective effect under these experimental conditions. 
 
4.5.2. Protection against HSV-1 challenge after s.l. vaccination 
with virus co-administered with adjuvants 
 
To this end, BALB/c mice were immunised via the s.l. route with either PBS, or a 
live attenuated derivative (still able to replicate) of the LV strain expressing β-
Gal (LVLacZ, 103 PFU/dose) co-administered with either c-di-AMP or α-
GalCerMPEG. Two weeks after immunisation, mice were challenged with 106 
PFU/dose of the LV wt strain. 
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Table 2: Vaccination protocol 
Group* 
 
Adjuvant  
(5 µg) 
Live virus 
(103 PFU) 
Immunisation 
route 
Challenge 
Route 
(LV wt 106 PFU) 
1 PBS - - i.vag. i.vag. 
2 PBS - - s.l. s.l 
3 PBS - - i.n. i.n. 
4 
 
c-di-AMP  LV LacZ 
 
s.l. s.l. 
5 
 
c-di-AMP LV LacZ s.l. i.n. 
6 
 
c-di-AMP LV LacZ s.l. i.vag. 
7 
 
α-Gal-
CerMPEG LV LacZ s.l. i.vag. 
* BALB/c mice (n=5) 
 
All control animals treated with PBS died within 14 days after i.vag. challenge, 
whereas 60 and 80% survived following s.l. and i.n. challenge, respectively (Fig. 
53). This suggests that the HSV-1 challenge model based on the LV strain is 
most efficient when infecting mice via i.vag. route. The analysis of the survival 
rates of mice immunised with the formulations based on c-di-AMP showed that 
only 20% survive after the i.vag. challenge, whereas 80 and 100% survive the 
i.n. and s.l. challenge, respectively (Fig. 53). This suggests that the c-di-AMP 
based formulations conferred marginal protection, if any at all. In contrast, 100% 
of animals immunised with the formulation adjuvanted with α-GalCerMPEG 
were able to survive the i.vag. challenge (Fig. 53).  
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Figure 53: Survival curve starting at the challenge day. 
 
Despite the stronger adjuvant properties of c-di-AMP, only the formulations 
containing α-GalCerMPEG were able to confer protection. In fact, vaccination of 
mice using c-di-AMP induced strong humoral and cellular immune responses as 
well as high numbers of IL-17 secreting splenocytes 21 days after the last 
immunisation. In contrast, α-GalCerMPEG did not result in late IL-17 secretion, 
stimulating only weak cellular responses. This suggests that differences in the 
quality rather than in the strength of the immune response might explain the 
differences in survival. More specifically, α-GalCerMPEG blocked Th17 
responses, thus, to further investigate the role of IL-17 in host defence against 
HSV-1 studies were perfomed using IL-17 KO mice. To this end, the 
susceptibility of IL-17 A/F-/- mice (C57BL/6 background) to an i.vag. challenge 
with LV wt was evaluated and compared to that of C57BL/6 wt mice. According 
to preliminary studies, the optimal challenge dose was 6.9 x 108 PFU (LD60). As 
indicated in figure 54, in contrast to what expected, KO-mice were more 
susceptible to virus infection and died between day 9 and 14 after challenge, 
whereas 40% of the C57BL/6 survived more then 20 days. This is in line with 
recently published studies showing that IL-17 is needed for neutrophil 
recruitment to efficiently combat viral infections [213].Thus, while by adjuvant-
mediated modulation Th17 polarisation was specifically blocked, in the IL-17 KO 
animals production of IL-17 by any cell subset is missing (i.e. also early IL-17 
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production by innate immune cells). This prevents a dissection of the specific 
contribution of Th17 cells to the overall protection conferred by vaccination.  
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Figure 54: Susceptibility of IL-17 A/F -/- mice to HSV infection.  
Wild type C57BL/6 and IL-17 A/F -/- mice were challenged with 6.9x108 PFU of HSV-1 wt strain 
LV by i.vag. route. Results are expressed as percentage of survival. 
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5. Discussion 
5.1. Mucosal immunisation  
Millions of people die each year from infectious diseases [1]. Most of these 
cases occur in developing countries, since hygiene standards and medical care 
are less efficient respect to industrialised countries. Nevertheless, despite 
improved hygiene standards, therapeutic and vaccination approaches, 
infectious diseases still represent a huge burden, also in the developed world. 
The reasons for this lay in the fact that more and more pathogens develop 
resistance against anti-microbial agents and that new pathogens emerge. In 
general, vaccination constitutes the most efficient tool to prevent infectious 
diseases as it prepares the immune system to successfully combat pathogens 
before the disease develops, making cost intensive therapies redundant. In 
addition, vaccination also minimises the spread of infectious agents and could 
even eradicate a pathogen, such as in the case of small-pox in 1980 [1].  
However, due to safety concerns, the acceptance of the public for vaccinations 
is only poor and until now only few vaccines are licensed for human use. 
Therefore, the development of novel vaccination strategies is urgently needed. 
In this context, vaccination via mucosal surfaces represents a promising 
approach, since most pathogens enter the human body via mucosal surfaces. 
Consequently, stimulation of protective immune responses in these territories 
would not only protect against disease, but also against infection. Furthermore, 
in contrast to parenteral vaccines that only stimulate systemic immune 
responses, mucosal immunisation is able to promote both mucosal and 
systemic immune responses. Due to the compartmentalisation of the mucosal 
immune system, local application of vaccines can also elicit protective immune 
responses at distant mucosal territories. Therefore, mucosal vaccination can in 
principle be superior to parenteral vaccine application. 
However, in order to increase the safety profile of vaccine formulations, modern 
vaccines often consist only of parts of infectious agents rather than of whole 
inactivated or attenuated pathogens. Unfortunately, this increases safety at the 
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expense of an impaired immunogenicity. This can be explained by the fact that 
subunit vaccines are generally less immunogenic than whole cell vaccines, 
since many components with built-in adjuvant properties are missing. The 
immune responses to subunit vaccines are even poorer when they are 
administered by mucosal route. To overcome this obstacle, subunit vaccines 
should include adjuvants in the formulation, to strengthen and broaden the 
elicited responses (reviewed in [214]). Nevertheless, up to now only a handful of 
adjuvants have been licensed for human use. Furthermore, there is no mucosal 
adjuvant in the market [8]. Thus, the development of mucosal adjuvants 
represents a priority in vaccinology.  
 
5.1.1. Establishment of successful immunisation protocols 
Beside the stimulation of mucosal and systemic immune responses which are 
able to protect against infection, mucosal vaccination is hallmarked by a 
painless and easy administration logistic. For example, oral immunisation was 
successfully used for vaccination against polio, since both children and their 
parents could be easily motivated to comply. However, it turned out that 
depending on the route of administration, mucosal vaccination can stimulate 
immunity only locally or in very restricted distant mucosal territories. For 
example, oral and i.vag immunisation usually promote mucosal responses only 
in the gastrointestinal and genital tract, respectively. In contrast, vaccination by 
i.n. route elicits immune responses in both the respiratory and genital tracts 
[112]. For this reason, i.n. immunisation would be a promising strategy to 
vaccinate against both respiratory and STDs. Unfortunately, concerns about the 
safety of i.n. administered vaccines containing A-B moiety toxins or their 
derivatives as adjuvants. More specifically, neurological adverse effects (i.e. 
Bell´s palsy) were observed following administration of a virosome vaccine 
against flu adjuvanted with the heat labile toxin (HLT) of E. coli [127]. Similarly, 
side effects were reported in clinical trials performed using vaccine formulations 
containing a genetically inactivated derivative of HLT as adjuvant [128]. HLT can 
be redirected to the CNS via retrograde axonal transport, since neurons express 
receptors for the B subunit of the toxin. Nevertheless, it is not clear if the 
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observed side effects are directly linked to the transport of the adjuvant to the 
olfactory bulbs. It might also be, for example, that the inflammatory process 
triggered by the adjuvant resulted in a mechanic trauma of the nerve or the 
reactivation of a latent viral infection. Therefore, one aim of this work was to 
investigate the potential of the s.l. route as alternative strategy to i.n. 
vaccination. 
 
To this end, comparative studies of i.n., i.vag. and s.l. immunisation were 
performed in a murine model, using as mucosal adjuvants the new promising 
compounds c-di-AMP and α-GalCerMPEG [207], [68]. The c-di-AMP stimulates 
ag-specific humoral and mixed Th1/Th2/Th17 responses. The adjuvant activity 
is at least in part mediated by its recognition by STING [68], [69]. STING is a 
transmembrane protein in the endoplasmatic reticulum that supports production 
of type I IFNs [215], [216], [217], [218]. In contrast, α-GalCer and its pegylated 
derivative α-GalCerMPEG are recognised by NKT cells in the context of the 
CD1d receptor expressed by APCs, promoting the stimulation of Th2 dominated 
humoral and cellular responses [78]. These two adjuvants were of further 
interest, since they exert a differential effect in the stimulation of IL-17 
production and differentiation of Th17 cells following vaccination. The c-di-AMP 
promotes differentiation of Th17 cells with high levels of IL-17 in the late phase 
of the immune response. In contrast, α-GalCer blocks Th17 differentiation, but 
stimulates early IL-17 responses which peak after two hours and revert to 
baseline levels after 24 hours [80], [219], [77], [220], [68]. Production of IL-17 as 
well as the differentiation of Th17 cells were shown to play an important role in 
host mucosal defence by linking the innate and adaptive immune responses 
(reviewed in [178]). However, the role played by IL-17 and Th17 cells in HSV 
infection is still a matter of controversy. It has been shown that HSV infection 
stimulates IL-17 production in mice [221], and that IL-17 and Th17 cells 
contribute to the pathogenesis of HSV induced stromal keratitis [180]. A high 
number of IL-17 (e.g. produced by NKT-cells) might increase the mortality after 
HSV-infection [222]. On the other hand, immunisation of mice using α-GalCer as 
adjuvant co-administered with gD resulted in protective immunity against i.vag. 
challenge with HSV, which seemed to be triggered by strong IFN-γ responses 
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[205]. However, the potential effect of IL-17 early produced by iNKT cells 
activated by α-GalCer was not dissected [205]. Thus, second aspect of this 
study was to investigate induction of IL-17 and Th17 cells following different 
mucosal vaccination strategies, and exploit a HSV infection model to gain 
insights on the role of IL-17 in host defence to viral infections.  
 
In order to allow a proper comparison of the different immunisation strategies, 
the first set of experiments focused on the setup of the vaccination protocols 
resulting in optimal immune responses with high ag-specific Ig titres and strong 
cellular responses. For i.vag. immunisations it has been shown that for a 
successful application, vaccines should be given during the dioestrus [223], 
[130], [224], [129], [225]. During this phase the epithelium is the thinnest and 
surface receptors (e.g. nectin-1, allowing viral entry) are up-regulated on the 
mucosa [95]. Moreover, neutrophils and mucus are also increased during this 
stage. These properties facilitate the uptake and processing of vaccine 
formulations, as well as infectious pathogens. Immune responses are poorer at 
the other stages of the cycle, due to a thickened epithelia and a different cell 
compositions [130], [131], [226], [227], [228]. The need for application of 
formulations during dioestrus is valid for both humans and mice [223], [91]. In 
humans, however, the natural occurring phases of the cycle are satisfactory to 
elicit antibody responses following immunisation in dioestrus stage and do not 
need to be modulated by external interventions [91]. Therefore, in an attempt to 
mimic the situation in humans, immunisation studies were performed using mice 
at natural occurring dioestrus stage. However, this approach was not sufficiently 
robust for further implementation and resulted in inefficient immune responses 
(data not shown). Different mice should be vaccinated at different time points, 
since their cycles were not synchronised. This is consistent with results reported 
by Marks et al. [223]. To artificially synchronised the oestrus cycle of female 
mice prior to i.vag. immunisation different methods were tested. The first 
approach is based on the so called Whitten-effect, where female mice are 
placed in cages in which male mice were hosted before [190], [191]. Here, 
hormones present in male urine are known to influence the female cycle. 
Unfortunately, no lasting and constant cycle synchronisation was obtained by 
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this method (tested in C57BL/6 mice). Thus, a dioestrus synchronisation method 
based on subcutaneous injection of DEPO was used [229], [193]. Despite the 
fact that this method is very commonly used, it is important to remember that 
treatment of mice with non-physiological amounts of hormones might change 
not only the susceptibility to certain pathogens like HSV, but also affect cell 
compositions, thereby modifying the resulting immune response. In this context, 
progesterone treatment has been shown to result in immune responses by 
transient generation of VALT consisting of CD11c+ DCs and CD3+CD4+ T cells 
in the lamina propria, leading to protection against HSV-challenge [193], [89]. 
Additionally, it has been described that hormones directly influence the 
presence of cytokines and chemokines that correlate with immune response 
severity [230]. Another aspect to take into account for the outcome of the 
immunisation studies is that progesterone can prevent DCs activation by binding 
to surface receptors, which in turn inhibit STAT-1 activity [231]. STAT-1 is 
activated by IFN-γ and leads to T-bet activation, the transcription factor of the 
IFN-γ gene and the main factor in Th1-lineage commitment [232]. This in turn 
might explain, at least in part, the missing CD8+ response observed in the 
present work following i.vag. immunisation of DEPO treated mice with β-Gal co-
administered with c-di-AMP. In fact, immunisation via i.n. route using c-di-AMP 
resulted in the stimulation of IFN-γ producing CD8+ cells [68]. In conclusion, 
Th1-development might not be supported through DEPO-treatment. This can 
also affect the susceptibility of vaccinated mice to the viral infections performed 
in this work [233], [193], [194]. Cherpes et al. showed that hormone treatment 
favours reactivation of latent HSV-1 resting in the trigeminal ganglion due to 
direct effect on neurons and inhibition of CD8+ T-cell responses [234]. 
Moreover, it is known that hormonal changes correlate with the susceptibility to 
HIV infection, because the expression of viral receptors on mucosal cells 
changes according to the stage of the female cycle [235]. 
In parallel to the establishment of the optimal protocol for oestrus cycle 
synchronisation, the optimal ag-adjuvant formulation for a specific mouse strain 
was identified. To this end, immunisation via the i.n. route was used as 
reference method, since this approach was known to induce strong humoral and 
cellular responses at both local and systemic level. In a first step the adjuvant 
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stimulating the strongest responses was identified. The MALP-2 derivative 
BPPCysMPEG tested in C57BL/6 mice stimulated only weak ag-specific 
immune responses after i.n. or i.vag. vaccination, compared to c-di-AMP which 
triggered robust responses following i.n. administration, and even stronger 
humoral and cellular responses after i.vag. immunisation. Thus, c-di-AMP was 
chosen for further experiments, since it was the most promising adjuvant 
independently of the administration route. After the adjuvant was identified, 
different mouse strains were immunised via different routes using OVA and β-
Gal as model-ags. The strongest humoral and cellular immune responses were 
obtained immunising BALB/c mice by either i.n. or i.vag. route with the model-ag 
β-Gal co-administered with c-di-AMP. In contrast, vaccination of mice with OVA 
and c-di-AMP stimulated comparatively weaker immune responses. The strain-
dependent immune responses reported here are consistent with previous 
reports [236], [237].  
It was described that BALB/c mice are more susceptible to HSV infection, as 
compared to the more resistant mouse strain C57BL/6. This could be explained 
by the development of a fast IFN type I response of the innate immune system 
in C57BL/6 mice, which in turn promotes protection against viral infections [198], 
[199]. Thus, further comparative immunisation studies were performed using β-
Gal in combination with c-di-AMP and BALB/c mice.  
One of the aims of this work was also to investigate the contribution of IL-17 and 
Th17 cells in antiviral host defence. Thus, α-GalCerMPEG was included as 
adjuvant in the further experiments. Interestingly, α-GalCerMPEG also 
stimulated stronger antibody responses in BALB/c mice than in C57BL/6 mice, 
although to a lesser extent as compared to c-di-AMP. While the use of c-di-AMP 
as adjuvant resulted in the stimulation of both IgG1 and IgG2 subclasses (i.e. a 
mixed Th1/Th2 response), α-GalCerMPEG promoted an IgG1 dominated (i.e. 
Th2 biased) immune response. However, when the obtained mucosal immune 
responses were analysed, α-GalCerMPEG stimulated weaker IgA production 
than c-di-AMP. The same was true when comparing the cellular responses 
stimulated by α-GalCerMPEG and c-di-AMP. The proliferative capacity of spleen 
cells derived from BALB/c mice receiving c-di-AMP was about two-fold higher 
than the one of cells derived from C57BL/6 mice. Similar results were observed 
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regarding the levels of IL-2, IL-4, IL-17 and IFN-γ producing splenocytes. Co-
administration of α-GalCerMPEG resulted in minimal cell proliferation and 
cytokine production, independently of the tested mouse strain. As expected, no 
IL-17 production has been observed after restimulation of splenocytes derived 
from mice immunised with β-Gal co-administered with α-GalCerMPEG. In 
contrast, when c-di-AMP was used as adjuvant, high numbers of IL-17 
producing cells were detected. These findings are in line with former 
observations made by our group [207], [68].  
 
5.1.2. Benefits and drawbacks following i.vag. immunisation 
The i.vag. immunisation is one possible strategy to achieve protective immune 
responses at the genital tract. This route, however, mostly promotes a local 
mucosal immune response, since cells stimulated at the genital mucosa are 
usually not homing to distant sites (see section 1.3.3). Nevertheless, this 
approach is still of interest to promote protective immune responses against 
STDs since, in contrast to systemic immunisation, i.vag. application of the ag 
triggers both CTL responses in the draining LN and local IgA production [238], 
[239].  
 
When c-di-AMP and α-GalCerMPEG were used as adjuvants, c-di-AMP always 
promoted stronger humoral and cellular immune responses at both local and 
systemic level. However, comparison of i.vag. and i.n. administration showed 
that i.vag. immunisation induced only weak humoral responses at systemic and 
mucosal levels, as indicated by lower titres of serum IgG and sIgA. In contrast, 
cellular immunity was stronger following i.vag. immunisation, as compared to i.n. 
vaccination. Remarkably, c-di-AMP containing formulations elicited strong CD4+ 
T-cell responses but only low numbers of IFN-γ producing CD8+ T-cell spleen 
cells when administered by i.vag. route. Beside the impact of DEPO treatment, 
the reduced number of IFN-γ producing CD8+ T-cells might be explained by the 
fact that in vagina c-di-AMP mainly stimulated Langerhans DCs, rather than 
CD207- DCs [240]. This favours a CD8+ T-cell-biased immune response, which 
results in IL-17-secretion rather than promotion of IFN-γ producing T-cells. 
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Accordingly, it was reported that vaginal Langerhans DCs contribute to the 
differentiation of ag-specific CD8+ T-cells producing IL-17A and IL-10, which 
seem to have regulatory functions critical during viral infections [241]. Despite 
the fact that their true role has not been fully dissected, the high numbers of IL-
17 producing cells obtained following immunisation with c-di-AMP further 
support this affirmation, that the stimulated CD8+ T-cells mainly produce IL-17 
and low IFN-γ [242], [231], [232].  
As mentioned before, hormones affect the function of APCs, including their 
ability to activate T-cells. Therefore, DEPO-treatment might also contribute to 
the outcome of the stimulated immune responses [243]. This aspect would be of 
particular importance with regard to immunisations against viral infections, such 
as HSV, where IFN-γ secreting CD4+ cells seem to be the key effector cells 
needed for viral clearance [244], [245]. Nevertheless, it is still controversially 
discussed if CD8+ T-cells are the main source for IFN-γ and to which extent help 
provided by CD4+ T-cells is needed for successful stimulation of CD8+ 
responses [246], [247].  
Vaccination with formulations containing α-GalCerMPEG as adjuvant were poor 
inducers of cellular immunity as compared with those containing c-di-AMP, 
particularly in terms of stimulating IFN-γ producing cells. Only IL-4 secreting 
cells were detected three weeks after the last immunisation, and, as expected, 
ag-specific Th17 cells were not induced. This is in contrast to a previous report 
in which gD co-administered with α-GalCer through the i.vag. route stimulated 
strong IFN-γ responses both in spleen and genital lymph nodes [205]. The 
differences might be explained in part by different intrinsic immunogenic 
properties of the ag (i.e. gD versus β-Gal) [205]. The α-GalCerMPEG containing 
vaccine formulation also stimulated strong antibody responses. These results 
are in line with previous studies, showing that this adjuvant mainly promote Th2-
biased responses [207]. However, α-GalCer binds to CD1d on DCs, thereby 
stimulating NKT-cells to produce IL-17 [80]. NK1.1- NKT-cells are responsible 
for the IL-17 secretion observed 2-3 hours after stimulation, which is not 
restricted to a single subset [77], [248]. These cells also secrete low amounts of 
IFN-γ and IL-4, which contribute to the recruitment of neutrophils to the site of 
infection [80]. This can be in turn critical for shaping the microenvironment in a 
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form which is conductive towards the elicitation of an efficient adaptive immune 
response. It follows, that it is also critical to enable an appropriate window 
between the vaccination and any challenge aimed at evaluating the efficacy of 
the stimulated response. In fact, the early effector functions from α-
GalCerMPEG might also contribute to microbial clearance, since γδ T-cells were 
described to survive around four weeks or even switch to memory cells [249]. 
 
5.2. Immunisation via s.l. route is a promising alternative to 
i.n. and i.vag. immunisation 
The exploitation of the s.l. immunisation route can lead to strong mucosal and 
systemic immune responses, with minimal risk for side effect. The s.l. mucosa 
encompasses a pluristratified epithelium associated to immune cells, which as 
inductive site enables the stimulation of local and distant responses, as 
indicated by sIgA production, and stimulation of serum antibodies and CTL 
responses following vaccination (reviewed in [83]). Vaccine formulations 
administered via s.l. route directly enter the blood stream without passing 
intestine or liver [143], [144], [142]. In general, only minimal adverse side effects 
have been observed in patients after s.l. application of drugs or immune 
therapies for allergies [250]. However, before evaluating the s.l. route as a 
vaccination strategy, experiments were performed to rule out that under our 
experimental conditions ag leaking to the gut might be responsible for any 
observed immune response. While s.l. immunisation stimulated strong humoral 
and cellular immune responses at local and systemic level comparable to those 
obtained after i.n. immunisation, oral vaccination resulted in only marginal 
antibody and cytokine production. In addition, s.l. immunisation stimulated 
similar levels of ag-specific IgA production in the different mucosal territories, as 
compared to administration via i.n. route. In contrast, oral immunisation 
stimulated significantly decreased IgA titres with respect to the other routes. 
Thus, the protocol for s.l. immunisation used in the presented work is valid in 
order to investigate the potential of the s.l. route as vaccination strategy. 
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The experiments performed in this thesis also revealed that the ag and adjuvant 
dosages for s.l. immunisation should be approximately doubled respect to those 
applied by i.n. or i.vag. route. Thus, in order to allow a proper comparison of the 
different immunisation strategies, studies were performed in which animals were 
immunised via i.vag. route with the same dosage needed for s.l. vaccination. 
The side-by-side comparison of the two ag and adjuvant showed no significant 
differences in the level of stimulated humoral and cellular immune responses. 
Thus, this confirms that the comparability of the different vaccination strategies 
is allowed, although the amount of ag and adjuvant distinguish for s.l. 
immunisation compared to i.vag. or i.n. immunisation.  
 
In this study, the humoral immune responses obtained following s.l. 
immunisation were comparable in strength and pattern to those observed after 
i.n. vaccination and superior to those elicited following i.vag. immunisation. The 
same is true when the cellular responses stimulated after s.l. and i.n. responses 
are compared. Again, ag-specific splenocytes from immunised mice showed 
similar proliferative capacities, as well as analogue levels and patterns of 
secreted cytokines. Interestingly, i.vag. vaccination stimulated stronger cellular 
responses with respect to the other application routes, as indicated by higher 
proliferative capacities of spleen cells and higher numbers of cytokine secreting 
cells in immunised mice. To assess if immune responses could be optimally 
tailored by combining approaches, a vaccination schedule was implemented in 
which s.l. and i.vag. immunisations were combined. To this end, mice received 
the same ag and adjuvant dosages as administered by the single route protocol, 
but divided and administered at two different routes. Interestingly, although it 
seemed that the combined mucosal vaccination strategy resulted in slightly 
increased cellular responses as compared to the s.l. immunisation alone, the 
differences were not statistically significant. However, as recently shown, a 
prime boost protocol in which the vaccine formulation is given first by one route 
and then a boost is performed by another route might be a more efficient 
approach to fine-tune the elicited response [251].  
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After characterisation of the immune responses stimulated following s.l. 
immunisation, the capacity of this route to promote protective immunity was 
investigated. To this end, mice immunised via s.l. route with a sub-lethal dose of 
the HSV type I strain LV co-administered with either c-di-AMP or α-
GalCerMPEG, were subsequently challenged with a lethal dose of the 
homologous strain via the i.vag. route. When mice were vaccinated using α-
GalCerMPEG as adjuvant, 100% of the animals survived the i.vag. challenge 
three weeks after the last immunisation. It seems unlikely that this protection 
results from a long lasting NK and/or NKT response stimulated by α-
GalCerMPEG considering the interval between the last boost and the challenge. 
Therefore, protection appears to be mediated by the adaptive immune 
responses stimulated by the vaccine. This is further support by the fact that Lin 
et al. demonstrated that the beneficial effect of α-GalCer also depends on the 
time point of administration. The α-GalCer was able to protect mice only when 
administered one day before a viral challenge [252].  
The α-GalCer and its derivatives are known to activate iNKT, when presented in 
the context of CD1d receptor on DCs, which subsequently secrete Th1 (IFN-γ) 
and Th2 (IL-4) cytokines. While the ability of α-GalCer to induce Th2 cytokines 
seems to correlate with the amelioration of autoimmune diseases, the 
production of Th1 cytokines is shown to correlate with antitumor, antibacterial, 
and antiviral effects [253], [254], [252]. In this context, Adotevi et al. showed that 
co-administration of α-GalCer resulted in an improved ag delivery to DCs, which 
was reflected by a stronger and longer lasting CD8+ T-cell response [255]. In 
addition, Gonzalez-Aseguinolaza and co-workers showed that vaccination using 
α-GalCer as adjuvant triggered protective immunity against malaria in mice. This 
protection seemed to be mediated by enhanced ag-specific CD8+ T-cell 
responses and, to a lesser degree, by Th1-type cells, Vα14 NKT (iNKT) cells, 
and IFN-γ [253]. Moreover, in a corneal HSV infection model, IFN-γ was shown 
to be very important for protection. IFN-γ down regulates IL-17 by suppressing 
IL-23 synthesis, thereby hindering Th17 cells development [180]. Surprisingly, 
co-administration of c-di-AMP was not sufficient in order to protect mice against 
the homologous challenge, since 80% of the infected mice died. This is in 
contrast to what was observed by Ebensen et al. (unpublished data), since mice 
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vaccinated by i.n. route with inactivated flu virus co-administered with c-di-AMP 
were protected against a lethal homologous challenge via i.n. route.The 
adjuvant c-di-AMP stimulated IL-17 production three weeks after the last 
immunisation. The main source for IL-17 seems to be Th17 cells (up to 50%). 
These cells express the CD4, which is not expressed by most γδ T-cells. 
However, as shown here, also γδ T-cells were stimulated by c-di-AMP to 
secrete IL-17 (up to 15%). Like NKT cells, γδ T-cells are thought to bridge 
between innate and adaptive immune responses, whereby the adaptive 
responses were preceded by innate immune cells [256], [257]. Innate cell 
subpopulations, such as γδ T-cells, NK cells, and lymphoid tissue-inducer cells 
are also sources for other Th17 cytokines, like IL-22 [258]. The γδ T-cells can 
be classified according to their functional programming and show different tissue 
tropisms [160], [257]. Furthermore, γδ T-cells are commonly indirectly activated 
by PAMPs which, similar to NK cells and iNKT cells, lead to early induction of 
IFN-γ production [257]. However, PAMPs can also indirectly trigger IL-17 
production by mouse Vγ6Vδ1+ T-cells which can be mainly found in tongue, 
lung, uterus and vaginal epithelia [257]. Previous studies using various 
infectious disease models indicate that γδ T-cells can carry out different 
functions in response to infections. Their response is staged, occurring before or 
after the αβ T-cell response. This might be in part due to the specific distribution 
of γδ T-cells in different lymphoid tissues (reviewed in [210]). At mucosal sites, 
γδ T-cells contribute to the initial stages of the response to infection, thereby 
bridging the innate and adaptive immune system, and promoting αβ T-cell 
responses [210]. In addition, γδ T-cell involvement could also trigger chemokine 
mediated recruitment of other lymphoid populations to the site of infection. 
Finally, γδ T-cells seem to act as anti-inflammatory cells at the end of the 
effector response, contributing to tissue repair and cellular regeneration [210]. 
Thus, the controversial results obtained using c-di-AMP as adjuvant in vaccine 
formulations against flu and HSV might be also explained by the stimulation of 
different γδ T-cells subsets and adaptive immune responses at different 
mucosal territories.  
In this context, infection of C57BL/6 mice by i.n. route with the influenza A virus 
stimulated the activation and expansion of two distinct populations of γδ T-cells 
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in lungs over time [210]. About 10 days post-infection, the number of Vγ4+ T-
cells, which are mainly found in lung, liver and spleen and epithelia, and 
primarily produce pro-inflammatory cytokines, increased, whereas about 13 
days post-infection an increase of Vγ1+ T-cells, which are normally localised in 
lymphoid tissues and spleen, and primarily produce immunoregulatory/anti-
inflammatory cytokines, was observed [210]. Thus, the differences in the 
expressed cytokine profiles might be essential in order to protect mice against 
infection. Accordingly, s.l. immunisation of mice with HSV co-administered with 
c-di-AMP might stimulate mainly Vγ6+ T-cells, which are programmed in the 
thymus to produce IL-17 and were believed to play a role in tissue remodelling 
and innate clearance of bacteria [257]. Furthermore, consistent with data 
presented here, Vγ6+ T-cells are not found in spleens of mice, which could in 
turn explain the small amounts of IL-17 producing γδ T-cells in spleen of mice 
immunised with β-Gal co-administered with c-di-AMP by the i.vag. route. Vγ6+ 
T-cells stimulation results in early production of IL-17 upon TCR signalling, 
whereas Vγ4+ T-cells produce IL-17 and Th17 polarising cytokines, thereby 
resulting in different downstream processes [257]. However, also α-GalCer 
stimulates γδ T-cells to produce IFN-γ and IL-17, although it is not clear which 
specific subsets are responsible [259]. Nontheless, further studies need to be 
performed to address open questions. For example, by performing an in depth 
analysis of the cytokine profiles and cell subpopulations (numbers, phenotypic 
markers, functional properties) stimulated after immunisation of mice by different 
mucosal routes using c-di-AMP and α-GalCerMPEG as adjuvants. Also the 
specific impact of absence of IL-17 needs to be elucidated. According to our 
studies in IL-17-KO mice, deficiency in IL-17 production seems to have a 
negative effect in protection against HSV-1 infection. Similar effects were 
observed in the influenza model, where Th17 cells appear to be necessary to 
protect mice against a lethal challenge [260], and in certain bacterial infections 
[261], [262]. 
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5.3. Conclusions 
Mucosal vaccination exhibits many advantages as compared with the most 
often applied parenteral vaccination. The use of the mucosal route is cost 
efficient and results in (i) induction of humoral and cellular immune responses at 
both local and systemic level, (ii) stimulation of protective immunity at local and 
distant mucosal territories (e.g. vaginal tract), (iii) an easy administration 
logistics, and (iv) modest discomfort, stress or risk of cross-contamination [91], 
[115], [263].  
However, there are also some disadvantages connected with mucosal 
vaccination. For example, although i.vag. application is a potent route to elicit 
local protective responses against STDs, but only female could be vaccinated, 
the optimal phase of the menstrual cycle needs to be considered and cultural 
factors might affect the degree of acceptance, making it unsuitable for mass 
vaccinations [91], [134]. Furthermore, in case of i.n. vaccination, the occurrence 
of adverse events following immunisation (e.g. Bell’s palsy) raised concerns 
about the safety of certain candidate adjuvants. 
In contrast, s.l. administration overcomes potential concerns of i.n. 
immunisation, retaining all the advantages of this appraoch [148], [119]. In fact, 
s.l. immunisation is able to elicit protection against lethal i.n. viral challenge, as 
well as promote protective antibody and CTL responses at the genital tract 
[148], [90]. Therefore, the s.l. administration is valid alternative to both i.n. and 
i.vag. vaccination, circumventing most of the safety and logistic concerns 
associated these routes [140].  
However, independently of the administration route, there is a general 
consensus that IL-17-producing cells (i.e. Th17 cell, γδT-cells, NKT cells and 
LTI cells) play a substantial role in host defense against pathogens at mucosal 
sites. Thus, cytokines produced by these cells are important for the induction of 
innate and adaptive host responses. Nevertheless, IL-17 was also shown to 
contribute to inflammatory responses at mucosal sites, resulting in pathological 
manifestations linked to Th17 responses. Thus, it is becoming apparent that 
there is a fine balance at mucosal sites that defines immunity or inflammation 
(reviewed in [264]). In the present work, the mucosal adjuvants c-di-AMP and α-
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GalCerMPEG showed opposed effects in terms of IL-17 production and Th17 
development. While c-di-AMP seems to stimulate an early γδ T-cell response 
followed by a late Th17 response, α-GalCerMPEG stimulates NKT cells 
resulting in a Th1 dominated ag-specific response. Although α-GalCerMPEG is 
also able to stimulate γδ T-cells to secrete IFN-γ and IL-17, this adjuvant does 
not stimulate immune responses resulting in stimulation of Th17 cells [259]. In 
the HSV based experimental mouse model used in this work, this NKT 
activation and the subsequent Th1 responses were essential in order to protect 
mice against a lethal challenge. In contrast, the responses stimulated by c-di-
AMP seem to favour a Th17/Th1 phenotype with production of both IL-17 and 
IFNγ, which is not able to protect against HSV challenge. Interestingly, 
Th17/Th1 cells are believed to be the main cause of pathogenic Th17 
responses, rather than Th17 cells [265]. This might be an explanation why the 
mice are dying after the challenge.  
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